var title_f9_48_9984="Small pericardial effusion I";
var content_f9_48_9984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pericardial effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the apical four-chamber view from a patient with a small pericardial effusion (pe), the pe is seen best behind and above the right atrium (RA), which is the most sensitive area for detecting small effusions. In larger pe, the RA collapses at this point, providing a highly sensitive, but minimally specific sign of cardiac tamponade.",
"    <div class=\"footnotes\">",
"     LV: left ventricle; RV: right ventricle; LA: left atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_48_9984=[""].join("\n");
var outline_f9_48_9984=null;
var title_f9_48_9985="Pleural effusion decubitus";
var content_f9_48_9985=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Free layering pleural effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left panel shows blunting of the right costophrenic sulcus (white arrow) on an upright chest radiograph due to the presence of a pleural effusion. The right panel shows a right lateral decubitus radiograph from the same patient, and reveals layering of pleural effusion (black arrow). Effusions thicker than 1 cm on decubitus views are usually large enough for sampling with thoracentesis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_48_9985=[""].join("\n");
var outline_f9_48_9985=null;
var title_f9_48_9986="Patient information: Brain cancer (The Basics)";
var content_f9_48_9986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/52/8004\">",
"         Patient information: High-grade glioma in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/15/5362\">",
"         Patient information: Meningioma (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/42/36515\">",
"         Patient information: Primary low-grade glioma in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/27/34229\">",
"         Patient information: Seizures in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Brain cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/brain-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H385097563\">",
"      <span class=\"h1\">",
"       What is brain cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Brain cancer happens when normal cells in the brain change into abnormal cells, and grow out of control. There are different types of brain cancer. Some types grow very slowly. Others grow much faster.",
"     </p>",
"     <p>",
"      As brain cancer grows, it can spread into normal parts of the brain. It can also cause swelling in the brain. These can cause symptoms.",
"     </p>",
"     <p>",
"      Sometimes, symptoms of brain cancer can be caused by a mass that grows on the covering around the brain. This growth is not brain cancer, but it can push on the brain and cause symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H385097570\">",
"      <span class=\"h1\">",
"       What are the symptoms of brain cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Often, one of the first symptoms of brain cancer is a seizure. Seizures are caused by abnormal electrical activity in the brain. A seizure can cause a person to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pass out",
"       </li>",
"       <li>",
"        Stiffen and then have jerking movements of the arms or legs",
"       </li>",
"       <li>",
"        Lose muscle control throughout the body",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other symptoms of brain cancer can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Headache, often with nausea or vomiting",
"       </li>",
"       <li>",
"        Vision changes, such as double vision or a loss of vision",
"       </li>",
"       <li>",
"        Memory problems or having trouble thinking clearly",
"       </li>",
"       <li>",
"        Weakness or numbness in the arms or legs",
"       </li>",
"       <li>",
"        Personality changes",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These symptoms can also be caused by conditions that are not brain cancer. But you should let your doctor or nurse know if you have any of these symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H385097577\">",
"      <span class=\"h1\">",
"       Is there a test for brain cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors use imaging tests such as CT or MRI scans to diagnose brain cancer. These tests create images of your brain, and can show tumors or abnormal growths.",
"     </p>",
"     <p>",
"      After an imaging test, your doctor may follow up with another test called a biopsy. During a biopsy, a doctor takes a very small sample of the brain tissue. He or she will look at the sample under a microscope to see if cancer is present.",
"     </p>",
"     <p>",
"      The right treatment for you will depend a lot on the type of brain cancer you have, and how fast the cancer is growing. Your treatment will also depend on your symptoms, age, and other health problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H385097584\">",
"      <span class=\"h1\">",
"       How is brain cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Surgery",
"        </strong>",
"        &ndash; During surgery, doctors try to remove as much of the cancer as possible. Often, brain cancer cannot be cured with surgery, but surgery might reduce symptoms and help people live longer. On the other hand, surgery can also lead to more symptoms or problems. This is because healthy parts of the brain can be damaged during surgery.",
"       </li>",
"       <li>",
"        <strong>",
"         Radiation therapy",
"        </strong>",
"        &ndash; Radiation kills cancer cells. People might receive radiation therapy after surgery, or when surgery is not possible.",
"       </li>",
"       <li>",
"        <strong>",
"         Chemotherapy",
"        </strong>",
"        &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells. People might receive these medicines during or after radiation therapy to keep the cancer from growing, spreading, or coming back.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with brain cancer also receive treatment for any symptoms they have. For example, people might take medicines to control seizures.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H385097591\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will be checked every so often to see if the cancer comes back. Follow up tests usually include imaging tests. You should watch for the symptoms listed above, because having those symptoms could mean the cancer has come back. Tell your doctor or nurse if you have any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H385097598\">",
"      <span class=\"h1\">",
"       What happens if the cancer comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the cancer comes back or spreads, you might have more surgery, chemotherapy, or radiation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H385097605\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all your doctors&rsquo; instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for brain cancer involves making many choices, such as what treatment to have and when.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H385097612\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=see_link\">",
"       Patient information: Seizures in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36515?source=see_link\">",
"       Patient information: Primary low-grade glioma in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/52/8004?source=see_link\">",
"       Patient information: High-grade glioma in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/15/5362?source=see_link\">",
"       Patient information: Meningioma (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?9/48/9986?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15364 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_48_9986=[""].join("\n");
var outline_f9_48_9986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385097563\">",
"      What is brain cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385097570\">",
"      What are the symptoms of brain cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385097577\">",
"      Is there a test for brain cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385097584\">",
"      How is brain cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385097591\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385097598\">",
"      What happens if the cancer comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385097605\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385097612\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/52/8004?source=related_link\">",
"      Patient information: High-grade glioma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/15/5362?source=related_link\">",
"      Patient information: Meningioma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36515?source=related_link\">",
"      Patient information: Primary low-grade glioma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=related_link\">",
"      Patient information: Seizures in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_48_9987="Transdiaphragmatic pressure";
var content_f9_48_9987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transdiaphragmatic pressure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 286px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEeAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiioYrq3mkaOKeKRxyVVwSPwoAmooooAKKKKACiiigAoqFbu3ebyVuITLkjYHBbI68VNQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8yPaalpd78XdQ8I+GdY07VrnyH0i5h0WWJmQMgmWJtn8TfMVH3sFsHGa+m6KAPn3xRD460i58V6ZpureKLmwjvdPktLuS0kuHlR4pWnRZIU3Km5YwTGp2nAwAxNYl14g8Wl7DSr5vGFnfSeGbi6isrMtcXLXYuysLyEIGCYI+8FwMBiec/SGkanb6taSXNmWMSXE9sdwwd8MrxP+G5GqQ2FmdSGom0t/7QEJtxdeWvmiItuKb8Z25AOM4yM0AVvDH9pf8ACN6T/bu3+1/skX2zZjHn7B5mMcY3Z6VpUUUAFFFFAHzZ8OdAnsPi34qvdX0jU7cy61qk1vcDw7KzGFlfEkd6PuAjcFUKck8H56ivvEXjzS/h74v1DXbjxBZXltYQto809uIlMBuMb5SMqLkggMhwQO3Jr6G8Q6smi2EV1LE0qyXdraBVOCDPPHCD9AZAfwqzqVhZ6pYy2Wp2lveWcoAkguIxJG4znlWBB5ANAHBfCmXW5tZ8Vvetrj+HzPD/AGY2tRGK4LbD5+FYBhHu27eAOuOK9GoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiivPPHXxRtPCPiKbSZdG1PUHttL/ALYuZbQxYhthIY2bDupYggcD1+uAD0OiuR/4WT4RFzb28mt20dxN5G2NwwK+civFu4wu5WXGcdat+CvE6eKI9aeO1a2/szVbnSyGfd5hhbaXHAwDnpQAnxI1GTSfAPiC/t9QGnXFvZSyRXRQP5bhTtO08E5wMV4P49+J+vnwV4Cm0rXfsR1TTVafVYvK8r7cvlCRJ2YHYqr5rFVBZmwoFfTbqrqVdQynggjINedfFfxpqHgtNPTSvBd74gtp1lknktkYx22zactsR8ZyeSB069cAFjw14m8X38fhbz/Ciy2N/pttc3+pm+SH7PM8eXUW5Bc4OO/8Xsa74nAyelcrZ+PvDc9xo1nJq1nFqOrW0N1a2pk+eRJFypXgZzg11ROBk9KAImdEieRXUKq7sluAMfoKgu5VRt5cIPKZtzHAAyverLKpjaMhtuMHGensaimdNrBiSoXkAnkcYoAZJOSW2hlI2HBIGfm5A569vrTrhuH25JQjcBjJH+fWpTIPOMbDgKGzz60jyhEaTaCoGcjJJ4z0xQBA7y7rmKNSDtJjJ6DgY6e9MmlmedxDwqopGT1O4ZH1xxU0s/7iWRVHmIvA5yMgH0P8j0pJ7ho2Y4GFxnJI43AZ+76H/PWgCskjmKQKjKBHGFQYBJJOce3+BqOUMBcAqXkUfKgAO4+XjBA+uf8AOKnF07RDIXcI43LDPOSePunpgfn24zE8j7Z2cR8pu2Mef9X0Pyeueuf6UAcz4Bhkfw1qZSPJbWtVIG0c/wDEwm5PqeP5V0kCNMLhihIEy4AUc7ZS358/mO1c38N5JDo2qIibiutatwcgHOoS8/cPv3PT/vnpbbcTOQWX51OCuDxKxPVTxz1z05G3qQCG/gkVgrLu8xkj4UHP7thzxz1q7LAM3CAn5iHI2ZBBXb6c/d9/5CqF6kxVRsO99ik4HB8t+5j559j9B0q1cW7SpdJtj2FiG+6f4F7GMg/r/QAEdqkLLeM8e5kuSSdmcYYN1wc9M/4Gkv2to5HQx4IZAcRdRzgdMHr79enWpoI0JnKhR+/BO718zPdT+H9OtNubZHQ78MSEwSq9QGwfu+/uPb1AOX+JsMU3hdURfmfVNKBDR8Ya+tRj7vP3Rxz/AEHUhI3luJWBwpzkJk7cg+h9Dx/LrXMfE23EnheJdkbb9V0tdvGGzfWg5+T2x347HgDrJFMs8gLfKMfKxB5Dg55U/wA/y60ARTyQRSoGSQsIx0jJyFVuPu8/e6e/TrT4Gil2CO3HEJwpj2gg4GOQPTGPYcdKk8mFUiKqhJQICMDgK2O2Mcn25pk4jjUdN3kvk4TPAX2/+t69qACzkV3LbMgbzvK4wN59vb9O1QM8cj6aFQKSzMBs28BHBGCB/eHH144NWbUxyvhkVjul5ODjEn59f5VCqW6LYbFjXJ2pjaOAkmPujHTd7daAJUe2lS3RkJLxkAGInjGCD8vHT2pLVUWLdITkSzYOM4/eFvQ+n6U+CGJRbhUTaUOBtXAGAMDA6YHtSW3zANhVxJKOAP8Anr9D1x6/4gAr/uopbGTyxFuYgYXHG2Q44A556e/SpoPIWG1SKH5fL2gGPGABjH3ePTtTRHAk1piJZCH+XCgeWdsnzdB/tD8T+L41hMFqsqqxEeMsqkj5Oegx09MD8KAIrCaNXAWMtveUq4Q/KC2ccDjODwcdBTZx5klgwhAPn5x93Aw/OeM9Rx/9erUUkJkUsIzIC6oQQcDeAR+e38qinkT/AEMxxgK1zt+UDj7/ADwf85oAcvmeXbjqEYr90jJCEfgM5qCwmLzgMrrueVRlCO479uh5NTx3AeRC0a5L8H5Qf9WGz978P/rc02wmGZy6AH7Q6jBycbgM5P1HFAEMk5zbqyMYpJSw+U/3+M5Hp2qaC6dvsikMWcE4MZHQHPbjnb/So55S32coiD/SSD8wHAkI9T9cfyPFTQT74LQ7Y1Zm4XYv9xjxhjjv3Pce9AEVpJI8YALKuSmQp4+Rccfn1qzbMWlXOeDIDwR/ECP0qvaTqZSArMfMYdAMHC9Pm6c+9XYGL8t1DOOvbdx3Pp/+rpQBNRRRQAUUUUAFFFFABXn/AIm+F2leJ/iIniTXmW8s10pdO/s50YKWExlEjMHG4ckbCpHf2r0CigDxjUPhjq2veN/Ga3lymm+E9TutNl8qOFHe8S3iT5UYPmEB0AOVyR04r0LwP4X/AOEWj1xPtn2r+09WudUz5Wzy/OYN5fU5x68Z9BXS0UAFecfGKPwcI9Nm8Y6/e6JMfMht5rK8kgkdG2+YCEzlOEyWGBxkjPPo9eO/G74Vap421qw1fQb6xSeO2+xXVnqBkEFxEJPNXJQEna4DbSMHauehyAep6BZWGnaJp1npAT+zre2jhtdj7x5SqAmGycjAHOTmr5GQRx+NcjoHgWx0m10FTe6pLcaTaQWilL+eKGXyowgZoA/l84zjB/GtLxf4p0bwnpqXviC/Wxt5ZPJjcxs5aTaWChVBJOFPGOcUAayxsd3mOxYgA4yAOOcUy4hi2OCGG5MYXrgY4AHp9O59ax/C3iLSvF+hDUPD2pi7hK+X5qpsZHwDyrLlTyDgjuK1ZLQ5Yi5nUMgVtoXk8fN93k44/pQBPLtLnIYn5c4U4xn1x+f60hbdAzPEOU3FCM846dOay/EWsaRoNsbvXdUttNt2aOIT3Dog3EnaAWGM8E+wBPGM1i6Z8SfBWqajc2Nn4k06W5jjZnJcKkiqDuKOQFkAAJO0tgZzxQB08iB1mZYzynK7cBuBjqO3br/SnzKJZGVolbIAOVzkbuRyP6/41R0u90vVrc3+j6ja3drJuxPZyJKj42g/MuQcYx3NX2eJZS5YswwmNvT5semepoAq27YiAMALG3iJbYfmznjO05xgcZPXkDjPNfEvWdR0PwNq+raNY291qFnbecsVyjbSgALnGBnauTj27dK0PEniTQfC8FqPEOp29j9rKQQSTgBWYBjjOOFGCSzcDPUZqrZeJfCfiC9u9I03WNJv55YWElvbssoZAihl+Xh/lOCBnAOKAPBv2ePiv4q8TeK5dB/s3S/sMsl1qVzPDDIJIvMmaU4O5gR5kuACMgHqcV9LW5mdJjs+YsuflyGHmMG5wc/KADyfw6nx/wDZ4+HL+B5fF00saTyT3z2tpLkNm3ib5T/wIvk/7gr2YM4kkVCGbbGQxQA4LEZ9+hOPegCnftNLHgo259uBtPytsY9155x6/QdKfNbyq1w0QYcEjrzhUwPunuW9f8Mvxb4p0nwzpTajrN7HY2gaOOMmJ3ZndSQiqgLMSB0A6AntUFv400O/vms9L8TaPc3cqh4oYJFZpPlU8Yf5iQQcDoKANtLRZXm3KWXzAMZPZ/XHp/kdaSa3eTz8DO+FMA5Bztb2yDwOx+nrU0/UrW8utTtdN1WwmuoJlEkcMgkaBi+DvUPkZIPBx6c4rUzOHAZ1ZUjG5duGztOcNn2oA+eP2ofHHiLwjPpFhaWVkdOu1huY7mVHZxNbzRy7BggYDInUHIYjjjHofwJ8R6r408FQa1rWn2dk80jRwJaiQK8SMF3YYt3Djr/DVP8AaO8DXnjjwGsWnxCbU7KRLi2Vc/MSVVxnJ42sT0/g61b8L+NfBHhOy0vwnD4msP8AQraO2Ekas8CyAkEvOP3aliD8rMDk4PUUAd5NAVlgL8yNEEZt4HRHzn9Py9qfJZp5UTfKGEDgfvO5APB+ueff8KZDfWd1eeRBe21zc2qDz447gF48qcEqCSuQfqcg54q20U0oj2TYjMLDAznJxg53Z/H9RQBFaWEUbLvUAIJEVc4O0ucd/Q0gsY1+wbgvyHCgnPO188/j19qLWKdlVi6q4eVSq7gD85w+N3sDj3x0rI13W9N0nUNJttV1zTtOupZCY4bq6CPKCrqNoZuTlgM9zjuAKANiK1Ia12bQiAhTvzxgY7c85qOwtdiKPMTcJZvut1XzenTsOD7/AJ0kRuFurSE3UfnoCZUJySDjB27/AG9+54zUmn280dsPNbawuZGIGeQZCex7nn2Bx9QCrNYhZ9HcMQ8VyWwHyOY5R+PUflV2COOCO2j85VXliNw5bbk/1PH8qjNtcbtPPnBxHKxYndz8rY/iPqR75HTGKq6nrFhoEFtNrmsWGnQmQqXvLhYlPy52gu/JA+vrjvQBLpsUEMbIzfKbmYhCwySZMA8noN2Me/ripJ44JGtRHGcfacsA4PZhk4PtTrEO0COJI0BlZsgYEoLfeGGAwTg554OO5zI8q/uApJXzuCxP+0Tzk+hoAcrpbiRQu0GTOCy8HaD/AHv8/TmqumvGvnb1OVu5AmTtP3gvc89f88ZumRFEvmyA/OfusRxtBx19KqQSwxQ3EksqxRpcOzuW2qAGGcnPHPr7j1oAZqKRMlkQrZS9XG1s4O4rzyeOP/1dBZM0LtASoIeX5WDrgnYXyPm56dOfpjmqrzQX1vZz2s6XUD3CSJJBJvUqWbBByQR9P/rDRTy0XLMwCn5i0h+X5e+T6f4+9AFG0kZTelRwt2RluAOFHcj1Pr/Sr8E5YsHGCGIxxn7zAHqfT/PQUrQLbfb2dWAe5LfKcZJ2gdPw/Wru4+a6Mm7BUjBzgEnn+dAFiiiigAooooAKKKKACiiigAooooApaymovp0y6LNaQX+B5T3cLSxA553KrKTx6H868a+Mmja7qOlaT/a17rf9qw292RJ4c0l7izkchdiSRFndWOAAx4+9ytdzc+NL698K+J73StD1HTr/AEq1eaEazb+XFOwVmG3a5LD5eeR1FeeeOPjDr+n6J4N/sGytH1fW9Ij1LZLC7xyyN5eYkIIChQ0jszEAKnUE0AemaAfGk66FcXraJZ2T2UD39kbaU3EcxjHmIj+aVwG4GQeO5611k6Bkz5aSMp3KG9R057VxegeP/wC018No/h/Wg+safbX32mC38y0g81N2xpcjkfTuPWu3dgilmzgc8DNAHB+J9B1W11SXxN4OSL+0TaiK90ufKR6lGv3BvwQkyruCuQw5CsMcieD4geGLnT7K8vtVtdMS7DxGLUJkgmimUqskLo33ZFOAR9fYnqmv7dUcES4VckCFzx07Dn6CsDVdF8OPqF7q1zodjNc3ln5d3PJp5kknjONqP8hLDC4KkE/KoI4FAGHa2Vt4t+JmqT31rBdaVoEEdlamRFkVrmTEszgY2nA8pPVSr9Mmuk1PwZ4e1LSINMvtD024sbYAwxSW6ssRGeVUjA6n65NO0W10rQrEWej2Mdhp0aiUQW1m0ahiQxO0LnJBHv8AkauS30VrbSJI7hEhAUrE79gCeAc/eX/INAHIar4Zu/DGqyar4K02zube5tjDf6K862scu0KFmiO0qkgA2sDgMNuSNgNWB8RvCqWIvdV1K00e6EnkTWWoTJFPBKrDcjrz7HIyCCCDgg10slwrs8KylZZI2CZjfdyEGR+P8xVa4stHTV5taW2gj1P7OqveC3PmmHcG2lwM44+7mgDmfCy6T4t8Xa3q9u9vqOk2unwaLb3CskkMwOZrgrjIZTugU57xMOxq5rngTwjf6N/ZV7o1g1pbRl4FSJI1gIUZZSuNpwAef5Vp6XLplhpKQaf5VlZR2qOIkhKKgO5mPyjHJbJx3zTLrU7WGQq10Vb7I8gZlc4UogDdPX8aAPN/DOj3WgLc634M0O2kgkvb3T9Q0iO4jtkkSC8ljglj3HaJUVFU5IDBvXBrutE8d6BdaLcXt3dppqWjJDeR37xwPbTbz+6kDNwx5wc4YcgkVL4YgTR7O7t3v7eRnu7y/BjkIAjuLp5lJ9MK4B7ZBqrH4f8ACWp6jb6vf2thNfw2SRrJcMWHl/N1Qna3DkBsZAYgHBIoAzZb201v4naNJY3SSafo+kPqDNbzK0bPcKFjzg44jRmUnsSQcVsar4Q8J3ukahptx4b0wWkpM8kawxJmQhMtkMCGxt5yONvPTNTwzoHhLwf9qt/D62Wnm5U3NwUmOCdm0McscKM4CggDJx1rp5NV00M7NqNqIzEZS/ngAIQmGyW4Bwef8kA4mb4eaJbW6nwpaHw7rNmqC2u9N8sTKvmco4LhZVJBBWQEZ55IFEXxP0/QrmfT/HU1po+r28UUkmxt0d5G24LJbqpZmyQfkAJUgjLDDHs7PUtPdZJFv4Nm1ZWJlVQF3khsZAx79/fpUVxd6G1xaLPcWk14kWbdmkV3iO0jep3EqSDjcDz0yaAPPPif4z0TxX4QsdM0XUZpo9Z1GztHuLNsSWkf2qDzWkG4NHt3Ih3AHdKg7mvSdO03SoNM/sm20+zTSzGyizSJFjILEbdmce3THHWs7WdI8KXt01zdDTodSY288l3G8aXEiwSxzRqzk7iu6FOpxgHkda1rTULK0WGOW8tlMqvMmZVXcm4ksATyAD1xQBxV98N9Ae10Z/DNgugXthmSx1GxEaywZDHnkiVWycq3BBbJoT4gP4e1J9J+Ik9jpdx5Ms1pqSt5VrfRggcAyHZKuVDR7mPIIbBrrptSsrm80hILqKVpWcgRzB9wEb56HoD1PrjmnSano10tqXurKeEZaNvPRlDr0IO773DYPUbTyMGgDjdZ+Imnr4SFx4V1G21PUdRvG06wFvNG+LiWQ7chmx8oOeRg7euCCX6N8OfDOn2FlFJpcN/PfSE6heXpE8l23kyAs7MzEltzNwcde+M6mm2fhVvEMfiJU0ltYJngW+Lp5hQyngHPPHAOCcHAODzqf27pdzPoqpfWksslyyoq3CMSwikyBhjkjp16mgDkE+E/gyGK2ittJNnOjFor+2uWjuIDhVG2US7wBxgcgAgY9Z7LX73waYrPxjqcc+kS3Ev2bXptsYUh2YwXO0qqvwQrgBWI27c439sdb01GjX7bbq7y+Uqvcpln6FQC3J68eoNVbXU7CS3WKW4tGaS8eMI8ijcTKSoAJGSQVI9QQRnNAHO6V8TfCGsWZvbXxFaR2mnyk3Uss4iAG1guQzZIYng99vrgVX8O6HB4rv4vFXiK0aZJFMWlWd6dwtrVowPMaMnAllyWOdxCFB8p3Z2tYGhXuq6JdajDpV1fWl/5EEziN3gkKMdqsSSrbggxkc7fatUa3aRggXlqT5nlYa4TO8KMry3UHdkexoA4G0+D3g+VnebTJcxXU32Xyr6ZVsx5+9fIAkAi+bso+97dYb/RdT8A/wBm6yut+Idf0eG5I1K2vJTdyJFtfbcRfNuHlggMq53LltuVye907UoBDIJL20Ja+lRSJlx/ruF5P3tvaiW5QCJYryJlW62ErKpCnD8deDkjigDM8OeOPDnia5uYNJ1JpbiICeS3mhmt5REyACTZJtOwgg7sY+Ydzmua1DUtK8e63D4X0+6ttS02K8a+1cwATReWkgMMEhGQC8i7uucREEYbnp/GHhnw94qhQeIbO1v0huC1u7ybSpMYDKGUgkEggrnBxggitDRbPT9Osp7fTzbQWsd2x8qPaiId6nAA4GAMYoA5XUvhD4OudiXGnTPZtemc2KXUy2okZiS4h3lASCASAOBjjpUzfCvRWVTear4muTC4Nozatcl7PIwBGQ2Rg85OTwM8AY6y6dYzDmQY+2KPlI4Jd+v5ircmVW4KyqWDZI3jK/u8fnkd6APOnvdd8Cm5vdb1GbXvC4utt3ctAsd3Yfc2zN5QVZYuMP8AKGXO75hkDrfCvjXwx4rubkeHtctL94dokSKQ7l5bnBxkE9COD+VXIEwmolpEYG8zyVwvKYB9+Kh1jRdMvNasNSvYrf7dYyxi1uCAJIixYFARzhgwBB4PHHFAHRUUUUAFFFFABRRRQAUUUUAFFFFAFTVdNsdXsJbHVbS3vLKUASQXEYdHwcjKng8gGsd/AvhOTTINOk8M6K9hA7SRW72UbRxs33iqkYBOBnHWujooAbFGkMSRxIqRoAqoowFA6ADsKSbHlMSAcA9fpT6CMjB6UAUrIxNZR5RVAhUseoA2+/tS3Ekf2ryzC0jGJyRgbSBs4OeO4/I02WzgdQScAx7VAOOO2KW5iVmFuEYxtCwIA7ArgZ/E96AJGkjExQxDfhTk47tj+fNQQT79OH7pUxbq3l7gw5U/LnPt7VYgkQhBGpwFAA3A4GcevtUETBId5QgNCCCSAOmT/F9PT60ARTzsbgFUwUt5MKcc/wCrPr7+o/rViaQmYgD5hjsP74H97/P6VXlkBvI4TG3lyW0jlsfKdvl45zgfePcZwfTNSqsEcyjyvLbbtwzjOC2P73f/ADzxQBDZOI7OBIhuh+yxhBnP8Lf7XsPT6ntSvJJGvbdsjcbK4OD1B2xd938mH171d06YPp1nk7i9rGQTgZyhPTI/u+n9cV75vLvLaXbgLZ3DY+Xn/VnqWHv3A9+hoAkjvYbuQ3FlKssSmWAshIAeOby2X74GQysOnY89i3QzL9ggL52G2jGHHzZ+fd/F9Ow6dT/DgfDvdHol4ibtv9qasM7hnjUpxx8w9T2/Hsei0/zTbwxs4RBbrypxyQ+cZIORheqjvyf4QCNkd1jberK1ucckFjszkHee/PUH3PWrNzBIzOpbarI2OWGPuAdJB/tdMdeo53UJGkZ7U+bl2tnZBuGGOwHj5sd/UcHqetWJ7W6Mbqk7bjE6qSSehXGfnHPLZ6duR3AF02JzbLsiwDt6H/pqc9GHb2/PpQlvtELMGWR4AoO4naQhzj5zjr1BBOOWPBEWjwymzRBNIymMDIkyfvkE5yOcDrjr69KSWK4IsmLtlYTuG7qShP8AePfHfp3NADPE96mkadFdSI8qSy29mFViMNPPDCrffHQvn164Iyc6FjHCWQjIUBgAXOM727Zx+lc58QNMvrzRNPisUluCl7p8jKoLNhL62cscN0Ch2PsucjHO/psTtDCzM7KrOmT1++wyf8aAEuLZDJprqrP5WSGBJ2/unG7r3yR1z796sRpFhNwZvkbOC2B0z3/I/XHU1nyWzw3Gihp5ctIQylmAP7pzjbn1HT0rUjt0Vok+YhSx+6efqfTn8cD0oApadDbooXaqgTzlUjJAyZmOcA469eKiktojJopjIJjuSdzMxJP2eUcZJPf19abp9rG1rEIZWdUuZhvVSWJ81s5b6g5PrzUj2qQzaQu+Q4uWKg5GCYnPQ/TH0JFAFpViAIzJvD4JJc5b5eg3dPb3PvmvpiRpZkoqrm9m7tjJnfJ+pP8AnGKsSWce4sN+RMHGFYg9M59f/rVFZ26SQPvMij7U7hUzgESMAe/Xqffk0AR3Hltc2e5EPlXO8s24gfun5BPfH9asyyQr5xEZYq+3ktz8q9OOnP8AP3qtdpbwm3iZHdWucjcpyP3TNgccjAIwM8EirbQxIJ9sbEmTI+VuuBznH4cccYoAraYsQtZ/kGReyN8o5yZiM9Pzpt3ZW88kEU8Skw3KyrlQwL7Wwc4HY9eal01lWC4wCx+1PyoY9ZSPQ9O/Yd8DmpLqaMPGWRh+8VoztYEttY4IwPQ9MnnpQA2aGLZcr9nQYlyoWMHcdgOfu9ck+v17CpY20QhvAbeP5r9pDhAcnzByeDz1/wAR1Go74SchWYhscoRn5c/3Tng4zz6deKp2Tl0uVAOBdtn5D2cD0P1z/wDroAq6hZxSTHzbVHDXCOMBR82XwxzHzxjuf6tZvLCKW0uBLbRSZIcDy1Y5C5zjyzzn2P8ASjURJIw25AWaN0PTnLZH3fb369PWeX7QEum3sAV4AUkg4zwNnPXHfp65AAKFrZiZ9QQxRhTc8DapGBt9UPv/APW6ia5sI1uWkht1DPNC7MqKCxDnJJ29gB3PQdOpfbCWM3oAZS0wIbaW3H5QW4B/L27datido5CZN5UlFUbehJI9B6Z69+nTIBbooooAKKKKACiiigAooooAKKKKACiua+IWox6Z4eE8/iIeHIjcQo1+Yo5CoLjKDzAUUsMrvYELnJHFfNOofGfxibUWsWttaI97fW9lqksVrsl8uSLYJ5NhhZUjZ2LQg7iUA65IB9d0jkhGKAFscA+tcZ4X8Ua7qeneG5rnwxdPHqNhbXN1fQzQpDBJJGGdfLeTzcKT6E/WuykcIjMwYgDPygk/kOTQBQeYqi+ZGUxCzBEc5XjoQD6UyT/j6gkeL995EgLiVsD5lyuP97H0wae2pRNcGIQXDEKzbmtpduBkcNsxzjpnpg81ROsQNqFsBDdfPayyhWs5Qcbl6jZkHjpjOSPUZANGH7SMsFTPlgbWdzhs+/brz1qnbTSS2ETWsaC1NqrIWdlOCvHTpx3HSlttaiaNZHi1EqYPOwbGbd16EeWDu6fL19u9UdK1iNdKtQ0F4cWUbnyrOV0+50UiMhuvQE/4gGoZZA4EqIP9HZg+9hjG3dz6cjn2qWWWYXIEaArjklm67sD2+tZdxq4F9AEguyGspJlBs5uMmMBTiM7W+9lcEjg4GQKv/wBrQqMtBeeWY/N4s5i3XOMBOvt19qAItNuWksrPy4Vihe1RggdsoCrED8hjND3TJcWvmxIXFvK+UdiRgKSB65yOTzVDRNZR9Msi9tfB2sYpD/osrD7p43bCCenGT9PVLjXITf2+y3vgws5pQhsplLY8sYwY8k54wAe3HIFAF6OSW1JSGC3iB3uUTKqZGkyzY75ZiSe+TTrKXy7OBbEL5XlLtWR+mc4ycezZPsPesTwf4nk1axuJryC4aWK7vow4sph+7ivJYkXiMjcEjGRndnqPS5BrENnZ7mt9RdUtom/d2M8hPJJxtjILYI4BJ7YHcAvTXE0kqOEG0QlldXOQSoJyMY6dPeppXvfNYhU3JGQNuTknaT2+mPxrMl1dftKW5julkkjCqWtZVG5lx94xAcHrw2ByQBU93qSl7gCK8JSInP2OU5yExj9ycng8DP0P8IBNYS3Sr8kSCMfKBvLAHcR6e/5Y4qB3v1ETMsQWKHcASQSdh4xt9qgttYt286WKK9MSKrHbZTHOJMkAeUcnGOASc9l61XuNZQXVl5sd9ue3L8WcxLnyzkEeUOeRxgnr8ooA2YZL1ki84BXNuzHyTkBuOOV68rj/AIFnoKqWMty6QBBF96Qk7sjd5jADO3p+RrnviFreNC09oE1GItf6a4b7HMh2m/tgVP7vgkbht6nptOeNrRtYRY7SNob1vOMsgcWcpCjzGOGKoVU4PQsD1GAc0AWruWUXmlFhCVklc/fwR+6bHGP7oP4+1TQm5byWQQBt7hwDgYyuP4eTnHp+PFZ8+vQpdaEHhvgbiVk4sZj0iY8/uxjn2HHPAzjRttTSeeBUt7pRM7Ab7WVMYwctmMBeAepHOACewBVs2DxW7Q4CC8kVzuDHd5r7sEg8bg3fpjvU0rNstyEV8TnByOR5TdQBgnb29fas/SNZge0QRQXuDfzJxZTAD99IcnEZGMd8gZ4JBzVm51qFprTFnfYW6MX/AB5zDnyX5wUBK54yAfX1wATzgbZc+XgXAPAUgYZODleuce/v0w+EpHFIELNm4O3cVb5jM3X0G7I9gBjBzSy6jbeVLmG7bEwUj7LN6g9kzj6ce9Mt9VtzFK32e4ZUuDHxaysSd55GEORz1HGc5xigCK+EsDFYtiqZDnaACy+U5wRt6455zz7VZvnnK3KKkTNlSrSDKg/LkdPcYqvfa5bwzSo1rf5SQJvSymIYlDz9z5gO+3djqeAanvdUigSVmgumwVPyWsznBIHQRnng5HOOPWgBu14WuIwsTKZUkUv/AHmlOAeOzZ/QjmkllljhZQlujIV8oKcAHaxyePrTY9XhWO6dra8IhkwVFpK2fnPKhUOeCOmeeu3rUU+tQqkhWyviBtGfsU/HB5AMefQcAn2oAuXUxSK7/wCPVWUgyHg4O1c598FevbFJbF1N0itBGvnbhv7sX59OvQe5pt1qVusN0TbXJ2ld221mO7dgdkOffAOABnHaG11a3Ml6DDeN5LlmP2SbnnOFwmGI9ASc8ECgC5LOW3q0iHYqyKwxtbgk/UcH07U6ecLaXJQRY2bvmO0H5RnP4EVVudYto9++3viEjD7Vspm3DHTGzk89Bk9eOKdNqsJW5X7Pefu4gTizn+YMBgD93yfUDJHcdcAE7TtHHMjpG0udwGcr1A+vX2qG5u7w39nFFDC0DPG0rNnKqVfpnvuUfhVeLXIN1wRa3xKEMf8AQpiSCRwMIefbqO4HWtC0vop7hIxBMjmMPuaCRAPbLKB36devAwaAL9FFFABRRRQAUUUUAFFFFABRRRQBjeLry8sdDlk07R/7ZuWZYxaNKsSMGOCXdgQFA5JwenSvF7345aQnhqBU8HR3VzFPIGsY542tyiTLD5tvJsxPueQBdi84fkbefXfiLo+ma74N1Kw1/UrjTNKkjzc3MFwICsY5YFyCNpHBB4IOK8x8Q/Dn4daXoHh5td8VahafZ9w07VJdTSOYwuAPKRgoURAMMYAC7uCNxyAen6V428OakmkiPWbCG71S2iurWynuY0uHSRQyfuyd2SD2roZf9U+emDVTS9MstM0+zs7C3jitbSFIIFHOyNFCqATzwAB1qxcvEkR+0NGqORH87ABixwF/EkD8aAKsG02EJVGceQCTtOT8v0qObyl1mAorCX7PNgBcDG+PP45/OgRW0FvGrQRORBgjCkgKM455/OnSxWqSqvlYUxvlVjG0jcBzxjPJx7E+9AEtnGgcYh8sBBgbMY+Y+w/yfxqvaiFNHhAUTpHargmPO4bD0wD1HYZ6/m1LmwCm6uPIjjSHmSXYoVdxHLdhkfSqdnLpUGkafNcvZB7m1jSORzHmbK5ADdGz1x0oA0ZHj81cQqX8h/3ZUjcP3eRjGT2HT/Cpyyfa9iwgnbnJXH8f09eev+NUJYbWK8j8qBFH2WTKLGoDAGPGe3GePqatGC3iUKLaNYQBEAFUKAWxtxjpQBHp0qy20DEBy1tE+9Yzg5VunH14yevvzBcTo0sKNCTF9mlZhsJyNqcbdvPBxjB6dO1R2moWaaRbXt00MMRs4maWRlARWUnljjjiqt5q2iQWa3tzcabHayQMY7h5I1jZQitwxO1h3644/IAf4b019Esri1utk0j317dqURiNk928yjO3qBIoI9QcdM1pWUihN23epjjG7bnOWYdh2+v5dTFDdWdxHJPYxQTQKz2pZFXlo5PLZOSPusGGP9mjTZYnty3lof3KKchcEFmX6446Hj070AJMNxWRQRmIkjyP+mfHbnvxg+mKsTuB56KrH5SeIic4Cei9ef8AOOM7Ubq3t4nvLpIFRLcyO7qgAUICASTjG7GMkDPeoW1/QG01tTS6042RBi875MMyhcIRnORzx6c+mQDUtJUK4Cq4DD5gu7nzSOoGOOvXjrx1qtcOvm2REBUGIkjyyRjy24PyjOOmMd+gzWfbeI/Driwjub/TJJNRSNIA0kZM4Z2VAOckEqQOxIwOeKvNHBuspRHH5bQ5+6ilhsJ6Ac/TpQBLqmlWer21tb3Ubqkc0VyPLjKnfDPFKvVehaNcjuPzEmmm28iA28bBTK6jjdzvfPIB7g96pa9qdlo9rZ3MlsJI2uIbUABBsM1xFCD04wZcnHbPcisTR/F/g2awgv49W0yUQzSRpKuwsPnYYUY3Y46rwQKAOolaHztJAi2pvIQCMgD9yx6EDtkdPb2q5GkQm3CLBBYA+XjHK+30/LvjjkJPEnhWL+wZotS0xI7mbZGQ8asx8tj0HoQD0GDzxxXVwLbJcDEUaybn2ttXOcgE8Dvn/GgBtrHb+WPLXf8Av5Du2Zw3mMT2PRs1HeCIzW+UC5mO4bMb/wBw/GCPm49M9PwDLC1tZBuMGZPtMsm54lDZ8xhnnn6H0xWBP4i8KkSf8TTSvItrsm4y8eFYQsd2AOTn689PYA62WKHy5MocGQMcR55yOcY56Dn2qFPIcuXUFtwJZE3ZHmNtGceufpntnnn/APhIvCUukz6idS0w2UtwI2kby+XDAbSMZJBPQgnnNa1pHZ3EB+eKaKbYdyqrpIC7kdjkHJ749MdaALEn2ZGcFSA7BSPK+/8AuzxjHPA6c+ntT5YojHcgx7w0gLBoyQfu/wCzz0Hr0/Kpd2FnOJQYY9pYFzsQZHlnBIxg464YEUtx/ZTTXtp5tmtyAJZ4v3e9U4+ZgQfl9yD1PPoAWLO2hiWYgBy8xY/LnB8xiO3Yk/T26065WBk8vDKDgNiPBYFTxjHPGeP07Vh6XqXh/U9Ovr6G/wBOurISkSzB42RcSEYYkfhz2xj1qyZNN1SwjurSWG7tJtpjljWN0cbW6HGOo75wR07UAassMBjuFZDiT5mAj64Cj056D1/TAYmyQy7x8wlAyBno+QM49f59utRyQxKL44UOxAY7U5AVcZ+XtnvnqfYBiQWzzXXCOZCI5AwU5G/BU5B47Yz9MdaAJrhISD5m7cyoCSmSeGwOnJ6+v0qQxwFJAUbDKQf3XbC+3049vbjNE2lakbu3gubO4mtkT7QgMbtFwfvDHB+XuMfL04pxuNGutNubv7RZTWqxkTS5iZFCgZDHGOMd+n5YANErEZT8m8HB3bM5+b1x/X396WN4d8SKuxiqkAoVyMNgcgdMHjt6CqyGyvApXyJ4Hj2qV2OjIXxgdeO3pQFhju7HyYwoZQqkKB8uxzjgf/W9KANOiiigAooooAKKKKACvm7wJZ+LNZ+Ieu6lpc+ofZdM8W6hHdXMuqOYZLZcYtFtyxHVgQ2ABnrwMfSNFAHzl4Z+LWvXM1tJfatFdSz6XqN7e6fa6ePN06WH7kQUkMxHXDEE+oBzXU/Ajx5rHizW9esdVv7bULa2t7a5tp4wm4eZv3KxQBSRtHAHByMmvQNC8EaBoervqmn2cv8AaDRmIT3F1NcMiE5Kp5jtsGQOFwK6SgDnfiLpl9rfgbW9K0qCznvL61e2jW7kKRrvG3cSFY/LncBjkgDI6jxDxh8GvGGuaZ4ZVZtKJs9BTQ76xe8kEcnlMGilWTys4Z1jZlAU4jChjnI+ka+cv2mPHHirw34psLDRdSudKsZdO+0QXCKqxvcq7syOxRi52RqqxjblpQScDBAPVfD3gBtKuNCuZPEmvSvplhBZNapdslpMYowhkaHnlup59K6rW9NtNX0u4sNRgW4tZ12uhH4gjuCCAQRyDgiuV8Pa/wCMrq+0aHU/CUcVhc2MMt3fi/RTBO0QaRPIILYDkr1rtpGCoxIB4PHrQB5rc+CodBW31Hwir/2zCC9z9vvD/p8ewBkuJCWIbAG1wp2lfQmpZ/EnifR72Cz1bSrXV7u6tJJLc6TvigEodA6TNIWEajcCJCeRuG0HaG7Nb4RW4UoNi24clDwOOnX8fpTLqcG4W5WFwUtXOCSG5KHbx34559KAOQt9N1/xTq9kPFVlpNpo9ihuFsbS7+2C4uCzKryFkT5UAYhcEEsCTlQAuheAPC1vEGWyN3bizVYFvJfNS3jdSSsKl/3YOCeMcng4HHYpfu0mTby/6pZMdOS2NuM4zUUN46WLgrNLIlqjFwc7jt69sfX2PpQBwt94JOj+XfeGbu7m1u2gkYPqF40iX6ARgwzMWPylThTxsIDc45021Lxnpt15l9puj6sJwVjhsH+zvavvO3zHllO+POAWVQwJ4RvujqTcS/anwoLxwttJPHIjPJ+v6VJ9vZrgr5Uq4jVsHjqemPXt9eKAOH8PaBf6vpWjXPim6sbi1t7SOVNIt4Ntv5mPkaQu5aTaNwAOFJO7GVGHXHgrw1/act22j2Lp9kmPkSqrQxh1QyBUMmxNwA/u9znBzXV6Xf3B0q3eWFlkNlC7Jk7gxByMHHPTHrg+lNu73ber+7kMkdtIyvn5TlY+/wBSCT2oA8v8J+BtNGhajPoe7Sdat9T1COyvoZMmFY9QlUIUaUBkIwpBAyN3OSCeqsL3xjp2k2832fRtXYoN9rbKbMqWZtjK0krZAIO4EAkNlSSuw9Ys6x+YltbPAm0zeWq7CWZwzHA43bmYk+p96TT9QzDEPJmJeFWyB8vc+vHf8vagDjYtL1fXJdPuPG11py29vGbwaXZRDyd/l/L50jSEv5eTgjYpPPOBjqW8P6NHrr69/ZNsdWMTBrlFUOT8mSCWAydqjPXC4J6ZmmuRNcWpSSNXNvIyky8cqOc5zjvn0Oasy3atcrhJVfyHbaXIzgrkAA9eMZ7ZHqaAOZ0/wZ4Vksb+0i0WxVNSiKzuqKGbMjsOchhhwWGAMHkcjjF/4R3xTpsWnXVn4wn1SaOA7bfVra38mZPLbhpIsOGA/j3HJxkkZrudElWOwt9+VfZnyy5Dcs+BtzjP+e1RyXG670hyk5Rkclw+VwEPOcnr1zn3oA8+8ceG/EOt+H7TTtS1Gz1K0vby0F/b29mI3WIXlv5ggdZcqoHzEsHOFPzLxXc6LpOkwXNrffYLOLUF8y3jmEaK4TzHIRT1AHJwK27aVJWgdd+GDfKXORyDyM9sY9s47mqunXEUkUIj3EmV+Q5C8OwPcc5z27e1AGbcaD4euLxLubTbN5tRLiSURITcBoWBDMOoKZHXBrCtPBkmnfZF0HxVrMVxbFxax3Nys9v5a4AieLILpyozneAMBlJBrr7ib5tMbKH94wbJ3f8ALJuVJ/PORxzSrebnhO2QliyhQSCRwc43dO2eeSPU0AcYNG8W3lrMk3ipYJLyWaF4VsI0W3XzSpeA7/MDkdGZnAznbnAG8nhXw4kGlqNNtnOlkC0JRGaLER4z2ypY845OfQ1o6TPutAZ98btdT4UsRn98xA6j6Y/nTbueIy25EjYW4IJ3Fv8Ali3T5uODu7cc+9AFY+HdAXWLvWDp1kNTd/La42JvJJAznPX7o5wTjHtXODwO1lHcf2B4k1nToUdfsVoJI2t7X943yBG+9GT0UnheEx27lirwzkyMAHB4kYYII+X7wwTjpwOffmG2kAicNPI7q4OWY5bLtgAbh9PwxyKAOUu7bxhFYLf3Or6Zc3sXzfYEthBZOoRiRvLNIhK5G8sVBIO0ig+ANGmtJ7jxElrqWpyT+fdXjxIuZG25UZPCAbVVGJ4UZyeT1t20TD5ptpWTGdxGzMbDP3umCT29fenF4la8BeQnzBuIkOFJC8fe46Dpjr05OQDmp/Bfhm6vVubjTLMSwSxtGzQxrhhI2z5eAcN0yD1wORgZ+ufD3SJL2e60/Utb0MysHeHS777PCr7G+cxj5d2M5J4Pv1rs4She4LyNkSquN5HSQ4xgjgk498YORwIr3Y5UCZsLIu7bKRtHltz97gc9Rj1z3oA5KW28ZwWGpD+19BnktgEjM0JT7YQqHfOwbERIKrhVwCN3RgorxeF9Q8TXc954nvLjTmGFh0zTLzKWz+ZzKZSEZ3OMfdCgEgZJNd9cMohuMO4UnBYM3ycAf3uOmeMdfc5iUx7p2dmG1wdocjJ35HAYdTx056cjigDktR+H3hO6tLaJNMFtDHGqkWTCISxlT8kpRhvQgNnccHPXjNSz/DvwtJe/aRYJFAYB51nE4S2mKBNryRA7WZQAATwOc9a6hpoo5HWSSX5YkP3jwMHk5bjgnng/KeTillli/fbXZR5ZYs0jY5Cf7XYY9OvvyAcg3gq6hvLiPw/4r1LR7F3eaKyggt2WF2bkKXUts35bZwvJ9an8OXPi2XUdIXXLPRbS0WNY5Psk0kzzt5TnzFPCxpkYCkPnP3uOeutWSFMFmL/McbvVjxj17VE6o9xpbeYDtO5T5mQ37thxyc9Sf17UAaVFFFABRRRQAUUUUAFFFFABTZHWKN5JGCogLMxOAAOpp1FAHC6p8S9FPgvXvEHhaa38QjR4fOmgtrgJxjPLEcfKGPQng4BPFcf8QPjjZ+HbfR2ttBGpS3ukw6wIpbnyj5crYVIwI3LuAJGbIUBUzkkgV6h4x8OWnizw5eaJqUt1FZ3YCym2l8tyoIOM+hxgjuOK4/U/gt4S1TT9Ftr5dRkfSbU2MFyLtkma2II8l2XG5MMy47BiBwaAN/R/iH4W1a702yttZtV1HULaK6gspHCzFJIxImV9dpBxXTXTbIHPbofYev8An9KSytYLKzgtLSJIbaCNYoo0GFRFGAoHoABTrjHkvkZBGDxmgDKtJ1j0xVEW0C1Q8bskbOAMKR6DjP8ASn3NwF1IERBnW3kIJJ6Zi4xtJI57Ajj14DIwh09jJCHUW6sp8nPRc/3Tk5xxzTr5oo7zPlAsLeTgISSoMfYKeOfQ/wA8AE/2gm4ZAh2qsbFvnPVyOu3HQZ69+cDBoSdltgxBx5SEcHuDx90/1/Du24ESzOiQKA3lBj5J+YGTbg/Lzx+XXgc1Uin8zTS5iaUMgU5TdnG4E/dOenT6dO4A+5umS4mVYTu8qQjO8fwR9PkzjJxwG5HrwLVxcsXYJGDtZDuG/pvHfYe3P+A5FO4cNLMxts7YHzmI9hGwGNvPLHjB5z3yKuMitM8bWykMACfL4K78YPy46ds/40AVtIuANMtt5ZmFnExOcnO05xgYz9PUe2YJ7hWljOyQgWkrKMPuYbY8/wAOc9uAT178Umk+S+lWbbFleSyi/eLFndlGPUKf7vTPp6jLmVFvLNGjZUazlDqsf3gBH1G3JI3NgY7njtQBR8J6xLq9jPNcsrzJfX8C7WZR5cN7JEnQEfcRec9jx1IveH3to9KshE37r7OmwlyBgb/TI/XuPbNXwn4eh0iyltrm2t5DJd30wKw8COa7klVDleyyAenBxkc1a0SK1fTbFREsh8hQGERwVIbjO3GPl/l6gEAS8mjSfT9kZZBbSkYLE42DvjdnjHTPtnitL7VD5iKOWZHcH5ugYZ5x36/hxx0zLiOFbnTo/KdAbeUFUjIwAi8Abeep4x17Vdazs1mQraKpWORAywYwNwG0Hb05PHpnqOaAItEkgNpbbTxtLAsTjG5+f7v4/wD1qS5a2Z9Ldt4+RyigsDjyzkEHnP65qHw7FBLY2paLzD5bJuaL+Es4x0Ixx0z6cdMuvbeI3OkOIRtVJOqcgeWe2M59sZ9qAMn4h3ccWi2HkSyoz6rpwDKzDKnUbYMM+4J+ozjIzW3pDwmzhba8R82QhQWVeJH644PUnmoNT0DTdWgtILmBlignjuIwkW3Y0U8cqjleBuQZ6ZBb6h2lRQyW9s5R3xLIFLLnGHcdQpxwMdRwBQBNJJGZ9JDKctIQMKTz5LZ+9z04/Q85qzHJD9phwZATvAzvxncvHpj0+nHeqckMMc+loiyKvmEKNpX/AJYsemB6Z/3vfirMNraxyx5twdpcoTCTt5HT5eOv8+vOACDTJ7drVfLk3brubHDdfOfPT3/zio7uCKSex2ylVW5LFSH3f8e7rjk5B5H5etPsdOtYooikESmO6lKCOMELmRvQcdvy9qLm1iVrP92NzzklvL+YnynOW4yeRn6gelAF1vs487fKwxIGIV2BByD0z6j6Yz2zUFm0SxOuSCGycZ4zIxycH/P5US2EbJdEIoaSUE4j+9yuc8c5GR6YJ96jGnxeZK2A+8qGYpkkB34yBzxgfgOlADroQqZA87bpGwcM/B8ojgZ/ljn3qzIYV+0bnYZcFh82c/LjHPTjt/jWdfWatJIVjz+83MTFy+IWx25OcH61cuNOt3W5Z41Yu4JzEG6BcY45xg+vU0AJH5IilKybAJwCTkAESE44P+e/HFRXqL8xjcBNygkl/lGxh6+46YP44psNhFLFdJNGro8+Spj3AjzT149MA+wpbuwhkQpJkhymVK8OQp6gj5umceoFAFpzGqXa+ad5YAj5mP3VGAM57dsd++ait0VnuGO9B5wPGRnD5ByDj/63XI4p09lAFu5BGFZnDZSLJ4C4PAySO2M0yCFZTcLlgvmgbQvGFfPp+H0/OgB8sUbSHLHcIwD94H7rdec/lz79KdM8CqdzttELBghb/Z9DnPH16+9QfZ1WRid5aWFULCM5OFbk8Zz049hTrrT7VyzGDKtAyE+Vk4+XAxt578e549ABbARxqA5K8swwzc5kY5yOCP6e1CpCLjTgju2zG0OSSMI4zyc55Oe/TPam2trHJKhkQMoQqMoTgb+mcY6ADGelTJb28dxaHYqOoCx7V2/wtkdOmO1AGhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTJlLJw23rn06Gn1FcLv2DKj5j1+h6UAU7WNPKtonCbzGA7BR8+FHB4wRzTWVP7Ut497GTy5Wx8vKhowQfl6dPfipYIFh+zr5q4VSF6AkbQOBj0Gazk8r+2bIfJ5hiuGMiup2/voyU6c/NgHvkfjQBpskLSxn5WZ8LuKjPG5genYjP4ZrL0p4jptgxdjI1qshVtpySpYclc8c4q7ZpDC1usLrKBkAhlz/EeB75PT0+tZmi/Z5vDOjyXDxIzWCbvnXp5XXnrxk/TrQBcO1tQt4mneRWtZywKpzgxD+7jjNWlEDTRkfM+0KX2LlsMevHqCeO9Upnsv7TtI2kUB7W4wmR93fFuO4ccHaPX5h2BxYt/s5njCfIQWYJuQn7zejHuSPw7UAU9GktjoekY+dHtlGHUfd8okAkjsMj8TT5DA15aDEawC2nUrtHKgRg8YxjGOMdhTNENtFoOjRpKrKYEWNy6fvMRHkZIz8uW9cA5AqZ5LY6vYKHjYGCcNyDj/V5yeg7cZ7igB9neWV20clo0cm2SaAyKq8ukxjkHTqJFOcdxUWiywXGm6bMsMcavEGVeGK5V8YY89N35n3rI+Hhi/sS63D96NZ1YqNwyR/aVx2J/CtnQ5LddM03yzhfJDKzsuTw2B1HONx6Y+U0ARytapcaYsiRtvt5QE2ABgEXIwOOmB6VfbyXlj/cxY/eKcovTeAeewzgn6VmTTQS3WlSlXVGt5mH3CCuxeSwYqOMEc4rVE0HnxgR/ORJgeYuRhxn+L+9j6ZAOOlAFTSPsQS1FvBErYIVsZYDMnGTz13fmabOYHutIZoUCKH2YThF8vpwcAY471D4bvoJbDThHEsQlLFQZUbHL8D5gSThugPQ/WrLtA9xpwWXAXcsYUgq42dc7um35vpQBV1jVbbSdPgu5LeKVnvIbNVSMA/vrmOHcOeAGdGPrirenIkdtbiSCAv5z4KRkBSWf5huJI7/nxWJ41E+o6NZxQWsvnDVtPlMeVLBI9Qt2dsKx4UAknt7Vs6TdLNZQFYmIa4kHLLxh25+965Hfp0oAPtNqWsAIo9kshEZUYCjyS3Qdfk4qbEYkiHkwhUdlJMa5OWUcc8ckHofu1XuZ1N3pLbCQbhgpVlxjyW+bhiMY5+nv1ti6QzxK0RUsWCkun95f9vnkjoPy7gDLeSARxrHDGF89xgoF+fewLAE/3gTn3pFaMRozQQqDJ8o2DCjyyecH+7lc+/TFLp91I9tkxOSbmVDgrwBIwH8Xtj8DxUd8zt9lIhkby5yGRSMxr5TjLfNjHPqOo70AWJIiIpcWsWWmB+4CG5GGPPJ6H1+X6VCHV0kmS3g3MiEExjJ+ZsZyQTg5I6fe+tWN7osp8s/f3A8Y+n3uvHt1HFRxXDJ5qmJwFiUqCy7iSW4zu9uMgfU9gCPCmOdhb2wh2hnUoOnl98HDcfL24qR1US3IihgMjEFh5Yy7YUbjzzxtHP8Ad+lMnnliWRhbuU2As+5MH5Txy/bqeR9TU0k0gMxSFwRg4JU5PH+2O3rj/EArW6ALdJGsDOzCRW8snBMjYJy2ThgSBwB2pZ4UljnKRQo0ao4AQZ4U/KcMAeCQM8c96sJjLiMKpLgsG7fvDnv35x9O/SmTS4VYlc+Y4Cqc5zlTyPm49c8dO9ADyhLzgRRAHrujB3fKuc888cc/3fpUYWR3ndkhJ3KiMUBIw3clux5A7duasPHMUnEci7j9zO44OB/tD0Pp1+uYoQzNLsR8CUZ+YEffye4x/nr0oASWBfNZytuY/KwsZQDjB4JzyMZHYDNPMKmQCVIHiaFgV8sf7ORyehGOOnA9qf5TBhgsdqDA6jOMcgn/ADjrRNbyuzFJQuUZR97gnbjofY/n9cgALSMOcQxY24BZMnO7d1z0zzio5I50urcWkVsIRtEoJKOiANjbjIbnAwcDknPapQJg7mRsooz8qnJ+Ynjn04xipIYvLbJdmbYqnJPbPP45oAlooooAKKKKACiiigAoorkviv4tfwL4A1TxHFaLevZeViBpNgffKkf3sHGN+enagDraK8bt/jNN/wAI3q97Jo1rd3lrqUOlWTadfedZ380oG3ZMUXAX+Lg9vXj0bwnceJJoLhfFdhptrcIw8p9PuWmjkUjn7yqQQePQ9qAN6iiigAqK4BKDGe/A78Gpajn/AIBuK8nkZ9DQBQ014vsdrG11G0zRhSA5BZgoBwM9sdO1QHa+s2s4kAQRSxhiepaSNgAc9wOB3H5VZtzCsVt5juzhPvjdgnAyeOOa4LWZJfGXjF9F02/urDRNM3Rarc2jPHNcTF0YWkcgIKADY0jLzhlRSNxwAd9bz2jiB47lXGSFbziwON2f4jnHOevT24q2NzZx6bp8auEDW48tUlIGAmMDLZOMfX8a4HwZpFh4I+IMOhaJZLZ6JrNibyKAPKdtxB+7lPzcco8PU8kEnnFd1pDwJommxJFK2LVAhwx6RA8kf5z70AQPdWTeJtLCzn97aXezEuQ372DPzZ/Iegb0rQt7qINbjeVaSRgAZCd3zNnHzc/4fkImW3OsWTkP5iwzoqEHoZYQTyM9Qvtg1yWta7qGueI08M+E5ls/szBtU1UoZWswzHbDEjKV85gM5fhFIODlRQB1+lSRJpmlxi4jbbGsZZZDhsR4OOee3X+dQ4hutasbmKWV444bhF8s7lcM0XJfPHTj159K5D4aJPot1/wj17qV9qUS2ltqVlc3UzyOyPEUlj3n76pJGHz0Xz0GBhc9ms6/21YxhWA8qfpuI4aIe3r6f1oAltHtrdFW2EccbzSNtRuCzSFmPXqdxb8ah0DYujaYiOCiqASr8YCkfzI698e1U/CWpzajpklxdjdIup31qpTcAFivJYk4HH3EXrXNf2jqHiCS38N+G726s7W0jQaprEa/vYy8bMtvFlWUSkbWZjwgZcZZhtAOxvFU32mXBd8LFLt2uSrZRerevHHNaEci7lPz4zIPvE9HHv8A/qGfpXmGgaBZ+BPiXp9lozTxaZ4itLmae0muZZi13FsYzFpCW3MkhB9cA4yK9O+0ESIPLIyzDI3Y++B/dxz1/lkc0AZfhVFtNJsIVhkh3bgIyfujc5Jx+XPuKbcTSNq+hZDFgZfMCnOP3POfx4q9pjlLKyXBYs5BIDYx8x7j2747e2cTxP4ktPDFha6lqf2gQiTy0hRS01zK0Y2RIhClpGbgD1znHOADoobgMCe/msgw3H3gPWqujCODToI4bhJUaeX5y2MkyOSB64PH4V5d8Qb7xBpnhRPF/iTUbnTLKzv7G5l0SxWN1SFbyHesshXc8pB/hZVG3b8w3M3qOj2/2Owht1jVALiU4BJHMjknkH69uvagCSXzWnsZFB2JKfMycn/VEce+7AqwJmWULt+8zAAkkn5h05+p/Cqs9w32q1PzIomb5fm+f9yW4GBnk+/Q9+BNeXsVpBNc3kiwW0AeSSaTKrGi4LMSVwBjJz0wDz3ABX0y4uPsxW5jjjn+1SqUVv4fNfB69Sm1vxqxdTypPZomAsk+wjrhfKcjd6fMB+leZy+MvE+oeHpfEfhjSre28O2hkvANQic3OpxCVmcwopzEpjDlWcFmJX5QOT6El+t9Y2N7arMUnxMnBGA0DMO34dDz2oA1XkCbi7IqgjktjHTrVWACCLapIiWFCpPGTk54/LNSM7uZF5ADjBJweo6Db09+abbysYgrq2BAjEspAyc57Yzx0yfw7gDlMkgkJYKdoYegJXsac8rnzBGOnQjnPT/E/lXn934t1bxSl5ZfD1FeIK0Z8RT4a1gYDDeSmM3Dg56DYDjLHlK3/CWsXuo2moW180L6tpd01ldmFTHHIwCOsighiu6N0bGTgkjJxmgDoEZmJIRgPl499xzUX77PGTIEyA3rt/xqSJpJfnR2KlVIzgc5Oe3pjufw6lGS4aEj5RL5e1jnODjsdvPPt+HagBzJMxmxt5+6G5HRfb1BpkNtIk0paVmDNuAOOPmJ9PT3qj4m1aw0HRbvUNburex0+3jy9xIeAPlxxtOSScAAEk4wCTgY3hrxZDretPaTaRqui3T263NumoQJE9zCsm1mUDLDB27lbDKGQ4GQaAOqeB8EJt+aPYxOMng4ycUrRsxCl8fu2XAx/s89Pr+f5V44DDMjDgmIIqjaAMA8cKD6flwB0qw0e2Z5uCzJhgccgdB0zgZb/vo+2ABVAkfcOD2cDnAbpnHSnQxrG+AxZwiqSQMkDOOQPr/9aq62aM6yBckKY/mC5xnkZxnpx1/xqO41Oz0670+zv76NLy9PlW8TsN8zqpZsAAZ4GSenHagDRooooAKKKKACiiigArn/AB74UsfG/hO+8ParLcw2V55fmPbMqyDZIrjBYEdVHY8ZroKKAPPJ/hH4cltdfsw+oRafrFyl61pFKqR2lwpz51vhd0bEjJ5I7YxxXS+E/Dh8PQXCPrOs6vJMwYzancCV1AGAq7VUAfQcnrW9RQAUUUUAFZGs6zp2n6lpNhqNwbefUJWS2LI2yR1XJTfjaGIzhSQWAbGcGtesTxboOn+JNNTT9X0601G0aTJiuUDBflYblyCQwBOCMH39QDD+IGtjQtIWPT4VfW9RnFhpcPks26dlwHYY+4igux6EJjOeKn8O6Fa6DYaXpFu9xMIFkZpZ3ZpZHMyl5GyuSWcs5bpk5zjBrG0TwCuleILfVHn1W/ltPMgs4tRvlnS2jdlLGMmPcScKuXZm2qBniugQXi3sLtp9un72QbVkTODIG3fd7tweM5Oc55oApeNNHur3SNOvNHV21rSr1b6ziIKJKyhw8LMU+VXjaRNxwAWU9hlfAPiTRPFOkWUukyXCS2scSz2ssLpLbkwqQsisvAKnhs7W/hLVs2rXj/ZXmsVDGViSrocYBCnO3uCemCPXrnlrzwXZ6sukXYtp9H1u2ijjGqWDxxzhVRRtYspEkeBgo4I56egBa8d6xPokFs+m2ouNUuDLbWFsxIM9y0kQXOQPkADSMeyoWzgVe8CeGrXwv4fsdPiaS6uBK891dSQlGubhyTJMwI4JYcc8DAyRgnkvD3h3xEPGOlat4suLXWGs4riG1C20VubR3kTdLgFt7twpYYwBwMsTXeW8zAWp/s0BzI3Ro/kGSc9PUnp7mgDi/Fkd5pFn4V8W6bDc3TaZA0N9ZxpvaeyljVpdo2n50MaOBkZ2bc/Nius0m+sb2bR7jT5I7q0mt5pormLLCRcx8jAGc5H/AHyKl0FLr+y9PiudP8p4kCOA6NtxGFGeO4x05/CuLvfBktn4jtLzwjv8N3100z3KR7J7KXmL5pLbIXJ2KN0ZR+ckmgC/eXc3gbwTPtRb7U59Vuxp8LAgS3FzeytEp3bc48zJ5GQrbc8GtX4b6JH4b8HaXZxv9quXZp7u6AbNxO4Z5JScHqxPXpwPauW8K6P4g8QavpeueOP7FvW0yeaG0h0nJgjuFlZZJn8wAmRSpQAZAIZs5Ix2ujXN2dJ0tZtPjeQNtJjmVlHyn5lJ5xjPvjigDnPiNpl3fWel3+kib+2dGmk1G0hC83W1B5kJDKCQ6M6jH8W09iK6fw/q9l4g0uw1XTJTPazF9rCNgQd4VlYFcqQwOQcYK+2RCj3p1bSidNjghPnblDoSq7VC4x7Dn8Otczq/hC5TV01vwvEfDeu3Eh+0vGscltd/Pv8A9IgBAkYkkeYCsgznJxigDtdDKvYWbQJ+63Mfmy20ZfuR6+/f8Dw+mxS+K/iLFrUgxomgTTWWnxGNl866CYnn5UZVCfJXAOCsnQgZzYtT+Ir+H7bSZvDumx312xt4dXsr5GSzZtwaYxShXJVSzKoJzjBNdrplgugado2m6bpfl2NifswjaRCwjWMKrk9ycAnvQBc8V6JZ+I9EfSb+KV7SWWN32qQd0c8bjPynILKCfUZ5xyOX+FHiRrjTYfDWsGQ+ItG/0aYTqwa5gQtHHdISDvVgoy2eHLA44z0Gra7LpdhHdXGkEhtRgsxtkj4865jiDdf7zqfwrK1vw/Br9nYNd2EsGp2125tr60lSO4tdzP8ANHJ7jGVIKtjBBoA6S4m8u5sSUKATtgBDlh5JbAGM8dOAen1A4fVmfx54tl0Vo2k8KaNdK2okKSl9diRSluRt+aOMYd88EkKeFJrO1KP4o2U721lP4WvlDGOK9uYHtZ1l8ojzGRS6NhNp6jPTHaux8LaUPC/h+PSrDTJpkhuBvuZpkeS5kZgzzuWYkszknk5HHYCgDctJHlVhsJAuXGduePMcYzj2/DPbvxHga8bQnuvBl2kiT6RK7acSrsbqxMZaN1yvzlN6xPjdhlHTcK64XFzBHLjThcFZmK4ZADmRzwSRyPfvmsnxx4fg8VaZdWt9pU/mQP5tnd21wsU8cvl8SRSZyjDjk8HoQRQB1JdjLLuixggA7Sc8jB+7+PXt+XCeMXvvFMtt4P064ntVubWK71e7QZaOzYsvlKw43ysjKCM4UOewDRPD8RdJutumT6RrlsF3GPVYxa3J5GP3sOUY9Rny0/x1PA+iXWg6Xez30EN5rmoKLm/vIdoSaTaFREyc+WigIoOOFyeWJIB0VpFFYWa2VlaQ21tFAEggjXCqiqPlC7enOMDP9K4vxdLceDfHH/CTFmPhzU7dLPVTtyLOVGPk3J4PyfOyPyMAq3OOOra5uoFmk/s4hlgLod6DfwoIxuwcYzzjjp3qxdXdwfMjfTC4aFX2s6ENuwGQjdgkevTkdaAH20qPZqbecSIyRNHJGpZCCxwQcEHPX268Dmm3tw8Ecj3MkNvaJCzyNK+1VULlssRgAY5J7c153a+GNd8NqZvAV1LaxNAsn9kai4nsd2SfLjO8PByW+7lBg/L0qK/bxd40W1sfEXhyXR9CSAzahHDqMUjaiRjECFWJWI4y2drMPl9cgFzStLf4gaxB4t1IGfRrbc3h+wmiaNCeB9tkDDl2GTGCPkXDY3E7dr4h2V9FBpuvaXFcTX+izCZ44YvNmuLV/lniQZ5bAWQLzuaJV966WS5uUwkenyACLcB5qDnHK/e7YA9OfrSQSXsJCtZvIBEG+WRR82Sdv3vw6dutAEGlTLqWnW99p15DdWlxbK9u8bAq4KnkHHTp/hxV8wTiMEyc+QykcYDcc/pXnreEtb0+5huvCWpzaIGHnTWFxFHdWcshVt5WPzA8bMzbmKSBSRkhiSSieLvG+nK58QeALuUQoytPo+oRXIlGF+ZIi6ydumCeeCM8gHW6rqen+H9CutT1WdmtbWLc7qcO7B8BVUYyzPgAdycd6yfAeg3DXQ8U+JI4f+Ei1CBV8okP9gg5KW8bewJLEffYkngKBg+HrPWPG+sWGt+IdEvtM0PT5Gm03S7shJHmzn7RcR7uCMkIvOOWPVa9EhFy0tjvgdNq5lLSA7flYAdSc578+5OKANOiiigAooooAKKKKACiiigAooooAKKKKACobkA+WWbaA3p1yCMfrU1RXCllCq20nIHBweDQBTiSFnkaPy33TEkk4+bjI6c9P0qtKgnvICDG0Ku2XLYO8SqwXGPY9vx71ZuFmMw8slxvPHIOPl9/rTJI53u43M5dVJGAhXjzR79gMe/WgC1CqKsQ3quxz8oII7jHQdyKitpIJVDC4QbmKbcrncFClfqCPU0yCB1+zHzD/rdxHzDja3vz2qPTreaKO3SR2BUADJ5/1SjkZ9QeP/10AOMNqs0TCePeXbacjks6uQO38I96nhEMSRrNKisHbapZeuScfXBqrPZyi+t5llBRPMB+Y5+eaNgOvYKR/TtUpiCNblZGI8773mN83LnH3jnr/nHAA+wSNLK0il2CURhSpYZBCgED+VVSLVNRtMTIhLSqqhwQzEocZ9eOnWk06CYWdjsY4AU/eP8AzwAA6+vPP/16ZsMes2alyHZZnxvJ/iiz3/T3oAxfAMsP/CPyFrmNP+J7qpUFlG7GoXB4z7enrXRWj2sFrZrLPHEI2xGJHUEnbjHbnmlhtFto0jgEcUZuZJSFbGWaVnbv1JYn65qvosEkel6ZGXGVPOHI/wCWbD1Geecfj70ATNNp82o2pE8RlLSBArbt5wM8g4HQcH0p63Nk4Ty7iGQiZhlZE4bdlh9R+dRLarHeWnmXBG3fhSzEn5UHXPbH61ZMKAITMUbzSRmQnP7zOPvfQfpjtQBBplxavaWgS5ikKu+DvXORkH8tw/MUj3VnNcwst5E6NKyZSRSC2wDBx39qraNHmx0/dIwxKxCbiCPlk6/NzkHPf6dw+7iU3VqqTbj5j5beW58odeePpkde+eQDM8deTc6BbJZGORv7Z02Rgjg4C38Ejnr/AHVLfQZrbtprZFQvJGjecUOXX7wJ45789OvNSpCzI4aYgCbcAHP/AD03dd34Y/DBHFVraJWiXc+wmVuBIRjmTtuHrnH86AJHvLRHkDzRhBOI93moAp8vAHXvgjB5zn2qSe6s4o5PMmhULOobdKgwxYccnjscdaivrUSsT5hXbIxJLsOTFt454/MfrzKYBtkxKRmdW/1h/wCegOPvcZxjH4Y7UABnsw8nmTRr+8Ctl1Xkk4HXPOfxzxTJruzilukMkCbG/fbpEB5QAd+Ow5x+VO8tYkm824G4k5yxXGWcjjcPX9PySZIpJJFS5TcwbdhySPkXkfN8vGD2659yAWGmg3l5JFCAbt5dduMgjv8Aj+NQ2k1slnFuMcLG3QlS4yFweOfTJ5qwIoRcOySYlJBI8wnjI7Z9sVTsgJdNglecs0lrHy7EEna3zHnqcn8vyAFnubVQsbOvl/Z3LHenC4Xqc4H16cVPLeWyTFzNGAkW8v5iABcjrk5/pVKeFs28qTNxaShQGOeVTBBz/s9cjr171buFVroFrgKoQ8biBw4/2vw/zigBLOezhRI4rqGU+UCAJFyUGTu69OetPlurfzYkkBMrRs6DIyVwM85x6e1VdMtlWwtm85uI0ADMRnbuPQEDv+nsMLI0atbAyFozA/8AGc42j3/XP40AWxdRTLG8TI6vEZFwynKnGD16H/J9W2UxKq0xCsUPJPXDHPftx279akbZ5yYfb8r/AMX+0M9/X/I719GlQ2kKx+YUIOGcjn5m9/agB0d0ZBGwO4vEJFCgEHg55DEfrj3Pad7hduxGV5WQsqqwyfoMj+fbrVFrjebGQMixmIvud+xQnOcn061bnuAqfMG5id96kBeMd8988f0oAlhwVDLvIJI5bPc805cb12vuyP73YZ59+oqC0cDEUPK5LZPpuOfx/CnxyPKYGCjYwDE59Qenr2oAsUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVBeAtDtUuCf7hweBnrn2qeoL1mSBmXAC5LE9lwc49D70AVbuzDIS0s5xIGHlzSjHI4OHGe/t7esZs/ndBLMAZVkObiQn7xBA/ecDAHHTqdvapJba4bz9jHDSAgPyccZxzwOB+tRS20gnl2Fi26Jhz/01c+o45/KgB9zaqrPI0k+A/mHbNIBwucYDjjIHHTtjvT3tQRLmWUAShv9bIPfAO/1J9B2xxUZt5madZXDZfCHpkbCPX0J/GnR285EyzOcM+QEPsOPve3557UAVRZE3cq+fchWZX/1svaQggZfgYABAOO+O1WHsmGUE0oDSh+ZpM9+h8zgZxx09vRzwt5pKM6jeCQxB/5aZ459e3p70eVMvQg5lJy2CQvPv168/p1oAc1szFsSyEGXcD5j8/Lns479sAdsd6ry2ri9hy0mTK0obe/ADKMff6EE8cAnB2nGKdD5zGLEyspkG3aedvljr83Xv+OcY5qBpbj+0bVXlRlMkm4L/dDIMfePcjr2B4zQBS8JXdzq2myXd3IxlTVr6AbXZRthu5oVGN4GNka8YIzzg1o6fas9np8hkk3bxI+JXA+4eMbwMZxxgj27jK8O6Zf6XYrbm4t9r6ne3LEHIIlvJpQB8w5AcA9ea0NKN79h08ZiyZMPxkBfLJA+91/Dr2xzQAC2xrFkXkmyGmIHmOR0Xr859+OPpxzcW3lVIwZGZhM7ZDPjaX4HMn93HqM87R92q0Yc3dmkjsJt0hYqAVPC9Du47dff2qdHuN8SlkGZJC27uN4Ax83qR+HoeKAKXhuF4tL07dHIpDvlTI2BkuT1YZ6DscZOOpw/ysXdj5gl3o7nJmPJ8sEn7zccnjI/HuzQHvJNI01yyhi779ykZGX9x/L0qbfK91phZkeRWcNsPqmRn5jztI/HnpQBi+Onni0O0ZHkT/id6epIkOcHUrdcZ3ngqTxjv0XodzSYo0toSsckR+0SnZ5jY5d+cbu+M9+vSotasX1a1t7a8XbEl7BckLgMTDcRyJj5uhZFJ9s9CRVm1uAUgEY2xGdl5wpPLdiw7g/px6AEEu/7bZhmJKXDANk4/wBRn++eM+uP6m1vZQFIfAmIGXzkb1Gc7/8AaPB/IcAxyXJa4tSSpJmcLtIxjyywz83p9OeenNTpKVYK/lhmlPG4c/MB/e9SP8OgIBVs0jECpmRVFw6AbyOPMcY+8OOOP69o7vdE0ZZpAPPYjDZ8wGBmIJLkgZA9PujtzVqyuXaDMu3d9pkTjC8eYyjqR6e+fSorm4WWa3bKMq3GTtYEAeSxO4g4HHrgdPxALABU3DFmz5wx856cf7fufT6esCEbWSY5UzgLvGP+WrAAfMOgAxx7/N0FyTY8U4UjHmAHkHByPf8AwqOMx7G3sVbzjjLDI/eMB1Pc5/PHNAFO6nL3VvHjBW5CYGDkGJn2/ePGQOOOg+tXXYRsF8sEh8DgcfKD3b6/55MVz9naSzCEYE/QHdkmN+Pbj6VOVheSTMi5WT5vmHXA468cbf596AKmnSolq6lQV+0yIoOOAJdo79s/57x3AtDNbOIo/MNxtZginPDcd8fd/SrVtEhhfyyyKLpmZTjk7/8AHn9KbeRxCaFnJZnuB77cK35d/wA6AHtJHDHK0SRoAxLcKcEoG5+Yf59uaq2Q8uCdI2DKt3tAU42AyAYHIxwT/wDX6VoOIgZHZ8FJMk78YO0e/Hy/4+9R26+THNkq2643YUg4ywHPT/PrQBTnLkqB5io90q8MTxuYEDDnAwB2H07CY2jETANIAsm4Zkfj5M4/1nTd24GOMfxU67nkMjLCFOyRCSWX5Rk5Jy3sfT8cHCzTSFLkF1wGwApGSNuSPvdcfTnnpQBHZQki6G+R/LuCECuw2jjg/MM9Sf8A9QqzbQCG4k5l24BG6RiMksMDLHtjjA/wqqt1It8LZ9rCfC719lzjBGR/9erWz9+7Sq7ElMYxwMnBxn1z+GO4NAFyiiigAooooAKKKKACiivMvjzrV3aeHdO0LSGvv7V168S1T+z/APj5SBf3k7x8jkIpHX+KgD02ivkzVPF+pXHw38J6Xq+o3Flqmk+I/wCytTa8u5bUvGEcoZnjbeFKFckHqpIr2n9njUL3UPhjZnUp7u6mguJ4Fu7iRpBcoJDtkjZgGaPBAUnnigD0qiiigAqrqbvHaOyJvwDkdT90+3rj8M/SrVRXTSJbyGEBpQp2g9M44oArNLMzuEVwRJtBYY4yMkcdMZ/T8IZZmWZ3WGWUCREJKZONzZIwOg9f/wBdW2nYBxsLMJAAPm6ZHPC/X1HHXriBLnE0iksAGUYIIxmRxnpnt9Md8c0ARiWR5pg6ElXKrwByEPOSOAe3P49qZHcyPKFlQkM/38DAG0d9vHOfXgjnsL/mBtzIFAB5Y5B6e465/wA9qjhkRo43kAYS4YEgkn5R2xxQBXW4y/l+SyzGY43pjK71JPT0I59e/eiK+kaWNSsmDNszjjHze3Tp/jVmVwLyCGQt8yu4xns6Y/nTovLKRlgu4sSNqkcjNAEH2qRlV44WYeYV+6f7uAenQnv6flUS3bPcQyFT994wmMkDK8n04z+YqxYNvs7RnLBwil+oydnP161W8xBqcEIdcuZWPzHOQyEDr/n0oAZY6zHexJJahnh+0ywM4U4DJIyMvTqGUr9QabpN4FsdOURzKsjbFGM4ATPP8+PSsj4cp5mhXBD8DWtWOOcZ/tG4Pr6VuaRERpenBt28AE5zx8hHIB9xQAw3skupaey20nlMJQ7suPLIAx9AcHrVuC98wxfupAHLjkHjB7/568VTm3xTWeXURGKRpCcjb8igdTx36n/GpIb2zEsbLfW2wiRgPNHOXBz97pj2/LpQAzSbgJYWi+TKDhn2rnI5bqP8/pUsjJJc6e53jO4gZJP3Kp6FcxGK1RLuKTg52yhj1fr83I5Hb/6135kewLs2MHd9dmOuTjn369z1oAra5rCaPYwXUsUsqzXsFoApI2ma5jhBPPYuDj0BFWrF44be3jXc6vNJtZPu53Mef5fhWH47trq90myjt4ZJWGq2EuIxxsTULd2YjceiKzZx0B+70Nm11jTYIIkl1Owj2TOXWS4XI+d/Vxjt2P09ADWlDmezMfmFPMPmAOeBsIH15x/OpVGHGS+WYkZJ6ZHYt+H4/nk2+sWEk9miahayMZcALOpLHysY4c5OfX/65uLcK90m2QEeY6f6xTk7l4+/6Z4x+A6EAlsAjW+Y18kC4kyCTyfMbPfucn+lJLGSygnG2Q4Jck/6thxzx1z1H+NbT7rbbxjIdpLuZQQyjjzXxwWHYjpn6GqOo6xaWrQGXU7SPzZyPmnVc4gYYGZP72O45I+tAG1IZjHNuUxASjaxf7wyPRuM9O3Xp6ghnRCAd/7zcACRxvLdc+hA/Dv0rLm8SaNscJrmmFzKAALtM9Rx/rB79x9Oxtx38ZWQ3NxFDtkOAZMEgSNj+LuoB6dPXoABbpJna3ljUs/nklQxwB5brkfNjvnjH51NMZykojiff5oCjzO3Gf4v8Pp60JdVAmA8yPPniM/vF+QmNjyA57gDB29fxqzNqUEH2l5LqCMJLtBeRQOVXjl/r1x0PHcgDLZpvLmWOBwou2+bIXI8zJOARwen4556Ut2Jmnt0IICXA/j5YFX9/f8AT6VS07WbB7e4Iv7ZlS8dSPPTIPmnvuHGOcdcevSrNzcEm3dJUdY7nLgMCQoVu+4gdV6469qAL/lybTuLKrPypc5A2467vbP/ANfmm2dvJEs4k3APcGQEv2zkdO3AGPzz0qK4vFSVwZUjYSbVDOvzfJ6bx3yO3I6fxGWJ3EUzM+MXGAWOcDcOOo7f5PSgCO/kWNovlc7p0U5JOMk89eB71NJdKoYqHAR9pPPPHUfz+nNV2Z45CxBYvKI/mOcfM/T5jzgj07fQWvIJWfeWw/IHOR8gHHP+H9aAM+K9AW8MImJFztYhR8p+XI6en8/xq6ZSJXJDcOqDg5PzH0HI5/Q590siC12WAAE5H93sp/E+9TS3CxMBjqyrzwMsSOuOv/1vXkAsUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVjeK/DWm+KdNSy1eOeSGOUTx+TcywMrgEA7o2U/xHjOPbgVs0yZDJGVWR4ycfMmMj8waAPKL7wnrHgS8GqeCkvtZ0hpM3+iXV0ZZQoK7ZLV5ckMuDlGYhhwCDg11nhrV9D8Vxz3WiXdteIkqGeLAEsMgkfIkiZQyP2+YA4Htmtp9KmYkjVb1czeaQI4ORj7hzH04Bz97gc1zHiL4WeGvEV4t3rFstxdiQP5zW9vvK5LeWT5fKkknP3uTzQBm+ILY+K/Gs3hKxnktdFsVS81uS0PlSzSyDMMG9cFeF8xiOSCgB61DF8FvB0lxBcXFpqc8y4Mc0urXReM7OSpDjBPOf6dK6zw14K0zwxBLBoG6wtpLg3JhghhVdxAGP9XnGBjk5wSM9MaUGkzRfZ86vfyeSxYl1gJkzwAx8vPA4yMHjkmgDzibwBq/hDU7fUvANxLcW8fmedomp3sktvLmRSpikcsYpMZG75gQADjkmW0+KHh6waxtvE8dx4YvVfP2fUbVlAJLA7JUUxspPfcM7cmvRRpcvnQSPqd67RbuCIgHDEHDAIOmBjGDTF0Ygxb9QvJNm7hhFhs+oCdu2KAPL7az034rX26VpLvwjZ26R7bZ5LeO5vXQmQl1Ks6xqseP4SZjydtSx/BbwFFd20Efh2Hy3jnkLR3dx5hYFNuX8zdn5m79/rXpWmaN/Z1tYwRahfPFaJ5arIyHeMYG7CjOO3SpU0vbd2tw19fOYFkXY0g2yB8feAHOMDHTHNAHmUvwsttCEdx8PL2fQ9Thkd445bqW5tLg+Z9yaORmOCMgshDDJPJ4pdB+IVlpFlp1j47iTw7qkS7fOnUm0ugVb54p8YwTtOxyrDHfGa9N/sw+espv74soYY80BTnuQBjjt6Uo0xDEI5Z55UCldr7cAnvwBg9R+JoA8k17UND8e+K/D/h+0vLTV9JtbWXVdUS1nWSAsqqsEcrodrZcyMUJ5wCRiux/4V54JLAf8If4byTIcHT4ezgelbem+FtP0wx/2d5lsqs7usQVRK7dWcbeT/k5q9FpSpj/AEy+b5GQ7p25z3+o7EUAefxfDPwNq+lW6WuhWFrIx3xXtjELW4hYM+HR0wwYEcZyOBkEcVnnxL4q8FzafaeK9Pu9c0xQ5h1fTE3XBXyidtxbj+Ic5dTg4BIBNem2ujx28KILu+fYmzc05GevJAwM89celOOkQmSGR57xniG1Sbhvpzz196APNtR+KlnrFjNpfhFr1/FN0rwWcFzp88XluXCeZIWQAImSWOeMY6kA6mg/DjwRbaZaQf8ACM6Nd7JGja51C2innnYO4LPIwyzMRu/TAAArq5PDVpMlqk9zqMotiCu68k+Yq4cFsH5iGUHn8c1NaaFb20UMaXF8VjYtzdONxJJOQCAetAHHah8NvBV+lnCPC2hwJKxAktrRIZMeUSCrxgEEHkEEdOOcVRt7Txt4IkkGmzSeMdEV2Edre3Ai1CBcqMLKTsmAyT84VuwNd9NoNtLLYyPc6hutJGkTF5IN5IIw/PzD5unsO3FXYrKKIYV7g/71xI382oA8vHxUaGxmt4vBniuDV5JZFsra6swqXMzSMAvmK5VVDcsWIG3kbuKfovww8PW1vZXvimwtfEGv3D79Rv8AUFFwZn8hmO0PlVQHAUKAAFX616Dp+hW1i0bR3GoSGOSSQebeSsCXJJBXdggZ4yPfrzSPoNuzxEXOpAJMZsC+lO4kEbTls7ec4GOg7ZBAOff4e+Ayk3meEvDKqsoBP2CBcHK8ZxxyRxxnPTnnmP8AhHPEHgaRpPAM1vfaJ5oMnh3ULhk8v944BtZifkztHyMCvUj0r0ltCtGaUmbUv3jiQ41G4GCPT5+B7Dj2oTQ7ZYZ42uNQfznMjN9tlUjLE4Xaw2gZxgY4AzmgDzq9+KBthbS6t4M8XWyLKW3wQx3KKfKfq0cpPTJ6AfzpNM8N2vj26v8AxN430mQQtKsemaRqcny2kIVcySwh9olckkg5woQeufQrnw9aTspNzqaATCYhNQmGSARjO7Krz0XGcc8ZBmfRbVzJmXUB5jBztv5xgj0w/A9hgHvQBxT/AAt8AXrSmbwzoJdZgMRW4iwBMSBhdvf5ffGDkcVk6n4Cfw4La5+Gd8+jXEMpUWN5PLcWFxlXO1kZyY8EcNGRjJ4Pb0hdCthHcI1zqTefJ5jH7fMCvOQFww2jtgYyOualm0mGRFQXF8i+b5rbbuTLcfdzuyF6cDHT65AOAT4rWemKU8a6Nq/hy5X/AF0rwtdWofaOBNDuGMEH5gvHPvVa48WR+PnGgeAdSu44p7hpNS1i2hkQ2sCuuUidlC+c/wB0ddqh2xkDPoraJassi+bfgSSCVsX8/UHOB8/C/wCyOPanWmj29s0pSW7PmT/aCDcvgN6AA42/7PQ980AcJdfCrw3IE/darcESoXkfW7wscEgs2JcZ47AYqST4VeGBHKbaTWYJerCHXbvltue8h5Pv6ZrvhYxBnYPcZdtxzO7D8ASQPwxSS2IkWQfabpd8gkJWQgjH8I9F46UAeZTeAdd0eK+bwR4mnDNMT/ZuvMb61k+7j5iPNTvk7n69Ku6X41vhdWlh4l8I6zot7PdxR70Rbq1LtIQpE0Z6HA5ZRjjJ716B9iIEgjurlC7bshgdp9sg/kc02Ww81w0lzO2HR8YT+E5A+70oAu0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Real-time tracing of esophageal pressure as a reflection of pleural pressure and abdominal pressure as a reflection of gastric pressure in a patient with bilateral diaphragmatic paralysis. Decreased intrathoracic pressure (more negative pleural pressure) on inspiration is associated with an abnormal decrease in gastric pressure (more negative gastric pressure). At the same time, there is outward displacement of the ribcage (upward deflection of ribcage) with a paradoxical decrease in abdominal volume (downward deflection of abdomen). The ribcage and abdomen tracings are obtained from inductance plethysmographic coils placed around the chest and abdomen to monitor movement.",
"    <div class=\"footnotes\">",
"     Ppl: pleural pressure; Pga: gastric pressure; RC: ribcage; AB: abdomen; Insp: inspiration; Exp: expiration.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_48_9987=[""].join("\n");
var outline_f9_48_9987=null;
var title_f9_48_9988="Leucovorin: Patient drug information";
var content_f9_48_9988=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Leucovorin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     see \"Leucovorin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/56/3974?source=see_link\">",
"     see \"Leucovorin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11508393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lederle Leucovorin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692160",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may lower the side effects of some drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691725",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692141",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with fluorouracil to help fight colorectal cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702369",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to leucovorin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have anemia caused by a lack of vitamin B",
"       <sub>",
"        12",
"       </sub>",
"       .",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694561",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Before giving the shot, bring it to room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10795 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-655B890CD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_48_9988=[""].join("\n");
var outline_f9_48_9988=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11508393\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020117\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020119\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020118\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020123\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020124\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020126\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020121\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020122\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020127\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020128\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=related_link\">",
"      Leucovorin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/56/3974?source=related_link\">",
"      Leucovorin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_48_9989="Spinothalmic pathway";
var content_f9_48_9989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    The spinothalamic pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 464px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is the major route by which pain and temperature information ascend to the cerebral cortex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bear MF, Connors BW, and Parasido, MA. Neuroscience - Exploring the Brain, 2nd ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy;2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_48_9989=[""].join("\n");
var outline_f9_48_9989=null;
var title_f9_48_9990="Respiratory chain";
var content_f9_48_9990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F82715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F82715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    The mitochondrial respiratory chain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 345px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFZAh4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKRjhTQAtFR7qN1K47ElFR7qN1FwsSUVHuo3UXCxJRUe6jdRcLElFR7qN1FwsSUVHuo3UXCxJRUe6jdRcLElFR7qN1FwsSUVHuo3UXCxJRUe6jdRcLElFR7qN1FwsSUVHuo3UXCxJRUe6jdRcLElFR7qN1FwsSUVHuo3UXCxJRUe6jdRcLElFR7qN1FwsSUVHuo3UXCxJRUe6jdRcLElFR7qN1FwsSUVHuo3UXCxJRUe6jdRcLElFR7qN1FwsSUVHuo3UXCxJRUe6jdRcLElFR7qN1FwsSUVHuo3UXCxJRUe6jdRcLElFR7qcrdaLhYdRRRTEFFFFABRRRQAUUUUAFNl+4adTJziJqTAg3Ubqh3Ubqm5dibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdUkLcmqu6p7U5ZvpRcTLNFFFWSFFFFABRRRQAUUUUAFR3H+pf6VJUV1/wAe8n0pMDO3Ubqh3Ubqzuak26jdUO6jdRcCbdRuqHdRuouBNurlrr4geGbXTNT1CfUttnpt8dNupPs8p8q4BAKY25PLLyAR710e6vBvEHwsubyy8R6c2r2UWt6zrsuq2MD6lOkTW+9WO6EfK0gAPOw44+bpgVuomet6f4q+2eMtQ0D+y76L7JbxT/anTCPvaVfwH7rg55yRgbeek3VDuo3UXAm3Ubqh3UbqLjJt1G6od1G6i4E26jdUO6jdRcCbdRuqHdRuouBNuo3VDuo3UXAm3Ubqh3UbqLgTbqN1Q7qN1FwJt1G6od1G6i4E26jdUO6jdRcDH8UeKrLw5caLDfRXLtq18mnwGFVIWRwcFskYXjqMn2rntR+JcEcmqQaXo2p31xpup2+m3ARYwuZJEXcp39MPxkDJwDtGWE3xN8L2Pia00m41i7t7fTdGvBqVylzAJIpY0VtyOCQAuCSTyMdqZ8N/CeneG5da1HRLq2l0zXJkvbaK1txFFFGUG0JgkMCDnIA+lO6FqdxbzGWCORo3iZ1DFJMbkJHQ4J57cVJuqHdRupXGTbqN1Q7qN1FwJt1G6od1G6i4E26jdUO6jdRcCbdRuqHdRuouBNurB8Z+KbPwlpMeoalFcywSXEVsBAqltzsACQSOPxrY3Vy3xI8Jp428PJpMt0ltGLqG4ZmiEocI24qVyOCOP6GhMRX1vx75N/4m0nRNJvb/AFrRbVLhowEEcm9Cy7Tvy2O4wD6Zrq9Gu7i80u2uLy0ezuJUDPBIykofQkEj3rgvht4b0G317V/FvhK6sm0XWIo4oLaztBDFEYiUYqQRnLBv4R+PWvQ91DYE26jdUO6jdRcZNuo3VDuo3UXAm3Ubqh3UbqLgTbq57x/4l/4RDwdqmvfZftn2KMP5HmeXv+YLjdg46+hrb3Vj+L9BtPFfhu/0TUZJo7S8QJI8DBXAyG4JBHUdwaLgcnb/ABKHiTxNL4b8IyabPdNo41Jb9boXEUUnmBTAyJj5gDnO4YJGRiu08Jrq8XhzT08Rywy6ssKi4eJcAtgZzycn1I4J6ACuE8CT+G/Efj7Vtb0e6un1HRLcaA6M6GOSEMHEoAXOSwdQd2Dt6V6Xup3EibdRuqHdRupXGTbqs2J+ZvpVDdVzTT87/ShMTNCiiitTMKKKKACiiigAooooAKhuv+PaT/dNTVDd/wDHrN/uE/pSYGHuo3VDuo3Vhc2sTbqN1Q7qN1FwsTbqN1Q7qN1FwsTbq8z8XN/xfXwCf+nPUP8A0WK9G3V5rr53fHzwqDyF0q7Zc9jkZI98U0wZ6huo3VDuo3UrhYm3Ubqh3UbqLhYm3Ubqh3UbqLhYm3Ubqh3UbqLhYm3Ubqh3UbqLhYm3Ubqh3UbqLhYm3Ubqh3UbqLhYm3Ubqh3UbqLhYm3Ubqh3UbqLhYm3Ubqh3UbqLhY5/wCKDf8AFtPFv/YJu/8A0S9Hwvb/AItp4S/7BNp/6JSovicf+LbeLP8AsE3f/ol6Phif+LbeE/8AsE2n/olKd9BdTq91G6od1G6lcdibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFibdRuqHdRuouFjzn9mw4+Cvh3/ALef/SmWvTN1eXfs4MB8G9ATPzIbhWHdT9olOMdjzXpe6m9GC2Jt1G6od1G6lcLE26jdUO6jdRcLE26jdWZqesadpQhOqX9nZCeQRRG4nWPzG7KuSMn2HNVdU8UaDpN4tpqut6ZZXTKGWG5u443YEkA7WIJGQRTA3d1ed/HbxuPBfgK6nt5NmqXubWzAPKsQdz/8BGTn12jvXT6r4o0HSHiTVtb0uxeVPMjFzdxxF1PAZQxGR7ip7/TdK1qOCS/sbHUEUFommiSUAMASVJB4OB060X7hbsfGP7P3i8+EfiJZtcSbdO1HFnc5PADEbWP0bGT6bq+5N1eNfBzw7od3/wAJv9r0bTZ/J8UX0MXmWsbeXGNmFXI4UZ6DgV6/upzeoorQm3UbqxF8S6G1peXS6zpptrN/LuZhdR7IHzja7Zwpzxg4qpF438LTQzTReJtEeKABpXS/iIjBIALHdwMkDnvSGdNuq/pR+eT6Vzuk6zpus25n0jULO+gVtpltZ1lUH0JUnmt7RzmWT6f1px3FLY16KKK2MgooooAKKKKACiiigAqG8/49J/8Arm38jU1Q3YzazA9Nh/kaT2A+ffiV8TdX8Ja1rUMNjay6daWMTJOysWjuZRIYw+G5jPlleMYJHNSzfFN0+JN1oKiybTkje3jk5837WkQkIPP3PvJ0B3DrXoN5pWm3ouxeafaXAuo1iuBJEreaqklVfI+YAkkA9M1j6GNC1eO9s/7ItYJrG+aSe0lt0zHNklZsYwS6ncHHUHrnNc91bY3szz7/AIWp4itPDBvbuLSbm6uNDOrweRDIiwEOiFJV8wkg7uGBGSMYrvfBfiy91/xH4jsruwexg077N5UcqgTfvIyzF8MynkcYxx1rQtPC/h6zsrmztNC0uC0uRtnhjtI1SUDoGGOR9a04bW1guri5gtoY7ifb50qIA8u0YXccc4HAz0ockCTPMfGXxN1jw94p1ew+wWr6dFLa2tpclGJWeQI7LJ83QqzlSMYK4OabJ8WZz4s8S6dCli1paW12dPbkvJPbRh3D/NjaTvxjBwh5r0m60nTLvz/tWn2k3nukku+BW8xkxsZuOSuBgnp2rnvFdz4L8MaLG/iCDSbayiZ3ggkt0JLODv8ALjxyW3NnA7nNNNMLNanM2Wt+JPF0X9gvqdpaX1xpltq6XmnRmMRq7YMEisXweQQQQSB0AzVzUkkh+OHhKOed7mVNHuVaV1UFzkZJAAA/CtP4SalpOs+F31XQdEtdGsbi4dY4oY0jLohIDPtAGeG47dMnrWbrrf8AF+fDB/6hN1/6EKd9WgsenbqN1Q7qN1Z3KsVdd1uw0KyF1qcxiiaQRIERneRz91VRQWZjjoATTNP8Qabf2kU8N0EWQZCTqYZB85TlHAYfMCOR1rN8b6APE+if2eWs1HmrJ/pdsZ0OM44DIwPP3lYEVwf/AAqGVX08x+I5GW3SFJRNbGQuIrkzqEJfKj5iuCWOAOapW6idz1ZtVsUM4e9tlMGPOBmUeVzgbuePxqrH4i0x7m5hN3HH5Hl7pJGCo29Sy7WzhvlBPFefr8LWjtIraPUrFo7S7+2Wry6aHkkbezFblt485fm6DbyAeopL74VJf3rz3moWbJLc2tzJBHp4WLMMEkW0JvIAJk3e2Mc9aNO4tex6Y2p2SyJG15bCR4/NVTMoLLgncBnkcE5qnpXibRtW0+1vbDUraW2ujthcuFLn0AODnkcda84074SyWuqaDcT66LiHSkgURNaEFhGjowB8zADbs8gkYwDjiqjfBcNpunWrazA/2OB7UE2kiK8ZYMGISZT5oI+8SQRt+X5ado9w1PaN1G6oQ2BijdUXKsTFwASeg5Nc/wCHfGejeIYEm02e48iTaIpbi0lt0lLEgBGkVQ54PC5NbLHcpXOMgivNbT4WW+n+EdI0zTL2K11Kxure7e/Frnz3iL7dybv9tv4qat1E79D0QazpzNGq6hZlpcFAJ1y+cgY556Hp6U5dVsG+zhb22b7RnycSqfN552888+leSwfBe3W1tYrnU4LloIbSFXksgSBDKztjLnAcNtx/PpTpPg63n2Bi11Y7a1uTcpALMgKftJmAXEgxwdvOR3AHNPTuLXserPrOmorM+oWaqrbWLTqArZIweeDlW49jVeHxJpE19qNmmo2/2nTyBdIzbfKyARknjGGHIPBODzXm2rfCMXugvp0GrRQPNdXdzPL9jz53nbtgba6klN3BJIPcY4qTUfhMLt9Q2avGiXLWsoH2QhhLCiJ8zLICY225KjBzg7vl5NO4a9j1iKZJY1kidHjYBlZSCGHUEHuKdurnvBmiDw14btNJWSOQQFzujVlXLOz4Ad3IHzY5Y1t7qRVibdRuqHdRupXCxg/Exv8Ai2/iv/sE3f8A6Jej4Zt/xbfwp/2CbT/0SlQ/Epv+LceKv+wVdf8Aol6Phq3/ABbjwr/2CrX/ANEpVfZJtqdVuo3VDuo3VNyrE26jdUO6jdRcLE26jdUO6jdRcLE26jdUO6jdRcLE26jdUO6jdRcLE26jdUO6jdRcLHnn7PbY+Gdr/wBfd1/6OevSd1eY/s+tj4aW3/X3df8Ao569I3VUt2JLQm3Ubqh3Ubqm47E26jdUO6jdRcLHkvxb8Da98QPEYgXyrPR9OsHa1llAk8+6cjICq6lcAKNzAgHPBzVe00zxcfEB1fV/C817Nd+Gk0u4iF1bFftAkO4uTIPlIG4lcn5sYzmvYt1ZfiS31C50w/2NdfZtQhcTRb/uSlTny34+6w4yOR17VSn0Jcep5Tpvw48TWt74ds1urZYbfw/Npt3fSILhEaSQny1TerHAbAY5AxyO1eueF9Ih8PeHdP0i1kkkis4VhV3PzMAOvFVPDXiK31yCRQj2uo25C3djNgS27Y6Ed1PUOOGHINbO6hyezGkkeefBh/LufH8DffXxReSkjphgmPx4rtfFE+pQeHdRfQrb7TqogYWsW5VDSYwpJYgYBOee1cL8IW/4nPxA/wCxgm/9BWvRbiZooJHjieZ1UsI0IBc44AJIGfqQKG9RJaHknwm8CeIPAXiWBpPLvNN1SwH2+SLCeRcqSwLAuxkPzOu5QB7Cqtz4J8Rv8GNU0GPTx/a82qm5jhM0ZBjNwHDbt2PujOMg/jXPeI/iD4t1n4laHoE9i+i6QNVt4bhIphK0p3qxjeVCRnH8APfnNfRO6qba1Eknoc54P8LyaFquu6rfX63upazLHJcNFbmCJQi7UCJuYjqckkk13ugn99L/ALorF3Vr+Hj++m/3RSi7yCS90zvi1a3F98MvFNrZQS3F1Nps8cUMSF3dihwFUck57CvDdC+H/i3R9X+GNzqLXd/pthcR/ZbaOFy9jG8Zkl+0AqArByqAk4AUA89PqCiugxPm2XWfiJ4mGuaVNY+I4tK1DRr+MQ31knmxTqrCNPMFrEg3jAwGkyG4YN00fBi+OzH4D0LR9T1rS9Mj0gf2hLf6GpEE0eweRl40wMAqpJJI5yx5r6BooA+a5dT+JGkeGYV8L6Zfxak19qLT2aaFFFALcFtk4IRMy9Cq5Pmdwf4voLw7K8+g2Ekst5NI8CFpLuDyJmJAyXj2rsb1GBitKigAooooAKhuv+PSb/cP8qmqK4/495P9w/ypMDit1YWv6Gb65i1HTLo6frUCFI7lV3LImcmOVMjenfGQQeQQa191VtUv4tN025vbg/ureMyMB1IA6D37VyK7aSOtq5if8JXcaWm3xRpV1Z7eDd2iNdWz9OQUBdPo6gD1PWlX4i+EGUH/AISLTRns04B/Edq8D8SeIr7Xr+SfUJ5Hxl1hXJSFfYdh7n8aykYuHaJJJFRQzmNC4RexYgcD3NewsspxjepUSa320/E1VLzPo5PiFoV05j0iS71WfnEdjaySA/8AA8BB+LCsHXvBC+PrxLjxLotlpdqCCQgSS/nAHCvKowi/7KlifVa8QSQ7WmiEjJFgtLGrFY/QlgMD8a9o+D/iq51NLjStRmeeaBBLDK5yxTIBBPfBI59/assRgFSg50pqVt9romVLQ6f4Z+Gn8G+Fk0VpvPSCeZopeheNnLKSOx5wfcelYeuN/wAX28Mn/qFXX/oQr0DdXnWuN/xfPwyf+oVdf+hCvNi7tmbVkj0vdRuqHdRuqblWJt1G6od1G6i4WJt1G6od1G6i4WJt1c1r82oaNqq6zb/aLzSmjEV7Zpl3iAJ2zxL3IyQyjkjBHK4O3c3CW1tLPKcRxIXY+gA5/QV4pdfFjW3ndre3soosnapRmIGeMndyfwFdeGwtTE35Og1By2PbNN1G01OyhvNPuIrm1lXdHLGwZWHsas7q+ZLrxhqkd/JqOnTRaVdSPumazUhJz6vGxKM3bdjd71pL8U/GCkp5uks6fKwks5FcH3G/g/lW0strRly6X9Q5JI+id1c74813UNA8PXF/pdjbXcsSlmNzdLbxxjHUsev0BGfWvFX+KXi6ZAv2rTIRJna8dk2TjupZyD+RqhbeKtSF9He6k0erXkbbopb4FxCfVIwRGp9woPvRTy2tU1VreoezkzrPgTrniLxB418S3Xi7z0v47aBY7eRDGsKOS2FQ9AcKc9T3Jr2/dXCfDfW18SQ3Op3drBHqseLaSWIEeZH95QRntluvTnGMmu13VyV4SpzcJLVEqLjoybdRuqHdRurG47E26jdUO6mTTpBC8szhIo1LM7HAUAckmncLEOuazZaJp8l5qMwjgXgdyx7BR3NeZ3vxjPmuLLSMxjO1pZ8E+hIA4+ma4r4geKZPE2sF42ddPgJW3Q8cd2I9T+g4rl6+iwmV01BSrK7fTsbRpq12ex3/AI9tPFHw/wDFts8BtL5dJu2EZbcHXymyVOBz7VLpnjux8L/D7wnbmJ7u9bSbRvJRgoUeUuCzYOPpg14pOZTa3KQPseWCSHPs6FSPyYiliDrbwRySF2iiSIMeu1FCqPyUCn/ZVP2t/s/r2J9kua/Q9ktPjHA0qreaPJHH3eO4Dn8FKj+dek6Nq9prOnx3mnzCW3k6EcFT3BHY+1fKldV8PfFMnhrWAZWJ06chbhOuB2YD1H6ipxeVwcOairNfiOVNW0Po7dRuqvFMk0SSxOHjdQyspyGBGQQfSnbq+euZWJt1G6od1G6lcLE26jdUO6jdRcLE26jdWHrniXTNEmtoNQuJBcXOfJghhknlkCjLEJGrMQB3xgVZ0XV7HW9Oiv8ASrmO5tJc7ZEzjIOCCOoPGMEZFO/UXkae6jdUO6jdSuOx5/8As/tj4bW3/X3c/wDo569G3V5p8BDt+HscR4eK8uUceh81jj9a9F3VUnqyYrQm3Ubq5b/hOPD39mxah/aH+iS3v9nK/kScz5I2Y257HnGPeujLYGSeKWw1qTbqN1crp/jnw9qF/BZ2uob5Lh3jgdoJFimdPvLHKVCOR6KxrpN1D0Bak26jdUO6uV+IfioeGtIBgw2oXGVgU8hfViPQZ/E1dKEqs1CO7Gld2GeP7nw3atBc6vcSW2qRKfs89kxW6QZ5AI/hPo3ynuK88X4ra7ZTMkBttTtQfle8i8mfH+0YzsP4KK4K7uZ7y5kuLqV5p5DuZ3JJY+5qKvoqWVUoxtU1ZqqUTpPDfjzXNButentLPTS2q3z3pEjSOIy2PlGNuRx7V1ujeM4delWHxXruoWqMfmgsoxa2789C6lpQO33gPWvLqK0llmHa0Vn6j9jE+oItE0WXSbK0t7K1FhBLHdW6wgBUkRgyOpHfIznvznOTWxur5++HHjSXQLxLO9kL6TK2GByfJJ/iX2z1H49evvYcMAynIPII6EV4GLwssLPllqnszJw5SbdWz4aP7+f/AHf61gbq2/C5/fz/AO4P51zQepnU+E6Wiiius5gooooAKKKKACiiigAqO4BMMgHUqR+lSU2X/VP/ALp/lSYHnma4z4uXRh8FXCKcefKkZx6Zz/7LXW764D40MT4WtR63qZ/74essCubEQXmd8VqjE+G9jHb+HUudo8+7dpHbHJAYqoz6bR+pqxoUNvo7a9BDCkcMU5uAFGMq0YbHT1DD6YrE8BW9/qOiBZL2a1s7eR44Rb4DyHcWLMSDwN20AenOat6PpN3e6hra6rqVwJRKsYW1PlBl8tQsjY6kjt0BzxXxmPi/rOI9rPq77/zafh9x9HRl+7p8sf6t/mbXhbT4bXw1ZweTGBLEJJlCjDO4y2R6c4+nFcv8M0GmfEg2SEiNZLiFR1+UAsoP4AVpeG9Nu73RYZZ9UukVU8q08giMLGvyo7LyGZgA2Dkc4ArE+HQuE+JUK3xBuxcXPmlRgFtrkkD0/pXt8OJqtiVz3913Wu9/0OPHO9KHu20/Q9/zXnetn/i+Pho/9Qq5/wDQhXfb6881pv8Ai9/hs/8AULuf/QhXoQZ4kj0nNGah30b6m5VibNGah30b6LhYmzRmod9G+i4WM/xa+3wrrJzg/YpsHpzsOK+aK+jPGp/4pLV/+vZ/5GvnOvo8k/hy9f0Nqex0vw8sY7zxE80yh1s4g6AjI3scBvwAb862viJo8d5faJKo2tcXS2UpXgtG2WP5bW/Oub8F/bJNea0sJvIW4hPnyqAWjRWHK9s/Ntyemc9q2fG9nqljc6KLG7kuYWvozElz85SfkKC3BKkFs56Y4NfH5y6sc6clUs7aenL+B6tJp4Vpxur/AKr9DpvFmlwXXha7t0iRfIiMkAUACNkGVx6dMfSvI0IZQw6EAivSPFNpqmneHLy4g1KW6fyWW5SZV2srDBZAB8pXOccjAwcnmvOAAAAOg4FepwUpKjV968br7+u/yJzBp1FpZ2PXfgYSLTVz2Mkf8mr1HNeV/BBiLTVlzx5kZA7Zw1enb63zJ/7TP+uiPImtSbNGah30b64bk2Evb23sbWS5vJkht4xuZ3OABXi3xA8evrqvp+mB4tNz8znh5vTI7L7fn6VX+J3iaTWNYksoHIsLRygAPEjg4LH154Ht9a4qvpcuy6MEqtTf8jaELasKKKK9k0HQQy3NzFb2sTTXEp2pGmMk45Oc8DHOTT7y1ubG7e1voHt7hQGKNggg9wQcEfSuq+F8KPq+oztjfFBGq+oDs27H/fC1c+KkKeXpdxj94JXiz6qVJI/8dFfKVOIKkc4WA5Vybed2r/8AAOtYa+H9vf8ArY4SiiivqzkPQPh94+bRI007VQ8mn5/dyLy0PPPHde+Oo7elez2l3BeW0dxaypLBINyuhyCPrXyxXbfDDxNJpGrpYzvmwu3CkE8RueAw9PQ//Wrxsxy6M06tPR9fMznC+qPd80ZqHfRvr5q5jYmzRmod9G+i4WOW8RaBqT+M9N8SaKbOae2tZLOW1u5GjR0YghldVfawPX5eRxkVxOtaHf8AhfwhDYxT6vJrd9fT3Xn6Slx9ntpJGUszrGCWVRwFI+Yk8dSPXWlVSAzAE8AE4yfas3xDd6hZWAudLthdtFIGlt+d8sXIYJz9/uAeuMd8i1JkuBq2zlraJizuWQEs6lCeOpXAwfbtUuaz9M1K11SwhvLCZJraVdyuufXkEdiOmDyDwatb6i5RwPwNbHhC9/7Ct3/6Ga9EzXm3wPbHhG9/7Cl1/wCjDXfXFwlvBJNKSEjUsxVSTjvgAZP4Vc37zJjsjygfCvUBottELyH7dHrg1Fwb2cweTvLYEeNnmdOdv41uT66178SJPD0HiGKe2lgmS8s38pDESvyJCQA7OPnZs5AHoa5vVfjB/aHjbR/Dvh62lhinvoY7i7uYyjMhcblRDyMjjc3PoO9ex5G7dgbvXvTk2viFFJ/Cebab4F1pbLwto1/Ppq6VoF8LxLmB3M9xsLGNShUBPvfMQxzXqGah30b6hybKUUibNfP/AMUtSfUPGN2pOY7XECD0wPm/8eLV71vr5z8bxNF4u1dXzk3DsM+jHI/Q16+SpOtJvdI1prUxK3vCfhttfNzLLcSW9pCfLBjALO+ATyQQAAR259sVg16X8MpEbw46KfnjuJFcd8k7h+hFPinHV8Fgueg7NtK/Y9DB0o1aqjPY5PSvCtzdeJbrS7uV0gtAHlniABkVvubc5wTznrjaaq+KNFbQdUS3WR5baZDJC8mN3BG5SQOSMqc+hr0bTriM+LdYtw4aZYbdiO4GHGP6/wDAq5r4pyobnSoBzIBLIfZflHP1/pXzeVZ5jsRmdKnUleLSTXT4b39bnRWw1OFCU1un+trHE17/APC7VX1Lwhbec26S2Y27E9woBX/x0qK8Ar2n4MwvF4YuJG4WW5YqPUBVGf0NfaZxFPD3e6aPJqLQ9EzW94TObif/AHB/Oub310Hg85ubj/dH86+Zg/eOaovdZ1dFFFdpyhRRRQAUUUUAFFFFABSMoZSp6EYpaKAPLt1cF8ZWz4Ytf+vxP/QHrt99cJ8YmH/CMWxJwBeKSf8AgD1hl7/2mHqejHc5vwJq0y+H0tLDT5bqW2klMx3CNQWkZgoJ+82GBx09SKu6dqt5eatqd5pWmmeDZFG/nyeSwkQHcgBU5Ybsc4HHWtDwFoPiCDwvaNDpNsqT7pwZ7vy3cOSQdoU44I4Jz61pWnhvxNaXF+8djpoW6lEqp9uPyPtCt/yz55UH618JjsZhXia7i46t7y3971PapYiKhBSnt5eXoc34X1W/PhyxFppMksNpAkMpkkEbu6KFcRpg7sEEckc9KyvBF7FqHxRS9ts+RNNKyEggkCEjOPwrvdJ8N+JdO0u1tBpti/kRhCwvjlyByf8AV9Sea888N79K+JxS8tzZyLeyK0MhBMZkU4GQcEfOCCOMEV7/AAzWoV8TiPZ2b5JWs79eupzYqqpUoRUr/LyPdd1efa03/F7PDh/6hdz/AOhCu7315/rLf8Xq8On/AKhlx/MV6cOp5UkejbqN1Q76N9RcqxNuo3VDvo30XCxNuo3VDvo30XCxmeMct4U1cLyfssh/Dac18719FeIVabw/qcScvJayqB7lTivnWvpcjf7ua8zWGx03w3mSLxM8bkBprZlQnuQykgfhk/hXX+Lr6C0uNCWdgDJqCAA9htZSx9gWWvK0Z4pY5oZHimiYNHIhwVPqKk1K7utVn87U7h7mQJsBYABV6kAADH1615OacM1MbmP1lSSg1r3vax30sX7Oi6aWtz1vxhMkHhbVmkxtNs6AHoSykKPxJArx4DAA6+9XL7VNR1C1gtr69knt4CCqsACxHQscfMR7/XrVSu3hrJquV0pqs1eT6dlsTi8QsRNSSskj1X4KHFrq3+/H/Jq9M3V5n8GVC6fqT85aVF9uAT/WvRt9cWZv/ap/10PPluTbqN1Q76N9cFybHzbqdnPYX89rdqVnicqwPc+vuO+arV754n8M6f4hiBuVMdyowk8eAwHofUex/DFeVeLfB914dhS4e4iuLd32Bl+Vs4OMr9B2zX12DzOliEovSXb/ACNlJM5itbwnpKa3riW9xn7LFGZpQpILjICrnsCTn6Csmt3wTe3NrrctvYQJJc3cQVGk+5HtbJZu+ME8DqcD3rLPqlWnl9WVF2lbftrr+BvQUXUip7XOlu/DFlZeI7H7L5kGn326G4to2ISR1UuoPoMK+QODj3NPbwzpt74mki8kpp1nErm0QkRNM5PIXt8qjgcHI98rrL64NW0ixb7HK73Blju1QoihY3DBk3EkjcCMHnHbmpIF1ey1+6s4Jra4mvES4a5kjIEKqNh3ID8xOBjBHfPTn8t9rW5VL2mvL389/ktNddLHq8lPma5NL9vLb7/kcj4z0aLRNYjW0BWzuYzJGhJOxlIDAH0+ZTWHXSeP579tSsbTUo4i0EcjrPECFlVigBCkkqRtIIyexrm6/TuHKtWrl9OVV3euu91fQ8vEKMaslFWQVPYWs97eQ29qheeVwqBeuc1t+FfCV74iSSWCSKG3jba0khJOcA4AHXqOuK9W8KeFLDw6heLM94w2tO4wceijsP8AOa68ZmVLDpxTvLt/mc7kkdQrEKATkgcnpk0u6od9G+vj7mNibdVPWNQTTdLu7yQblgiL4/vEDIH58VNvrI8WW8l74a1KCAFpXhbaByWIGQB+WK0pJOaUtrodjwbVdSutVvpLu+lMk0hySegHYAdh7Vf0nxVrWlEC0v5vLH/LOQ70x7A5x+FYtFfculCUeRpWNrLY6ceNL+3vpdQ02KGzvZjunSPJtrg4+88eeG/2lIPruHFdPYfF1QgGqaFdK46tZyxyKffDlCPpzXmUKSTput4ZZkyRujjZhn0yBV/R9NF3q1tFqMN1FZZLykxONwA4XOOMkj8M14mOhl9KnKpJ6xWyevpYlU4yaSZv/D7x9B4b0G5s7jSNSmnkvJrhSnlBNrsSASXzn8Kt6n8UtZvCU0+yt9OhPBlZ/Olx6qMBVP1Dj2rM8Y6ZpyfZrnQbZ0Yt5c0ENuwUrgkNjbwQRj3zXNTRywJvnhmiQdWkjZQPxIrlyx4DG0lWejfSTV/0uOdCNKXI3cvanqS3cllPBaxxX1rdC7W/lJluXkGM7nPUcfdCgDjAGKhv9SvdQk3311NcP6yuTj6DPFVOtLX0dLD0qXwRSBRS2PUvhL4juZ55NIvZXlURmSBnOSuCMrn0wc+1en7q8R+E9s83ikTqDst4nZj2yRgD9a9o318vm0IQxD5eqRE1qTbq8q+L+hP58etW6FkIEVxgfdPRWPt2/L1r0/fTJkSaJ45kR43BVkcAhh3BFcuExLw1VVESnZnzK+8rtiG6RiFUHuxOAPzNeof8InbWGjY0seVq0MZaO8UfvHkxn5j3UkY2njHasz4m6BYeH1sb/S4jGxmDGHcSCVIYBR9Riti91HWtN059SvIbWS3VS8trCpDwrjrvLYYjvwOOnvycU4upiHQ9jK0XfR6Xd7W8/noergfZtSclf9P6+8z59Nsz4d0ufT0MeoXjwtFegjz9z4LOzfxfLuODx26dGeMvC9hBoE15YW4iurRPNaQZLSqOXDn+I4ycnnNMntNZ0jRNCaSe2untJIYxaKmwsdpRQr5OT82SSPcYxip/F93q1h4dvF1AWtzBdRNblrdGjMLuCozljuXnGeDntzx87h6laGIpyoVLvm01312+7vpq7HVKMHTlzwtoum2m/wB//BOG0nTrnVdQhs7NN80hwPQDuSewxzX0RolhFpGlW1jb8pAgXPdj1JP1JJrA+H0GmxeHbSXT1gMzxr9odMFy+MkMfqeldPvr7nM8bKvP2aVlE8KTuTbq6LwYf9Juf9wfzrl99dL4HObq5/3B/OvOp/EY1PhYp8eWS+Ob7wxNp9/DLZWv264vpWgW1jgwf3hbzNwGRj7uQeSAOavweNfC08FzPD4k0WSC2RZJ5Ev4isKtjazkN8oORgnrmuZ1j4d3+peM/EGtf25bR2+r6S+kNbfYGLxxlThxJ5oBYM2fu4I44PzVzep/Atb3TTaLr4iJ8NweHy4sc5MU6S+djzO+zbtzx1yeld5xnqMPivw7PYXd9Br2kyWVm225uEvI2jhPo7bsKfY4qCXxr4WitLe6l8S6KlrchzDM1/EEkCffKtuw23Izjp3rgvEHwXh1e88RXH9tS20mp3Wn3kHlQFRbyWsZQbirguG3E8FCDyDkZpNP+Cenpq2iXeqS6be21hdXt3cWbWUssd49xGiln+0TzHcGjDZyQT2BySAevggjI5FLSAADA4FLQAUUUUAFRzv5UMkgUuVUnaOp46VJRQB4OG1E2p1I3IKM2TAAMYz0A/rXIfElbq78INezy/u/tAVYRgbTtbHH0rrZMpqjk8Ri9eLZ2+6ccfUGuW+Iy79Eu3U4RbtFCjgZ2nJx+NcOA/3mC8z1jqPGPhy68W+FPB0GnSOiw3EN011C4BgAtpAkoOecOyHAzn6VxMHgjxG5sZ/EHhldVuCmpeakc0AVJ5pg0cgLONo6kFcsPTNHgjRNYtfB0OoXWpx6dpssh8hrnWri0TazYXCoQoB68nJJ+lakun32kif+1vF9gmLlogbjxLdReU2A3lHkcgMp9cEZr8/UZYScsNSqxkotpaO/W9mpL+bX0QvZxlZt2+//ACNmw8P63Y+MPBV1dWN7qElhpr2mo6gLiMxl3VACFaQMduH3Hbk5B+Y9POfii4b4ka+8bBgJYRlTnkQRDH17V2cWj6paCxtr7xTZtd3g3W+/xJdo1wCeNi5+Yc44zXl3iTRb/wAL395Yarg3SKZxIrlxIjEkMGIBPQjJ5yDX0fBkaazJ1Z1E5KDSSVrrm5m93trokvwG0o2s7/f29EaFvqniVtOlu7e41Z7CPKvMkzELjrgbskD1AwKrltburb+3T9umhgRkW9MxLqmfmK87tvqRx+VeueH/AAt4ih0Kyt0s9LtkSFU8ma5cuOB9/CY3dyAT9TUS+BvEY8PNpKy6QIvLMIdZpcqmThcbP7p21vPjeKnJJQXvf+S/11On2VG3xPbt1+48vF74lttMTU/P1OOwcgib7QcYzgMV3ZC+5GPzrr/BXivU74S6fcz+ZMcNHM4GVXOGBOOeo611934V8QXFjNavDojRSRmIx/aZACCMY/1fH5V5b4MtrjTfEV1YahHsu4IZoZV4OHVc5B9MgEEV6mWZ3TzqhXhPl54q6tvb/gGdWFOLXI7/ACPVbyS/0zMLTidpFBVzg7CSOT7c9+9Lctf6WitJOLkSoSAcHYccH6e1Nsgi3E8cg3rJCkgDc8YOf5VHoxIYJMd4kt1cFznAyQR/KuX0MiWZtQ063ju5LgXKyAkxnHHB5HpTg+o2tvDezTiaOQ4MQAHHtVfTciSyZyWWaN+GJIByCMDtwcUWTFdQTkmJpJlVSchduMY/I0XCxNHJqQsxqLzI8JPMOBjHoKwx4TsLyK41H7PbRlXJEQAAxk8ba1oWK3a4OIDcvGE7D5eMD6g0XLYvZ2HCLPCpA6HI+bI79RVwqzp6xk18xnimqCMandiBPLhEr7EHIVdxwM/SqjMqlQzAFjtUE4ycHj+Zqe8z9rn353eYc565yc1nX3/H1p3/AF3P/op6/QU+WK+QmXK9H8HeHrDXNNtR9mhRxGTI7Eku24jOSeOB0FecV6h8PyZfD9pHnaxupFDLwdu3JGfqc15mdSlHDqUW1qthm9pNk8Ui6XY+XZxqxZniAXzDnqT+GKso1/NejTvtW3aTmYYBYcYGabG3nWumIeHLkMRwcAHdz+FEbeZYacp++0oBI4JAzu5/Cvj3Jyd27iHtLf8A2tdOW4G7cf3+BkjjjPrz1onfUI7sac1wNxbmcYzj0z/WmK27SrUH/WNME3987iCc/QUjMTproeZftPlh++d+M5+nFICS6a/tLj7D9p37mAE/BKjnIz+Fec/FBrqHXI7G4uXnjgjDKScjLdTn8AK9DkbGl3y9XWUopPJ6gLz+NcT8S7VBAkxGZY7gxBj1KlQwB9uD+depk84xxUbre9gOArq/h9aWQubvUtT1e506JCtlClpAJp55HBfai7H7IOApJ9sVyldX8P5dPW83T6xFo+qWdyLyynuYvNgkBiaORGG5c8N6g+nevQ4sc1lk+S/S9lfS/o+truzstbA5OLTjuelnw3ot7Zwag/i7UzDbsJkdzbIY2KHGVMAIO1m+U8+1VH0vw/BoM3iuLxZrEunvHGr3MSW7Eruwg2+RxzJ0wDzzWXc2+g3njuHUNS8T6fPYyWStd4kRBc3iB40k8sdNscjdc9F64zVhLTw5/wAKvfwY/i7RwdiKt1HAF+VXVgWj3/Mx24JyM1+O/vI8ic5NNxv7m0W3zfZ3VvK99rl+2qvW7+9/5mN8WfDZstO0vVrXWZNTs/Oa3zMIiVLAnKtGqgjMeMY615zXc+MZ9H03wlFommatbanfXWqPqc5tY/LhhDBgQq5baMlQFyT1NcNX6xwW6v8AZtqt7KUrNrluvTTrclycm3J6nV/Dq8uodXkgtpnRZIizDqCVGQSPpkfjXp1uL6/inuxdG28onEXAA9iO9cH8NLaMJJdsoLm4SHJ5+XaSR+e38q7e6bN7M44RZokIHQj+LI79QKxzicZYp2W1kBNb/bdTlkP2k2wjjDbVOMnAJPv1pLZr3UrhIGufs+xCS64HmHJ5z+FRagxbUsqcJGYkbHAO5jnP4VNquGnRE+Ty4ZHJXggYAH868u4hkDX15drY/afLC5zKMAvzxzUV1dXELNb3d75FvFlnuc4JAA4z689uTU0v71NNjUYZlLkrwcbeefqRXE/EfUG/sXSbNDgSgzSHoSQABn8ya6cJh3ia0aV9/wAgOG1OaKfUbmaAERPKzLu4OMnBPvUEMaTXEEUg3JJIiMOmQWAI/Wm0hBI4JUjkFTgg9QQfWvuKlJui6cN7WX3WB6o+lfGGs3OiT+H9K0aOytpNSuTapPcoTDbqsbNjYrLknbgDIrmNe8e6zpx1YwnRnXRdPgvbn75F6XZgVhO4bB8uMnfyQPeuW0zx1rfiGzXT9Y0nTdUsApLTzaZLcI7DGNyqSu7k8jFaeoa3csLGU+H9HuZbN40tg2g3GYE3AEoT90KMnA9OK/Av7EqYOao4mnGUlvZp313v5rS3T4tyrSmuaL09Ubtl421m++INx4WQ6Xbuu+4jupInbMflqywlN4/fKXBYbgNozgZrofhrrF94n8FWup619kaa7MoKW8LIgQOUwQzNk/KTnjrjHGTwM2t3VxcNBceH9HkgBa43voNwwMr5DnH94jqe4OKr3ni7VvDOiGLw/pGmWcDSEuLbR54EiypJkIJCk/Ko59uwrOplEsRGNGjBRm+XXTzu79L3XpYajKPvN6eq/wAzzzW7eKz17V7W3QJBBfXEMaDoqrK6qB7YAFU6DI0zPNJIZZJWMjyHBLsxJLH6kk0V/QGEpypUKdObu0kn621IWx6B8Npof7PvUivTbXsbiQJnAlXAwcd8Ht713MIvr62luzd/ZzEBiIEAfiO9eG2N09leQXMP34nDDPQ4OcH2r2m+Zblri4jHypDHIB0zk5OR34GK+ZzrDexre1T0l+Yyzbi61NJJZLs23loCEVtu44Bz70Wf23Uhte7+z+WhOVOC5yef0qDViJJpmX7sUKYx0yXz/IVPqyq80SAYxDKxC8cAAAfma8W4jya9jv8AVPHcduqS6hd/bhtiVgC6o24gEnAG1e+BXqV5oviG6s57d9Fj2SxshzeJ0II9PeuM8GXCWHxSlnKvIEt55BHGMvIfL37VUdTweOtaHh1PGFxo3iS08S22vpc31g+rWMiTyq0Nx837hDG2V+9HiM4+6flryeK8RUeKhGPKlCELXvd3bvZXW27NaeJnRvGPU1f+Eb8TumjrLpUDGxYPIfta/vGETICOPVs1U8e2OtReEtSe90WRbcRlmkiuEk8vBB3MuQdoxkkZwOahu/Dvim8l8O2OlXWsWzSaH509zd6jdosF2Xj3M33t7jLDymwMZ6Yps8niiHXvFJ1xb64sTa6gjSyCaKCCBY/3LJ83kyb+mAu8HOTjivAo4iftYVFKD5dbap6S/wAT31/KzuinjavK49/Tt6GV8K5Lh576zgl8pZdhL91xuGB6df0ruZpr+3uzp4ud+5gBOcEqOcjP4VwXwz/5B2rrj5ma3UHuDl/y4Nd3LiKC+gUYYzptPUgNjBz+dfo2bv8A2ufy/IwRJeNf2U4sjdbxIQPO4JQdxmu3+HdvPaanewS3RnUwqwLNkg59a4WZj9lvIh99rkRqTyQCVI5/E13HwrwbzVPUOVHrjIrjofxEZ1tINnMeK/id4k0rxRrVrZxaQ1hp+s2GlqktvIZXW5j3Fy4kAyp7beR6dTm2/wAQPEGta3pVhMLOPUY9c1bRTPbfaY4nMEAZJPJWYBskjKuWx2KnmvY7rxZ4ds9Sawu9e0mC+VxG1vJeRrKGIBC7S2c4IOPTmmt4w8NLpSao3iHR10x3MS3hvYhCz91D7sE+2a9U808J8A/EvXtP8BeEYb3XNKeS8ku473VdWWSUae0QZlhuD5wJkf8AhLFMDAAauj0v4s61qI8OLqg0bwfFqGltfSXutRO8MkolKCKMGWMAlVEnzMThhwep9SvvGHhqwaJb7xDo9s0sSzxia9iTfGxwrrluVJ4BHBNYHjX4laToGif2hpk9hrPl38FjcR296n7gyNjLkBsEYJwQM0AeW+APFWq+GvEOpQWsdlPpesePdQsJomjYToxCkOkm/bjgfKV/Hni5b/GjxFJbyT/YtKlnbTtTvJrCOKTztIe2VzGt0d/zByoH3YzzxXsh8ZeGBZRXp8R6N9ildo45/t0XluyjLKG3YJA5I7DrT7fxb4budUXTbfxBpEuotgLapextKTjPCBsnjnp0oA8dm+MPiaw0jVri507TL6eHw7Za5brbRSRBDOyKyyAuxZU3liQRwvbqOa0vxvrOheJvGmo6HdaBrGoaprmk2AuVR1s5PNgcbk2yMQMgDO5u5x2r6H07xb4c1O7FrpviDSLy6KNJ5VvexyOVU/M20MTgc89qsaN4g0bXDONF1bT9RMJxKLS5SYofRtpOD9aAPGdU+Ims+Ftb8Sp4glsbfULWLTI2ktori6tvOmV9wWOS4jjjT5fv5j/2iTiszQvGd9448VfDfUNUgtYbu213U7Jvsv8Aq3CWwIYfO4/i7Mw9CRX0dRQB4RexlZJnLx5S+eVjuGMbyDz64Ncz46iH/CJXbMwO65EilSCCN2B+lb+sAJf6nbjlWv8AaP8AvoE/yrnPGhC+FtQi7JcjaPQEgj+Zrz8E7Yqn6r8z1ktDobDQk8Y/CHw3p0TQSwK9o1ykjEBkikHmpwDzgMMevesvSPhz4j0O5s54LnTdUez1S4uk+2TvGZYHtVgTeRG3zALyMHOOvPHP+CfD058OWl7Oul2cd/dNHBJe37wtcOWIVVVV64XgdTzx635dJh066kN9rnhmNbiUpFHNrEi7WTCOq5HJDDkdjXweIpewr1qFKsnFylpy3vd2eql29Nu6KVODSbl+f+Rty+Atct/D3h/QoItIvNPtZBcXxed4HlYTGVYkIjfbEpI9yBj5e/HfH+aObxlOkThmi0uONwOdrbpWwffDKfxrftvDclncWuk3eqeHpNVdBiKTVZVlmJ7hMZ59q878U6Bf6Lr93pl3aotxcOJIUhlMiyiRiF2sQCfmyOcEV7PCtOnLMva1KybjGbWlubm3e7/BbK3QmcYqOj/r7j0L/hDNel8WrrulFZdLv9fivLiHz0KvboUeO4T5uv31I6kEcVF4K8FeJ9MTTjpumQ+H9QtbW7ivL2aWN0vXkYmL5I2JbZkNubB4x0q/p/wx1aDQ0s3udOjl8shpEmnBVjklgQQOp9MVMfhrrB0s2i39iJxF5f2jzZy4bGN33uuefSvn54ylyun9Yjbb4Xsk1d+9Z6Pqn07B7Fb3/rtsZHh3wh4o8Oa9a3k2kyahb22tXN4RbXMbSzLJaiPzMyuuctzyQfvEjpWVNONR+LOqPbcCaWRMMQcEQbWUkEjIZSOMjius1D4b6zcaZNb2t3pyT7NqyCefIPucn0rzXwNG9h4psbeVDHLbyPBIhxlWAZGB/EGvq+F/ZYqpXxPtFKUabjZJrRu93q+v5hycjsj2N4mNwJI3QsIzE6n8CPpVWOJ41g2FC8cBhkXcAVJAI/UYqC4bH2ybOGjnRgfoB/Qmqmrapp1lJfxahqFpayyFTEs06xlyFGNoJGefSu3fYexrpE8X9ndMwrtcZAxlcZ6+tQxAwpaM+FeOR5JFJAKq24ZPPTmsxdRGoX13B9kvExbcSyR4RiCSCDnkZ5FaULC5uXJ5D2qA575Joe9gHbGSK3DYEpuDNtJHIycnP0OafLA5iuF3IJZZhJGCfvAAED9DVW1YXH2JX5At3DfThT/KltHLHTQxyyh1P4DFFwsZOpeD9LvLq/vGLx7iWGyQBd2PmyMcc1w2sr4QtdesbW8uns2tbordxTsyvGPs8xyOOQW2YK5B3D1rv9Q1rTLZr62lv7VHeRCEMq55xuOM+1effEjRdJ8R+JdO1GK5HlqwW6JRgGjAJxnHquP+Be1d9PG19pzdjKpKy0aOp0DwvomqadBqAW4WzmjBR3YpvJJG4AjIBGMZxW7prabo8llpovLKKW3d2MTXC+YdwJBK5znBriPGelQ+J7u2XSdVsZrW0dlNj56AN5gGCo2OAQc9V47YrrNJ00aTor2c67porZAHeQTMDgr9/aueAOcCsq2IqVIWqTb8mUm27HQW0Dx3EWWQxwtIwIPOGIIz+ZptnCQ1oFaNkiZ2BU5yGztP6mo5m8m7k7B7Yk47lT/gaZbt5Elqw43Wu0+5UAg/qa5S7E0ERItlVo2jWZ5QQw5XnB/M0qRM77FZGC3Zm4YZxznj/eOKxLfXdMEdn9kvIbue3UiWC0cTSqCMfcUk9cVa0m6S6jtLxI5oxJPKpE0bRsQc4yCPUUWtuguaJhMgmVHRka5D5zzwRuH14riPilJtkhjDIyySFyAckEKBgj8a60n/AIlXmj7yTGRf++yP5E1578Rpi/iF48/Kig49yOf5CvTyeHNiovtd/gBy1dR8NVRvEszNjeto2wexddx/lXL1Z0q/n0rU4L61Ad48qyMcCRD95Se3QHPqBX0OdYWpi8DUo0via0+WtjSjNU6kZvZM9X14AXWjOP8AWi9AX1IMbhh+WT+FFkA3ifVGb76wW6r7JmQ/zLflXA6r4vvbzV7G8trdYYbNiywSMCZSwKsWIHHykgYzjr7U8+Mrv/hIRqK2UaW5iEDwByXdckht2AMgk4HoTzzX5yuG8x9kl7PeL6rTW9v67nqvHUue9+v6WuaXxUVPP0l+PNIlX3K4TP64/OuIrR8Q6xNrup/apo/JijTy4Ys5KjPJJ9SQOnoKzq/QOHsHVwWAhSraS1du13c83E1I1aspx2Z3vwyffFcwhkDR3EMoDHG4YYED3wM13Dwn7PM3mR7hc+aSW4ABHBPbgV5n8OHI8RLGT8rIWI9wOP5mvQrg5W9iHHmzIoH1Aya8TOYcmKk+9vyMC7LbM9rehim+ZyynOAOAF5/CpXgeSeZ3YYeERD65JP8AMVnXbFRfx5+UvEwH1I/wpbpisWpRgnBZSPYsBkV5lwsXLeNlkieV0CwweW2G+63GT7cCvN/iQjRz6ZGzISkBUheQDuJz+RFd5dts/tJV6MiAD3II/wAK4j4oQiO/tHUcGMgn8sfyr08nkli4/P8AJ/5AcTUF6SLOcjgiNiD+BqemuodGRhlWBBHt0r7SSbi0hNXR714s1iXR/FVnpH9sJ4b0WPTxLaypbxuLmYOV8kb1OQqhTsXDHdwayT4v1n/hK2t5NU8q5OsyWMmj+VGPJsQrEXe4ru6YfcSUPTFYnhTx94zmhtYIrb7bZLlDfnSZ7kqADjJiYBjkYyBn1ro7rxh4tjRWgtPOYyIpH/CNXy7VLAMxJfsCTjv0r8Ar5TVwdR4erCEpJNXunr3vyt37pu/blWg1FzXMn+K/zOYXx5rv/CM+JZb7xCbS80+x83TJfs0UX9oR+awS5w6HO7CptUDrkcsMdb4b8Ry3XxI0/Sx4qN/Zy6Il2YN1sfNnJAIyiA/d/eYBHr93ioX8X+LTdpH9j3QNGSZf+EavvlbIwu3fnkEnPt9Kpa9438Y2doJLOxEpJw7/APCPXcIiXBO7c7kdcDBpPBPEN04UoRc721SSukt+TSzTe630sHs5RV29vNf5nnXjO3itPGOuW9tGI4UvH2oowFyQcADoMk8Vj06W4kvJpbqeYzzzyGWSVsZdmJJP5noOlNr92y+jLD4WlRm7uMUm/NJIS2CvbtKiVNKXz5UQy2sa4JwVAQDn8TXiIBJwOpr2p0Dx3CryEtEVfbgkD9K8jiCVo016jLTWp+z3Ecs0YkliVRzgAKACfzJqw6Brt3eRP3kXlxDPOMEk/wD6qqKwuLpm67rUD8yTTbF/MmsiTnbbEj65ANfM3QWPMLrTr3UPHMdlpGZL77QpjeOUx42AFmDg5UYB5HPpzXqEvhjxgYn2XsaNggMfEF0QD2J/c81xPhe5msPibdvZwie8EV0tvAWC+bKEJVASQBnHetLRPh/4itfCfirRtY02zvxqVgb62bzVlCaiY2Rj84G2Q5U7hwMferyeKsS/rMISlGKjCFrrV33+0vh3+8Sm4t2V/kv1TN3/AIRXxsY7VRqke9CDK39uXJ80bSDgeT8vJB49MVk+O/DviWHwrqEl+r3dvHEXkWPWZ59gHJcoyKGC8nGT0zipdS+Fc2p61pUMNpZaXpkOixQSzpbxs8VwJd7+VhhskPJ8zBHXrmqQ8M63o3iHxjrup2i29hPZ6j5k7SqVcPgxBCG3v06SKAvRewr5/DYqHtIzjVg2tbWs3rotJbv52+4HUla1vwX+RR+GEIlivlEiKWlhYg9SF3E4/MV3VxD5s8jRyRkSOgxnnKE5H1rgvhmpihec9BMkZH1Uj+eK7JSF06J+jRXG4n33kHP4Gv0bNZXxc/l+SGWpIS11IBLEA06SbSecgZIx+ANdt8MkC6rqxVwQwQlR/CcD+defTkZuZ+8dyhB+gAP6Gu8+FZ3avrLZ67R+QFclB/vF/XQyrL3GV/EPwmGsaxrF8dZEX9oavY6rsNpu8v7Mm3y87xnd68Y9DWXefBBZrqW8i8QSJd/2xfanGPKlSJUulRWiIimjc4CfeV1zkggjivZ6K9Y808an+CUT29zFBq8FpFN4eOgrFBZyFIwbgzeavmTsxHONhY+uccUusfBZ7641Ga38QLBJdf2YUDWO9Y2s02gkCQbg3XHGOmTXslFAHjy/BS3udQtr3W9TttRkOtTaxewPp4+z3BkQL5Sxl22qMA5YuSanv/hNfX/jPT9ZufFM0llp+qJf2di0Em23jX/l3QCURquMDcI92OCSK9aooA8Xs/gbBDp/h+zn1ySSLS4tUhkaK18t51vVZTht52lNx67s+1dB8M/hqPBeoNdyX8F9N9iSxSby7lZTGhG0MZLmRMADoiIB2wOK9IooAKa7BFLN0AJNOooA+f75J7q9utUWPFu05m2d+46+uDWB4stpbvw5qV4oxACjEfQgAn869Xk0S3SWaNXkFq0hYwcbevTp0/Guf8eaTDD4R1qS1MkYaEsYkwEPIJ4x+PBrgw1JqvB+a/M9NVVsjmNL8MReN/hl4QtPNiNraXBkuvnIZcJMh2YB+cM6kZx0zVXTfh14p08Wkjy6PqVz5GoQXLXM0iK5uJQ3mECM7jwSV454z3rK8F+F5G8MWF7d3mj6al/O0VubguHuWZ3KA4dQWPIC8nA/AaFzoNjY3Za98X+HofOYwpFLM6gOjFXCgzddxwR2Ir4LFNU8RVo069480tORvdyvqn5vbsuxfs4NJtm+vgTV4p/CtrHJZPY6JJbSG7e4kMk3lqFYNBs2FuoVi+UHTkVy3xlvbdPiVpDNKgW0itmnOciMeeWOfTgZ+lbI8Dy6dHp9rea/pPnzgQwmfzQ9w4HO0ecNzd+K8z8e+HL3QtfvNPuBC8t2gmgeDIRw+UHBJIOVOck+veu/hmlQxGPvOunaE7e61e6d3d+remnoE4qMdP60PQPih4J8Qa7q/iHVvDgDPcadBaQp5yhLyJvN81OW6jMTAnA44qa28HawPGVxdQ6MbW5bxAL8az50QzZ7FDQ8MZG3bWG0gAbs5qeTwLY2sotr7WfD9ndiBrl7ZbNVCRjOXAMgO0f3sAfSqMXgrQpLtNIj8XaM2oF0lWERIZ2BIkAx5uSpBAxjlTXkU8TD2SpKsrJW/hz2sl0eq066avpZBKnFO9zb+Evhi88L3mptNpv9naW0KENeC2Ny0oZi5MkP3ohnguc/QV5hp80V948vLm2ffBPfXc8bqCcozSMpA78EHivQR4D069vLrTLTXdCn1GFCZLX7GrvHz1dBLkDkDmuK+GukPH4/t9MvwBJaPNDLsJxuRXXKnHTIz9K+r4TVGtWxdf2nNOUErcrjp31vfpqDShax0Vz4hsoI54ZTdO1x8wJsZxzgDps6d65DxVpthqGsyajJd3W66txbywzWF55bgEEfcaMnp0yR7Z5r6HbRbSSNlnDzMQFDyEFlGcjBxxSNolrJGVuDJP8ALtUyEZQZz8uAMGvWjTcXeJi5qSszyOy16z0u2jWY3Lr5KxLixuFGFBAHK9PzNY/iXxVNoehNqGmvI08RRtk1lMiSICQVLFRjhs5BHIFe6f2LbOm26Z7lQpVRJj5B6jA6+9ZXiLwXYeIdNi07VZ7mXT1lDvArBRKBkhSQAcZ2ngjpRGilJNhKq2rHkHg/4g2eq2r3MVpdC4iURtbiMkbnYbVWQfLyzAfMQfarWreZBqem2N/D/aeqag0jxWXnGG1gQAM24gEt6cg57Ba9RvfBVp/wj39maW/2RIGEtoqooSKRWDKSABkZUA+ozXCazZ217qVgmtG50TXrNibeRWUFsjDeWzKUkVvTBPqAa5MWpU2nFe7rff5ba29DixdWpZa6dbDv7d0rQLeKDUYItMuTGZntrWNplSNWK+YTGvCZ/iYD3weKr3ni+R7/AFG30Swj1GPT7ZLm4la58sEOu9Vj+VtxK89h71JqPguzv2MkuoaktxLatZ3Eyuha4iZixV8oQOc/dAwOBgVT13wSfs0zeGbptOuZLeO0lj34inhQABWJVirbeAy8ivKgsM37z1fe9v8AP8TzFydTdsX0zxPo1pftaxXFvcRiRBPGGKg9j6EH0qlqGkXFhHJcaNLLIgTa9lK5kDLkEiMk5VvboemB1rHTRrmw8U+HZ7XR3htbK0ktpnhuVkiiDABdu9lYgYYk7QTn+Ksz4c6VrZ1qaDTLYNL9l+zXd4HWSB5/NZjcMwJ3EKfu/fJ4IAGRvQozu/Yy+W/V76mtFzjK9JnV3ev2Vytq/niNZYSykozblcDpgenNVrnxFpl8othdbGWNo2ISToQVOOPTmvUtM8M2ml2dnBYPJC1tEsO8AEyADGW46981YGiW0ciS27PDOBgyLgl+c5PHWvX9ie57U+dvCun6XomoWZj1SOd7RXjjkeC43opYnAzIU+uEH512P/CS6YEhs1ugJInDbzG+OORxt969ZOiWwMbxF47hSSZVxuY9Tnjn+lI+iWzbXy4uQxYzjG4nvnjpx0qpQc3eX9fgKM1FWR89T/Eu30jV7zQ9WXzLPfmC+jQgqjfNh0xnjJGR6dO9VfFcpn1yefcXSUK8blSoZSowQCOle3Wvw30Qa3fa3qCPfazdS+aLqYAmIDARUXGBhQBnGT19h5d8TtakuvEF3YBVeK1fyvNkRTIxA5+bHA68D8a9jKIcte8I9LP8B0pSbszi6KKsWMdrLNtvLiS3Q9HSISc+43Dj6Zr6huyubFeiu0Pgm1l8H6zrllr0N0thZzziOKIg70jLKG3EEDj057VasPh19o8HaXr8usw28FxYQ3c/nRECMvGGIBB55OMYzXI8fQUuRvX0ZHtI3scDRVm/htoZdlpdG5QdX8soPwBOfzAqtXWndXLNvwXMbfxLZyBSygsGA542kE/1r0/yLll/tBkHkbxIVHsMDn6VxPwy1iK28QWdheW1vJbXUojLeWofceFBbHI3Y4Ne5R6Jbovlh5DbbtwgONuew6cj8a+UzunKddNqysQ5qLscEYri5WS8RP8ARyyMR3IUkjn8aRknuvMuoo/3BZGI7kKcj6V3q6JCiyRRyOlrI25oQBjrnAOOBSJoiRrLDDL5drIcmIIMgdcA9h+FeN7Bh7ZHC+TPe+ZdwoDANpIPVgpyPpWF4x0241zTJbu1jLC0G7AGSwH3v55r1ldEgjMiQSPFbyHLxIBg85wDjgVV1Swt9M0+/vbdnghjheSSKMDBCqScccdK3w0Z0qsakd0xe1R8x1FdEi2mI6hDj8qmdizsx6sSTjgU1lDKVIyCMEe1feNXVi2ez6b4i1CDVNUs11IWl1p+IdL0BbZCL2IW4ZWB27zlsjKkBcYI5rKsPGer3GlX7x+JzOo0RL6e8FpEfsF9vULbbVTndll2MC/HXmsDQviT4i0yKzs5b62ayQiIz3Fv5jxpjAJIYZA45POOSa6rxD4+1fRms1k1bTZGuJFzssidkfeQ4k6Divw7GZBisJiPY1KMXJ2ts723fwPffXXvdaFRpylFyT0X6/MoSeONWk0nSbnU/EZ0bVbjXlsb7Ttlugs4cYYDzEYkABW3k4+f6VHr3jW+trTxhJB40ZJbDWLa1tFzaH905XeMeXzgNJz28vn7rZ077x/qdrq1haNrmkOt0CTItoSIzxsJPmYAOSMk9cVS8V/EHxBpVzHZ21/ptxO6lpStngxDopPznk56Gs8LllWvWhTp4eN5apdLKSfWntZNa9H16uWHqRTbe2m//BOK8bxQw+MtZW1cSQmYOrrjD7o0YtwAOSSeOOeKxafcTTXVzNcXUrzXEzmSWV8Zdicknj9BxTK/asuw88LhKVCbu4xSfqkQjR8P2T3+rW8KruXeGbsMZz1/SvWmhn0w4uE3+aioO3QYA+nNc98EktbvUtTsrqEOzwCVHxyoVgDg+uWX/Oa9dOi20hJui9ydu1TJj5R7YHX3r5/OuepiLPZLT+v62JdRRdjgvJuNKCvOu8OgRe2MZx/Ol+zz6YsdxON0ZQqAOCBknj8TXejRbZ2Bume5VVKqsuCFGPp1oXRbUsvn+ZcIgKqkuCqjp0xz+NeR7Bi9sj5r8UOIvE1xPcIdsV0kzqhIOAwJAI5zgHpXoOufYtP0C51EXV6Y1hLxsL+chyR8oHz85yKueOPhjdX2oS3+iTxv5gG6CY4OQMfK2Oeg64+tcBeeCPE9tGkE+l38kERLRxRsZkQ9yqqSB+Ar0sfldPNfYTjVUeVJNd1/mdFHEQgpXim3tfodRfxxWOl6PePqN40BliWeX7fLiVXUqDnf03Mrcdh6VH4+trK08NXHmtcSyykRQpNcySDeTjIVmIyBk5xxiuHtPD2p313cadb6feTT2eDLbFGJgLjK7kP3Nw55AyK6nTfhn4n1Foftim3ijXbG15cF/LX0Vckj6cVwQ4YVGrTqVMQrRd36XuvmayxVPlaUFr+BY+HEE93YXMFsAXaYPk9toBrp9s3lPYOo89pCc9gM5z+ddd4a8HWmh6RDaQyublSWe5UAM7EAHjnjgDFaJ0GyMW3a/m7t3ncb89OuOntW+OXt8RKpHZnF7ZHCXMM8AkspkBlnYsD0HPJ4rvvhZbT2mp6hHcjJeNZMkY5JxSSaLbTKxuC8sxwRK2Ny46Y44rofCVglvc3DiSSSRkVd7kZAHbgYxWNGk4zTM6tRSg0dVRRRXpHAFFFFABRRRQAUUUUAFFFFAHGT/wCvk/3j/Oue8d/8iZrX/XpJ/I10M/8Ar5P94/zqhrFkNR0m9smO0XELwk+m5SM/rXNTkozUn0Z1rRnlOmaNY+Nvhv4U09r21WGwuyb1Hm2SR4jmT5ePvhnRhnHrmq2m+Btf09bSR77QNSufJ1CC5a5unRXNxKGEhAQ7jwSV454z3ri7Uv4V1G8stb0OG5LNuCyou9HxjIYjlTjPH1Gc1V0zWUs7m+ludF026W5fzFQoqCI4ACg7TlcAenOT3r5/EcM5gqtVUHendtaJ35m9nzL+Z322R2qnTlZuWvzPTm+HU0Go+Fru38SwXR0h7VSLrbmOGKJlYRkZ+8xzg47ZPyrXO/GnVLSfx3aPbTJOtlbxCcxEMFIkZyvucYOPcVyWlawLC0uYptG0y7kkdpIneMKIyxJKkbTlQTwMg44rKiTYpBwWJLMQAASTkkDtyelejknC2KpY32+Nm2oRcVolfm9G9r/eKUIpWi9z2P4heHLPxpfzaxpPiDS4Jv7LFvYz/agCJC77w3B/dtG5U989uKqt4WuJby9tpNV8PJp93c6fcm6F6TPD9mjiUhE2gAsYz827gHpXn+m689hoxsF02ymlUFYbmQDKDtuXb8xH1Ge9Q2+rywaA+lfYbGQlTGLt1BcKc5yuOW565/A15cOE8zpx9lF+7F2W2107rXZWT9b6DdOm9b6+j37HrHgXRW8L+Iby7uvEemHSj9pZgL8ubhpJfMEjo3yxFQdpKE7uprm/h/dw6h8Xrm8tW329xcXUsTdNyHeVP0I5rjZtbnl0MacbKyVyvlteKo8xkx0244bHG7P4Zr0f4KeGLmO7bXLuExW4iMdsGGC5OAWA9Mce+favZyfI62Wuvi8Y/ekuVba9b6X/AK8rEVFGMbRen6nsdFFFbHIFFFFABUF5a297btBeQRXEDfejlQOp+oI5qeimBzD+BtC/5dre4s/9m0u5YU/74Vgv6VEPA9jwDqGrsvcfayMj64/lXWUVm6cJO7S+4l04vdHMxeCNAVg09k94wOR9snkuBn/ddiB+ArooYo4YljhREjUYVEAAA9AO1SUVaSSshpJbBRRRQMKKKKACvD/iZ4G1Ua/dalpdrJd2l03mFYQWdHI+YFepGecgV7hRXThcVPDT54lRk4s+UL/SdR05VbULC8tUY4UzwNGGPoCRzVKvrHVNPtdUsZbO/hSa3lGGRv5g9j7ivNL74O2kkxay1eaCI9EkgEhH4hlr26Gb05r977r/AANo1U9zjPBbkeB/iGnOG0aVvbiKX/Gur11ivwB8OAEgGwsQQO48pOD+Va2qeE7Pwp8LfF8VtI8882l3LSzMAC2IXwAOw5NXvDuiW/iH4Q+HNOumdEk0qzYOuMowiQg/57V51XEwlivbL4boxck6lz59qxZ2N3e7/sdrcXG3G7yoy+30zgcdK9ctfg5bLLm61iaSP+7HAIzj6lm/lXRrYXfgt0fSLaS+8PlAtxaRIGuIX5zMmBmUEfeU5PGVz92vSrZtSiv3Wr+42lVSWh558M/BeqT+ILTUb60ltbK1kEuZlKl2H3QoPPXnOMV7xXM33jbQ7TTdO1H7dFJp95dpZidGG2J2BI3/AN3lcEHBGecYNdISFBZjgDkk9AK8TFYmeJnzSVjGU+YdRXJXXjeyZ2TR7W51Ug7TLAAsIPfEjEBh/u5qmfFeuucpo2mxr6PfuSfY4h4/M1588TSpu0pJMwlWpx0bO5qG7t4ru0mtrhd8M0ZjdfVSCCPyNchH4yv4Wzf6A5QdWsrpZiPfDrHn8Mn2rodD13TtbidtOuN7xELLE6lJIj6MhAI/Hr2q6daFTWnK5cKkZ/Czw/xl8O9T0OaSaxjkvtN5ZXjGXjHo6/1HH06VxUUEs0ywxRu8rHaERSST6AetfWk7SrBI1uiPMFJRJGKKxxwC2Dge4B+lfPfiHx3431H4h2fhaOCx0dLq8W1kubBvOcqCDIBMRjKqQSAARxnFe9Rzaoo2nG777G3t+Vao6nwf8KUms1uvEjyo8gytrGQCg/2zjr7Dp69q5L4heCD4UvzLYwk6VOf3cmBlG7qxx19z1H419FgYAA7cc80kkaSxskqB0IwVYAgj0Irmp5nVVX2ktV2/yBVHe7PkaC1M0iwW8G95SFEaLkuegAGOTXsehfCGwGhxjUppoNRkG5hAVCRHsMY5+uaufB62gTVfG48mHfb6/cpFIUG6OMhTsU9lHYdK9NrTFZnObSpLlsDq31R8xeL/AArf+GL4w3a+Zbt/qrlAQkg/ofY/yrJ0+wu9SuVgsLaW5mPRI1JP1PoPc19YSRpKjJKgdG4KsAQR7imwQRW6bIIo4164RQB+VawzmShaUbsr2rtscN8MfBD+GlkvtQcHUp4/LKIcrEuQSM9zkDnp6V31FFeTWrSrTc57mTbbuwooorIQUUUUAeb+DcxfGf4iIefOi06UH0AhK4r0ivN/Cn/JbfHX/XpY/wDoBr0iqkKOwUUUVIwrW8N/66b/AHf61k1reG/9dN/u/wBauG5M9jXv76106zmu9QuYLW1hXdJNO4REHqzHgD61W0XWtL121a60TUbLUrZH8tprSdZkDAA7dykjOCDj3o8RGf8AsLUBaWkt3O0DqkMRRWckEAAuyr37kV4r4U8H+M4/Dnw50W4tdX0m0003kOsLbamkO9GTMTBoZcsNzYHcEE4AwT1HOe3vqVimpx6a95bLqDxmZLUyqJWQHBYJnJXPGcYq7Xzx4Q8DeN4PEHgzW/ElvqdzqUGmT2V5P/aYZrebz2MLyATASR7CpZVLbsfMCaqWnhX4sx6JqouNQ15tYlsZof3d2nkSzGQMkiStdlo2xwNkMYxwR3IB9JUVxPhXwlqmmabpq3Hi7xJJKm2a5iupLacSuSGZGdoSwX+HCMMDoc8121ABRRRQAUUUUAcZP/r5P94/zplPn/18n+8f50yuM6ivd2dteIEu7eC4QdFkQMPyIrP/AOEY0D/oB6V/4CR/4VsUVSqSjomO7Mf/AIRjQP8AoB6V/wCAkf8AhUo0HSAMDSrAAdB9mT/CtOin7WfdhdmDq2kaJaadc3U2h2dwlvG0xjjtI2dgoJIUEcnjpmvn7U/iZ4Gl8eaLqVnpUqaNDbzR3lsbKMB2IzGwQHBIPc9B0r6fr488f/DO4h+Mkfh/SovLtNWmE9qwGViibJf8Ew/HoB61pTqS6tkTlJbH0j4Dn8M+KNFj1rRdChtbZ5GSN5bOONn2nBYYzxnIz6g12VUND0u20XR7PTbBNlraxLDGO+AOp9T3z61frGUnJ6u5WvUKKKKkAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPIfjV8TNK0Cx1rwvf2GqC9vdOlSCZI0ML+ZGyq27eDgNkH5c8HrUXwb+KWkazaeH/AApY6fqrahbWEcMsrRxiFPKiAZiwfO3IwDjPI4pP2mvCX9t+DV1m1j3XukkyNt6tAcbx+GA3sA1M/Zl8HDRPCTa7eRbb/VQDGWHKW4Pygf7x+b3G30rX3eS5GvNY7z4m+JL3wr4Un1TTbIXc6SIh3AlIlY8yPyMqPqB6kDmsfwXf3/jjSp59TvRaSWly8UcujXsRSaMhSpcRyShWx/CWOPxr0OiovpYq2p4/8UvhbqHjjWYzaTabpVhGo82dUZ7i6fH3pAAAQM4GST1PtVu80PVPD3hPSPD+s62dXsJbsQGY25hbyhG7LE53tuBZVHbI45zXqtU9U0+11Wwlsr+ETW8oAZSSDnPBBByCCMgjkHkVNS84OKdiZQunbc+f/CF59oMo1HVbm38TLdyxpYtO+xAM7F8gHBj24O4D33DrWTf+MPEOueFddMMK6fLptuFunhV1kW480grGQ3ChFyTyRmvZLjwxrennGnXVvqdsPupeMYZlHoXUFX/ED3JrI0rRNR0aOeKz8LXqieVriUx3cEgeRjyxZ5QSeK8eVCpCTk6d3dW103/L5HnyozT+G5j3uvXWn/D8axamHVrlIVYPAD5b/MAWOGY/KCScEng9O0ukX/nTaXqtrqenahqAvobVZdOTarxuyh4WG98/KWbkjGAcDGa6RNN8R3Pyw6Vb2mf47y6BwPXbGGz9Mj61veH/AAomn3i6hqV0b/UQCsblNkcIPBEaZODjjJJJHGccUYXB1FJSlHl1v5+n9WKo0J8ybVjM8Qz6oNOnvfFGqW3h3Q48CRLJ2kuJASAFMu0bSScYRS3o1Q2dxod5baY3hXRZb8aJdOqwRgWslpIYyrB0mKNkiQnnqeTzXS+LvDmn+K9Bn0nVkc2spU5jIVkZSCCDg/rketQ+EPC1n4XtriGxfes7h2P2W3g5AwOIY4wfqcmvburHfbU3YmLRozoUdlBKEglTjkE/4VzfjnxppPgmxtrzXPtK288hiV4ot4DYJweeOAfyNdPXMfEjwxF4w8GalpDhPOljLW7t/BMvKHPYZGD7E1KtfUp3toePfDr4teGdJ1bxS1096x1TV5Lq2WO3LF0YAKCM8HPavoZW3KGwVyM4PUexr5L/AGcvBEuq+OZdR1O3K22iPlkkHW5yQqn3Ugt7ED1r62q6iSehEL21CiiisywooooAKKKKACiisHxx4ktvCXhbUNavMFbaMlEzgySHhFH1JA9hzTWoHGeFb+1/4Xz42tPOjNxJaWbKoPJCIN34jevFeo18GeGfGV/pHj628USyNNdfaTNc/wDTRXJ8xfxBP049K+67G6gvrK3vLSQSW9xGssTr0ZGAKkfgc1c42Ig7liiiisywrW8N/wCum/3f61k1reG/9dN/u/1q4bkz2LPivXbbwz4b1HWr6OaS1sYWnlSEAuyjqFBIBP1Irgbn416HaRXk13pGuwxWUdrNcM0cBEUNxjypTiU5U7lGBlh6da9F13SbLXdIvNM1SEz2N3GYpo9zLvU9RlSCPwNc5ffDTwlfwX8F3pO+K+t7e1uF+0yjzI4CDEvD5G3avIwT3zXUc5kRfGXwtJ4xHhyOS4e6N62nCYGLYbheq7d/mYz8u/ZsJ4BqhY/G/RL2xtby30TXzFdWNxqNuCluDLDAxWUgedwV2scHGQOMnArtLfwXoltrM+qWkN3a3M85uZltr+4hhmlPV3hVxGxPclTnvVCy+GXhGytbS2tdJ2QWlpcWMK/aZjsgnJMq5L5O4s3J5HYigDgh8YDaeLNZ1KddQvPB8ekWOoRxwQwh7YTYzI+WViOVBALEdhjmurt/ivpV1rOr6fZ6Trc/9l7xPdiGKO1BChgPOeRUUsDwGK++OKsy/CXwXL5Yk0iUxpbw2piF9cCOSGHBjSRPM2yAYHDA575rTufAPhm5sdcsp9LV7XW5Vmv4jLJiZxjBHzfLjav3cYxQByln8bvDd5ZSXFvZ6nK8WpQaU0MRt5SZpg3llXSUxsvytyHNJc/HHwxa2CzXVvqEF2by5sGsp/IiljlgAMu5mlEQA3Lj5+ScDJ4roYvhh4Sidn/s2aSR7q3vWkmvriV2mgBETlmck7QSME4PcGpH+G/hctI6afLDM99NqXnwXk8UyXEoAldJFcOgYKAVUge1AGz4S8QWPirw7Y63pLs1jeJ5kZdcMOSCCPUEEVsVU06yi0+yjtYGuHijGAbid53P1d2ZmPuSat0AcZP/AK+T/eP86ZT5/wDXyf7x/nTK4zqCiiikAUUUUAFebeMP3Xxp+Hzt92aDUI1x6iIE59q9JrzT4qv/AGX4v+H/AIgkO22tNRkspW7ILhNm4+g+XrVR3FI9LoooqRhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN/EhS3w78UqoJY6VdAAcknynpvwzYP8OfCxUggaVajI9REuR+lb1/axX1jc2k43Q3EbROPVWBB/Q15/8AA6/dPDM/hrUGxq3h+4eynQ8Fk3ExuB/dIOB/u1VtBdT0iiiipGFFFFABRRRQAUUUUAFFFFABRRRQB5r8IsLrfxBQYDjX5mI6HBUEH9DXpVeX6bKPCvxp1Wzuj5dj4ohjurV24T7RECroD/eIO78hXqFVLcUQoooqRhRRRQAUUUUAFVdQsLPUoPI1G0t7qAMGEc8YkXPY4I681arM8R61Y+HdEu9V1WYRWltGXYnqT2UDuSeAPWn6Aea+FfD+i3Hxg8cW50jTpLW1gsQsRtUKRM0ZJwMYBPXjrXrFtBDawRwW0UcMEYCpHGoVVHYADoK4P4OabeLpOpeItXiMOpeIbo3zRtnMUPSKPn0Xkexwa9Bpyeoo7BRRRUjCtbw3/rpv93+tZNa3hv8A103+7/WrhuTPYf41gvrnwpqlvpMl7FfywMkMll5fnox4ynmOi5Gc8sPYg4rwXUv+Ey0G18L2euJrcZu9fS3EdvrEwur6DyTkOWupFjYkZwsoXPPGK+l6K6jnPnbUPDvxTk8GWFh5OoNf7Lxluo9Zf7RalmzBFIVuYlc9P3hM2P7p79L4X0nxrHr9nceMLbXb+NrPT1gNhqixQ2c6xqLg3ESzR+b+8yxx5gIyAO1eyUUAeKfC/QPiHp/i2C48XahqssYE63XzpLaXGSSjLm6JTHygBIE44PrXtdFFABRRRQAUUUUAcZP/AK+T/eP86ZT5/wDXyf7x/nTK4zqCiiikAUUUUAFY3i7w/Z+KfDt7o+oAiC5TbvXG6NgQVZc9wQDWzRTA8o03xvqngeBdK+ItjeNBbjZDrtrE00M8Y4DSYyUbHsc/qdcfGHwEQD/wkUPPrDKP/Za9AqqbG0JybW3z/wBcx/hTunuKzOK/4XD4C/6GK3/79S//ABNH/C4fAX/QxW//AH6l/wDia7X7BZ/8+lv/AN+x/hR9gs/+fS3/AO/Y/wAKPdDU4r/hcPgL/oYrf/v1L/8AE0f8Lh8Bf9DFb/8AfqX/AOJrtfsFn/z6W/8A37H+FH2Cz/59Lf8A79j/AAo90NTiv+Fw+Av+hit/+/Uv/wATR/wuHwF/0MVv/wB+pf8A4mu1+wWf/Ppb/wDfsf4UfYLP/n0t/wDv2P8ACj3Q1OK/4XD4C/6GK3/79S//ABNH/C4fAX/QxW//AH6l/wDia7X7BZ/8+lv/AN+x/hR9gs/+fS3/AO/Y/wAKPdDU4r/hcPgL/oYrf/v1L/8AE0f8Lh8Bf9DFb/8AfqX/AOJrtfsFn/z6W/8A37H+FH2Cz/59Lf8A79j/AAo90NThpvjN4AiA3eIYzn+7bTN/JDUf/C7fh7/0MH/klcf/ABuvQYbaCFi0MMSMRglFAOPyqajQNTzj/hdvw9/6GD/ySuP/AI3R/wALt+Hv/Qwf+SVx/wDG69Hooug1POP+F2/D3/oYP/JK4/8AjdH/AAu34e/9DB/5JXH/AMbr0eii6DU84/4Xb8Pf+hg/8krj/wCN0f8AC7fh7/0MH/klcf8AxuvR6KLoNTzj/hdvw9/6GD/ySuP/AI3Xn/jfx54QfXovFXgzxTDaeIok8qeKayuPJvouPkk/d8Hjg/TpgEfQ9FNNITTZ4p4b/aF8PajEkeq6fqNjdkDcIkE6H1II+b/x2uj/AOFz+Dv+fm//APACb/4mvSKKLx7DSfc83/4XP4O/5+b/AP8AACb/AOJo/wCFz+Dv+fm//wDACb/4mvSKKV49g1PN/wDhc/g7/n5v/wDwAm/+Jo/4XP4O/wCfm/8A/ACb/wCJr0iii8ewanm//C5/B3/Pzf8A/gBN/wDE0f8AC5/B3/Pzf/8AgBN/8TXpFFF49g1PN/8Ahc/g7/n5v/8AwAm/+Jo/4XP4O/5+b/8A8AJv/ia9IoovHsGp5v8A8Ln8Hf8APzf/APgBN/8AE0f8Ln8Hf8/N/wD+AE3/AMTXpFFF49g1PFvG/jbwT4y0b7FcR65I0biS3vLXT5Q9tMOjKSBz7en6Y3hf4y6zpTGw8Q6LqWs28ZCx6la2jxSuvYvGwALfQgfXrX0FRT5la1hWfc8zX4zeHSUV7LXUkYEhG098/wD1/wAKl/4XB4f/AOfHXv8AwWyV6PRSuuw9Tzj/AIXB4f8A+fHXv/BbJR/wuDw//wA+Ovf+C2SvR6KLx7Bqecf8Lg8P/wDPjr3/AILZKT/hcvhMDazaok3Tym0+Xfn0+7jP416RRRePYNTzNviZe6n+68J+DNf1CY5Cy3cItIAemd7H9OKSw8Dav4j1S21b4kXtvdC3bzLXRrQEWkLdmfPMjfXj3I4r02ijmtsHL3CiiipGFFFFABWt4b/103+7/Wsmtbw3/rpv93+tXDcmex0FFFFdRzhRRRQAUUUUAFFFFABRRRQBxk/+vk/3j/OmU+f/AF8n+8f50yuM6jobLTbWS0hd4suygk7iO31qf+yrP/nj/wCPN/jTrRxFpkUjZ2rGGOBzjFcZoHinWL/wy/im4SwGkeTPcCzjRzOqIGx+83FWYlcY2jr14xXZClzRvYw953Z2P9lWf/PH/wAeb/Gj+yrP/nj/AOPN/jXDWPjDWYR4buNUj06S115GMUdtG4e3bZvQMxYhxjgnC4NcrZ/F3Wp9HsGbTLVdQluEaVtjiEWzMEDD5s7i2R1ONp4rZYOctkv6/wCGKUJvY9j/ALKs/wDnj/483+NH9lWf/PH/AMeb/GvNpfiBqqeI7yyi/suYwautglgkbfaZIj1lB3nAHrsx7it3RfFl/feBdd1qaK2F1YNdiJUVgjeUDtyN2e3PI/CplhZRV2hOMkdZ/ZVn/wA8f/Hm/wAaP7Ks/wDnj/483+NcFYeKdfvPBlxrVvLYNdR2aXnkz6Vc20QGNzKJXk2vxnBXjv0Nb/gTxFdeJ1v78xwwaas3kW0RUicFQNxkycA5PC4BA60pYdxTb6A1Ja3N7+yrP/nj/wCPN/jVTU9PtoLGWSKLDjGDuJ7j3rG8Ja3q2peJvEVhqElibbTJUij8m3dHcsAwJJkYcDIwByecjpXSa1/yDZvw/wDQhWdWmoXTFqnZnL1r6LZQXNvI08e5g+AckcYFZFdB4c/49JP9/wDoK56avI1m7Isf2VZ/88f/AB5v8aP7Ks/+eP8A483+Nch4Z8UavrGhP4lZLBNHzM62io5nEUe4bjJuwWyv3do+tVNM8Zaxs8L3uoxae1hr0vlJDbqwltywJUlixDjA5+VcV2/Vndqy0M+WR3X9lWf/ADx/8eb/ABo/sqz/AOeP/jzf414zF8YNbbw5HO2lWo1JpRJu2P5H2XzPK3j5s7vM+XGfet3UPiDqlv4j1Oyg/syY2uoxWkVgsbm5uEYAsynfxj12EVbwU1o0inTmj0n+yrP/AJ4/+PN/jR/ZVn/zx/8AHm/xrmPD/im91Hw74lv547dZtNu7uCEIpCssQypbJ6+vI/CsjRvFXiHVPCE+rW81gLtbT7UIZtJuYIRjkjzmk2uMA8r9elR9WeuhPLLud9/ZVn/zx/8AHm/xo/sqz/54/wDjzf41zvgPxNdeKhfXwjgg0yN1ihiIPnh9oL7+cAZPAxkjn0rPt/EWvT654xshNpgj0WON4G+yOS+9DIN373sAV4xk88dKX1d3cXbQLSu1c7L+yrP/AJ4/+PN/jXLuAHYDoCa0/AOq32t+FNP1PUjb+fdR+btt42RVB7YLNn6/pWbJ99vqa568OR2Khe7TLmjwRXF2UmXcuwnGSOcitv8Asqz/AOeP/jzf41yd1q66Dpeo6o8RlFrbPKIwcbjxgZ7fWotS8Ta7ofg2TXdUTTLvzIYmhit1eIRySMoAZizBl+bO75emMc5F0aTnG9utgkpN6HY/2VZ/88f/AB5v8aP7Ks/+eP8A483+NcB4g8Za54ck1Sx1GPTrq9i0s6jbzW8TpGCGCMjoXJxk8MCM+mao6H8S9V1PxD4f0xtOhgNwxh1B2RsLKFLARHd0wFbJzwwrdYSTjzJKwuSdrnpv9lWf/PH/AMeb/Gj+yrP/AJ4/+PN/jXlnh34k6xqNrZzkaVdST293LPb20ThrLyQ2xpD5jfK+B1CnnjNb2reMtRtPhTaeJYorU380cDsjIzRguwBwobPf1olhJRaTS3sDhNOx2v8AZVn/AM8f/Hm/xo/sqz/54/8Ajzf41xmp+KNW0vR7fVZZILq0S8SC6RtLuLOYxuVH7pJHJZgT6EHoOQa3PBup6hrnhqLUrk2ccl4GltlhBdY4z9wP83zMP4sEc8cVEqHLHm6EtSSua/8AZVn/AM8f/Hm/xo/sqz/54/8Ajzf415pL448RR/DvUfEZOlGe1vDbiL7LIFZRIIzn97kH5gfbGOc5HRXGs63bePNJ0N59Oe3uLRriVxaOrZQgMF/ekAHtnOPeqeGa3t1/AbjJdS1qcKQXsscS7UXHGSewqtV3Wv8AkJzfh/6CKpVwS3ZrHY6NdItSoJD5IH8VO/se09H/AO+q5nxTquoDxZoOhWl62mW99HLK90qIzuUAxGm9SuTnJyCfSs+fVtTuvFkGgx+IVtbeLTmuzfxQwl7lw5Qj5gyAKBltoByD0HTujh7q+m1zK0u5239j2no//fVH9j2no/8A31XkEPj7xTcP4YuraL7UslvNNd2dvCCbtI5ShaPgtnHzAAgEj0pieM/FA0lm1K/ktrv/AISKGwlFvbI7xQuhZo0XYdzA8fdJJHetfqMvL+tC+Sfc9i/se09H/wC+qP7HtPR/++q860/X/EsWseH7bUJp0tb3VLmFDcWyxy3FsseYy67RtOc9lPqKu+INW1pviNJpFhNqhso9NW58nTltN+8yFSxNwOmOMA9fxqPquttNrk8su53H9j2no/8A31R/Y9p6P/31XnOt+ItZsPGEuhx6xizuLq2Uag8MZNkXDEwEbdpZ9g2kg43c9q6H4pahqOlaLZ3Ok6hLZytexW7lEjcOrsFP31bp7Y980vq2sVpqFpXSvudL/Y9p6P8A99VR1ewgtbZXiBDFwpyc8YP+FcH4t8U6/oOu6joMN2815qK239jTSRR5QswSTdhcHnJ5HH0r0HWUePSrdJZDLIrKGkIALnaeSB09eKzrUPZw5u4LmTV2YddDZabayWkLvFl2UEncR2+tc9Wn4hn1C18EXs2ixmTUUtC0KqNx3Y6gdz7dzWFGPNKxU76JGr/ZVn/zx/8AHm/xo/sqz/54/wDjzf415dc6oIvAd3c+FNc1LUNX+yRNdA3D3Lwgsod9rZ8twC/yjbxk4O3Iz9b1iWCPxAvhTWr++0aPRvOkuWvJJvIudwC7JSSVYrklQRj0HSu6OE5nb+un9IShJ9T2H+yrP/nj/wCPN/jR/ZVn/wA8f/Hm/wAa8f0q48XW/ifwXFrd/MLF3aGIrMSb1PLLiSUA8nBRcNzkE96r+DG8R33hiy1iK61VYI7S/a9urq/aRbgjeIvLQuSrKR12r0/iqng0le6/q/8AkHI+57R/ZVn/AM8f/Hm/xo/sqz/54/8Ajzf415Jq3ioTfBS3ez14SazFDbG4aK9/0hCZFDb2Dbl64Jq7qGo7dK0xtA1OOTWW1NFtra012bUIrkYBdZWfGF25JGDjgjlqn6p37tByS7np39lWf/PH/wAeb/Gj+yrP/nj/AOPN/jXKfDuQa14Hcvqd9NfXBlS7kkkIkt5zkOqDPyBc/KBjjB71zHw61LXNd8S2thqNzdovhuCSC9/eti6uC5RN3PzDYu7Jzz9c1P1Ze9/dJ5Xrrsej6np9tBYyyRRYcYwdxPce9QeG/wDXTf7v9a0ta/5Bs34f+hCs3w3/AK6b/d/rXI0lJWBO8WdBRRRWxmFFFFABRRRQAUUUUAFFFFAHGT/6+T/eP86ZT5/9fJ/vH+dMrjOo63Tv+PC3/wBwfyrJsfCejWN009taFNzO4h86QwqzAhisRbYpIJHCjqfWtbTv+PC3/wBwfyqzXZGTS0Zzt2Oc0zwdoWnXEc9pZMskSskIeeR1hVvvCNWYhM99oFSf8Iloo0C20UWf/EstnEkUPmv8rBtwO7OTzzya36Krnl3FzMzdM0ex0ue9msYPKkvZjPcHczb5CME8k4+gwKyoPBWiW0dxFDBdpBciUTQC+uPKfzAQ+U37edx7cdRjArp6KFOS6hdnMp4K0RdO+wGK8exAQC3lv7iSMBCCoCs5AAwOMYrT0/RbHT9Qv76zhMdxfMHuGEjFXYDAO0naDjuAM9606KHOT3YXZh6R4b03SdTu76xiuEurs5nZ7qWQSH1IZiM9gcZA4HFXta/5Bs34f+hCr1Uda/5Bs34f+hCoqNtNtjTu1c5eug8O/wDHrL/v/wBBXP10Hh3/AI9Zf9/+grnpfEa1Nita+E9GtL1rq2tDGzSNMYxNJ5PmMCCwi3bA2D125puneD9D068gubSyKyW5YwK00jpBu+95aMxVM/7IFdDRXXzy7mPMznh4R0MeG10AWJ/slW3iDzX4O/fndnd97nr+lX9O0ax067vrmzg8qa+kEtw25jvbGM4J449MVpUUOUnuwu2c3b+DdGtpLpoILuNbp5JJolvp/KdpMhyY9+3Jz6cdugqNPA+hpph07yb1rBlEZtn1C4aMKDkAKZMAcdAPbpXUUU/aT/mYczMuy0TT7DVLzULODybq82+eyu219owDtztBA4yBmqCeDtHF1qdysV4J9SG27cX04Mo7fx8Y6DGMDgYHFdHRSU5LZhdmboWjWWh6dHY6bHJHax52I8zybR6AsSQPbpXOSffb6mu1ripPvt9TWFdt6s0p9S5pEEVzNLBcRrLDLEyOjAEMpxkH1FTWvg7QrazntBZNJayxeQ0VxPJMojznaodjsGcHC45A9BSeH/8Aj/P+4f5iukqqMmo2TFUbTOZj8FaAlreQGyeRbyIQTPNcyySNGOib2YsF9gQK0JtB02ebS5ZbfdJphJtDvb92du315445zWtRWvPLuRzPuZGm+H9M0zQf7Gs7by9NKOnk72bhySw3Ek8knvWb/wAILoP9lPphgu309lVfs739wyKFIK7QX+XBA+7iupooU5LVMOZ9zAXwtpiy2kjpd3D2s3nwm5vp5tj4xu+dznA6Z6dRzVjSNC0/SNPmsdNha3tZXdyiSv8AKW+9tOcr/wABxg8iteijmk9Gwuzkz4C8PHSZdKNpcnTpZfOkgN9OVZ85z9/15x0JweoFXf8AhFNKOr2mqMl419aoI4pXvp2wo7EF8NnvnOe+a36KbqTe7Ycz7nLa1/yE5vw/9BFUqu61/wAhOb8P/QRVKuGW7OiOyOn1DTLHVLRINTsra8hGCI7iJZFB9cHPNQ3mg6Re2sFteaVYXFtbjEMUtujrHxjCgjA49K04/uL9BTq7E2tmc9ykunWQuIJ1tLcTwJ5UUgjXdGn91Tjge3Som0XTGcs2nWZYzi6JMK5Mw6SdPvj+91rSoou+4rmdqmj6bqyRrqun2l6qElBcwrIFPqNwOKpzeE/DswjWbQdKkEabED2cZCLnO0ccDk8Ct2impSWzHdmU2g6Q9vNA+lWDQTSebLGbdCrv/eYY5Pueak1PR9M1ZI11TTrS9WMkoLiFZAp9RuBxWjRS5nvcLsoPpOnPPazPYWrTWg227tEpaEYx8hx8v4VD4i/48Y/+ug/ka1ayvEX/AB4x/wDXQfyNRP4WOO6OerrdO/48Lf8A3B/KuSrrdO/48Lf/AHB/KsqW5pU2LNFFFbmIUUUUAFFFFABRRRQBR1r/AJBs34f+hCs3w3/rpv8Ad/rWlrX/ACDZvw/9CFZvhv8A103+7/WsZfGjRfCzoKKKK2MwooooAKKKKACiiigAooooA4yf/Xyf7x/nTKfP/r5P94/zplcZ1HTwTxWukLcXDiOGKHzHduiqBkn8q8btvjkl7N4jnsItOuLO3tLebSoI5zJczvLOYR5qoWK/MUYoql1Vhnlto9q07/jwt/8AcH8q8y8Varo9xqviCRPDj6jElutjqWoTXi20AWIs4RSzdULsS4Awf4srxrWxFLDwU60lFeehz8rk7I63wFrr65ps5u763utQtpvKuEi06ewMJKhgrRTsZAcNnccAg8CsbRvilpGrRxSW9jfpFLfQ6eheS2ZhLKSF3xpMzx428h1Vhnp1xz3grxfaJFexeFNEgvndxNdyxeIY72VmIwpkkZnY8LgbjwBgVE2mxSLcef4L1C4mmMRNxceJJZZ08pi8eyVnLptZifkI5Ncc86wFN8s60U/UpUpvZGtqHxHmj8ZolhYane6XbWmpLdWsEcG/zba4hQygu6/KAXGA2TuHy56btp8RdGvI2ltY7uSEX9pp6yBFAd7lI3jcZbO3EqZyARzgGvObu10O2hniuPCclslnFK1z/wAVQ8RWK4bdJ5zCQEo5jzh8g7fak/tbw3qEzeIIvDtjJFZSwTPPb+JUW1jkiAWF3RXEW5QFUFhnHHTiqWb4Jq6qr7++33h7KfY664+K9lJoN5fQ6dqlht0241K0nu7aKVJ44WVXKokwJILrwxTIPBxzTX+KL6aNcl13RLyO0s9XfTbe4ie2SNgFDDe0k4CHG47m2rgqPvHbWHNLpdxYDTn8HQNbW2my2/lDXFylnOQzkkNnaxjB3n+6cHrU0F/o91d/2je6Pq+n6drFyjyahpfiCb7OZWwiOywSqAGO1SygjOC3AyHDNcFUkoRqxbei1XXYTpTXQ9a0u9GoabbXaxNEJ41kCOyOVBGcFkZlP1ViPQmm61/yDZvw/wDQhRo+m2mjaXa6dpkC29lbRiKGJckIo4AyeaNa/wCQbN+H/oQrulsyY7o5eug8O/8AHrL/AL/9BXP10Hh3/j1l/wB/+grCl8RtU2J9b1Sz0PSLzU9TmENlaRmWaQgnaoGScDrXDfCj4ht441DX4pH0yNLSWJrWG0uVmk8l0DZkKsQWBODt4ByMkjNdf4m1218PaY19fCV13rFFDAu+WaRjhUQcZJPrgDqSACa4AeN7PRNcuHk8NXFlqusujtHPqloslwyqI12oZuuABhR+tFbGUKElGrNRb6N2MlGT1SNa4+KekQX2sW72OoEaXOtvO4e23FjMkIxEZfNClnyGKAEAkE8Zh8TeObiDxVpVho1pf3Jg1iTT760hSHfcn7A1woRpGAAG6MkllPykdOuJqFvZalc3VxqXgbX72S4jeM/adaWURK7KzCJWuCIvmRDmPaRtGMYqncWukWNk8tx4N161jjujfteN4hEcqzGMRFzN9pD5KfLy2D+NcyznL27KvH/wJf5leyn2Ovh+KehzaZqF8lvqBisNPTUZl8tAwVpZIjGBv++rROCM49CadP8AEiyW/uLQ6ZqkCrc3NjHfSRRNC9xBG8jKFEm8/KjEEqAemQa881m78GtcW2i6l4UktriO2SySxGvwW7yQ7i6I6LcqZBuYsNwJySRya2LzxBoe69iu/CkyNYXMmo3SPrFspt5J43VpJB5/yhkkfhsDByB0NX/amD39rHXzQvZy7GppvxRnWPWrzVNGvZNKsILOZLm3jhTd50UbfMrTkrlpM5+6q53Nxmu+8Ma1F4g0W31O3geGGfJRWnhmyMkZDwu6EHrwx98GvLBc6XHqZs7bwrrllfyWcaG3tPEK28jwRYRHKJcqTjaF34zjgntXd/De60h9HuLTRrK7097a4cXVreuZJ1mc72Z3LMXLbt27cc561rQx2GxD5aNRSe+jT07+gpQlHdHX1xUn32+prta4qT77fU1pW6F0upo+H/8Aj/P+4f5itPXbi9tdHvLjTILee7ijLxx3ErRxsR/eYKxHHoDnpx1rM8P/APH+f9w/zFaPiCCzuNFvk1WWWKxERed4ppIWVAMsQ6EMOB2PTiqpfCTU3OOvvGOtRfCnQfE9pZ6dJdXtvYz3SyO6JGJvL3GNQCW5fABYY6knGD1Pi3xDbeF9Bn1W9huJoIWRWWHaD8zBQSzsqqoJyWZgAOSQK8puHtZ/A9vZDwxPb+FLZVmg+3+Jri1dIlxsLkFiqgBSEZyFwOARx0d7qeu3mlJp8vhvbbqqoGi8STxTYXGMyqgkJ45JbJ75rzpZ5l8HaVaPbcao1H0NP/hZOlLp17eS2d8i2mknWXVGgm3QB3XCvHKyMx8snhsYIyQcgZelfEV7PUtYh1201CSyGry2VpepHD5KYhEiQnDhy3DfMVIyQC3pzt74bhvbJLSfwNB9nWKSBgniW5Qyo7l3ErKoMuXJbLknJJ61XuNU0nTL6LXb3RNEgM9w88T3fiuQ2zz7TG7pG6+Vv25UkLkUQzzL5u0KqfoDozW6O8vfibpNtpFjqH2LU5UvNPtdRiijjQuY7iWOKNSC4G7dIuRnGM4JrP1z4lmHTJ57DTruC/ga+glsbuGN3WaC3M2C6TbAuCpypfI4+U8jkLGDSbQ2UMHhjSmN9HGlkkniuaTzY4JEmRYQyn5UZUbanAHGMEitCfUbWT/T5/DOhNFe3kwEr+IjsmuJY/IkUfu8FiqbNo6EHAzmn/bWB/5+r+v+GYexn2Op0r4kxTajomlajouoWeq6jBFNslmtI0w5I3JmfMg+UkiMOwGMgEgV6HXk3hqw0m41nTtH1rR9Usri2QXGnxS67c3lrL5Thhwz4LoSpAdegGCQvHrNd1CvTxEFVoyUovqiHFxdmctrX/ITm/D/ANBFUqu61/yE5vw/9BFUqyluzojsjtI/uL9BXH+KNR1ax8c+Dba1vYU0nULmeC6t/s+ZJCttNKp8wtwuUXgKDkdccV2Ef3F+grz/AOI0djJrWjQReHdF1PX50kkgu9St1kW0hhKFnzgsSHlQBQRktnIxW1atChTdWo7RWrZzpOTsiO/1jULP4k6Jb2+s3U+j6hPPbypMLV7cSpE58iLy1EwkVkyTIdoGRksQK0/EXi680bxZYaY+lRpptwYUOpXM0qR75JCuxSkLpvHy4Ejx7iygE8kcGdSudN8Y+YbTwraa9dSeUL8+HblDM7Lu2i53BWJA6biTjHUVsXWn61d6xDq13ZeC59VhwIryTSZGmjAzja5k3DGT0rx58S5ZCzlVtfb3Za/garD1HsjO8WfEqfUvAcT6fbSWN/qWjT6krRXZElsYpoo9oIUH5jI3zcY2kYPbotP+Ily3i238PappEFtetfNZTywXpmhi/wBEa4VgxjQsSF2lSBjrk1zN/YS6a7zXWmeAom1OUWsjDQ3JuGlYEq5D/MGIUndwSATWSdXs1iPh17PwXHYJe+T9nk8NXCWYuumN5PleZ265PQVUOIsvqK8Jt+kZf5A6E1ujp5fi3dtYyX1p4ft5bK201NUunbUSrLG1xNDtjAiIdv3O4ZKg5xkYyZJPGHiGXx7badpUMVzaC+vraaG7uljLiKOBhsKwEgDexAJJJJBbGMc3a+JYZY76ztn8E7IbmPRLmBdEnADmVgkLLv5TzGfB+5ksc9avfb59a1u+0vyvA9/qenTLeTQy6RL8kzKCJA5cjfgKCy5I4z2FVLiDARvzTatv7stNv7vmvvQKhN9DvPAPi278SyX0OpaZHpN7bLG7WTSzGdA+7l1khjGMqQGQupIbDcc7niL/AI8Y/wDroP5GsP4aR6Q3h43Wj6DYaFJJK8N3bWkKIBNE7RsMoAGGVOD3BHA6VueIv+PGP/roP5GvVclOHNF6MzjpI56ut07/AI8Lf/cH8q5Kut07/jwt/wDcH8qiluaVNjgvEutwaf8AF/wtZy+JPJS6t7hH0t7mJELnYImKYDszHcBuJGR8oB3Z534WeJb288Xtb60z3WsXn2tp1h1eWUaeEkGI5bMoqQDoqv8AMzc84au28YeINTttXstG0AWaX00LXU1zeRtJHDErBcBFZSzMW4+YABST2B4weM/GS+IrfSbibTrc3MskNvdy6FIIZnRS7Bf9OL42hiCVAOODXFic5weFqOjVnaSV2rN6fJPpr3sTGlOSuka3iTxxqmnfEP8AsK3n0popEUQWyRrcXMjmMth1FwskQyOvlOuOSRmuJ8V/Eg+JvBNvGl3pAdbHSdRvnQnZaXZv7fejnf8AKq85U/MO5rrdV8V67pFxHBqvjHwXYzSAFI7nTpImYE4BAa8GeQRWVqHxJ1CxisZm8ZeDJba7uzZieLT2aOJwhcl2+24UAAD1yy8c1hT4iwFSzhNu/wDcn/8AIlOhNbr8S7pnxRuoby1bW7zRDor3V7ajWYVaK3ujFFE8RizIwBYvKuMtuMfyntVTTviV4mvNGi1fy9GS0gtdInuYPs8peU3jBXCP5mE25yMq3ofWorX4h+LJ7mMST6fbWUl49gl/LoTGAzLKYtp23zOoLjALKAePWq2kfFLXNVaJLfVdJSZ9QGm+VJoMoYORIVkP+m/6s+U4yMnIxitXnmCs3z6Lf3ZafgL2M+wL4u1e38apKdb03TLHOtW8cOpyymC5lhvkVU3vMAshUcEAhBv2pggL3vwo8W3XizTr6a/ubK4uLaVY2+xQqIlJUMQsiXEySdeoYEd1BrltC8b+J9b1bVtPsNV0E3OnPhhLos0aT/MyEo32tsqGR1JxwR0Nek+D9aPiDw9bag8H2eZmkhnhDbhHLHI0cihsDIDowB4yOa3wuZYbFzlToyvKNm1ZrR7bpEypygrsva1/yDZvw/8AQhWb4b/103+7/WtLWv8AkGzfh/6EKzfDf+um/wB3+tdMvjQ18LOgooorYzCiiigAooooAKKKKACiiigDjJ/9fJ/vH+dMp8/+vk/3j/OmVxnUdbp3/Hhb/wC4P5V5h4dvba1u/EVncTRx3kGq3UjwOwV9skhkRsEjhlZSD0P516fp3/Hhb/7g/lXzj4j0i08Y65rWo69DHe3Ud9d2Vt5+5o7eOGZ4lVUBHHybj0JLHnpXj8S4alicFGFWTXvK1lfWz810ua4CjOtVcYdjufBcYtor7VNYmtotZ1SXzp4xOreTGuRFCCCQdi9SOCxY965a30O/udYhmv8AV9US2m1O/a5EeuOii2LsbcKqyfKOE4XBA4PHFeWHQ9OWPUIk8P6fcS21zDEZo9PnUpG4O6Q2+8uwBGAQcN1HCmtXQdB8LXnh691K80G0Js3mSUxwvHvEZOSEc5UkD7rcg8Zr5V5WqTlUjUfvWXwrTR2t7+lk9L6qyPRWElO0br7/AL+htXHh3WrjS9QbUIbq71a/0K1tjKurII1uI1kDrKpmCtncuDtYA5OQSSdvxbpt54ml1a9i0yKwMtnFZiC4urcy3Z+0ROWfY7IAiowGWJO48V53ead4angji07w1BZ3sk1qg+3Qhx5c7FVcBJOfutwSD6iqmsaNZaeZ7GPw5ot1qkV1BGpVJFjmjlVyAFLEq37sjqRyDXasHKU1Pns1t7uy93/p5a2i9N/MyeEceun/AA/lvud0fCWtW194h0qzuLU6New22m2d21xGfIs/MkeRWTeGbYHMYAwSCuOhI6CKC50nwzqHh65ns7hrjUo10v7IAgmE0quY0i3uyhGL9SQE5zgHHj7HwrPpN/eWmj6NH/pkNpZtdbo0UvGrN5p3fw5fPT7uOtdn4Sg0vS9O0fxb4YtIrC+DRMxgY7XVnVZYmGcMp+ZfY8jkVawbdSm68nbmj9lL3lazvzOzaVn030uL6q+WXI07Jvfp9x9ZVR1r/kGzfh/6EKvVR1r/AJBs34f+hCvvJbM8aO6OXroPDv8Ax6y/7/8AQVz9dB4d/wCPWX/f/oKwpfEbVNjm/ipIttZ+H7ydglra6tE88pOFjVo5YwSew3Og/GvNvGum3l3qviCGzhhuY9Yt7SCK7FzEoszFIxYuGYNgbtw2A89h1rvvjdK7eFrKwDstvqV/HaXIUkF4djuyZ9G2AH1BI715Fr1n4Z0DSZb280nTUgiACgW0Y3EnAUEjA9MnAHfivlOIKCljac4P3uVK1r/auuq1uehgMK61KUm7Jf5HoXi6JtV1HQIrbUJYtPS7dr42l+bdjH5Mm0FkdWI37OBz3968/uvDeuT+GWs59QvbqW50iVbqO41kuGulniaIAmTCkoHGVwp/iOazfAq6R4g025muNK0Ezw3MkLLawxyKFB+U5xzkc54B6gVmX+saEdGubmx8M20E32SS6tmu7OIxyhGCtwjEjBYcHGe1eLhsvq4eSowlrFrp1u2vtef4LsdcsHFx53PRnbTQXWzxLaQ6BcXNtrFtDFCdQ1G3lWIhCpMzmZ3OCc5XeeOD6c94z8Datc23iW60i4gm1SZYLWNmuYx9vtzawxyg5YbSHj3jdjleMg85OvY0Nb23n0fw7cXQtlubaZLDYmPNSNldNxP8YIIbnmqqa5pIt9Xln0DR4ZNOs4zJC9silLpneMxsx/h3KhHTg5rqw+Er02q1Fp7La9/h7y62Se3XrYzlhIJ8spWf/Dno0+kaw3i+TxYlxp/npqKolllfOayAMRAl83YAVZpdpXOcDIPFel/DyZLrxJ4tuLdhLAJ7eDzE5UusILKD3I3Ln0PFeJ+D7fRNc0UXD6Xokk8UrwTNa26NGXRiMqcHgjaw9jXqnwQxY3XiHRrX5NNtmguLeAfchMu/eqeikpux0BJ9a7cjw6hj/ffvRi4rS2l1pu9radddWZY3COlQVRO6bPV64qT77fU12tcVJ99vqa+xrdDy6XU0fD//AB/n/cP8xVrxnaS3/hDXLO1TfcXFjPDGg/ido2AH5mqvh/8A4/z/ALh/mKueLr6bTPCetX9qQJ7WynnjJGQGWMsP1FVS+EmpueLeO7/S/Enwuns7FLPUrye2EcMEs0KPbzbSNzCVl2MhyD/ED261t+LdcXUvAmqLo99FZ6xPZuLeI30McschBwN6uVB9w2PevM/EGn2mkeELnVINK07UL9Ijczzagu95mxud3bBLsTzgkZ9RVbxRHa2F1fx6douh7NP086jN59kGMoy42KQRtP7tuTnqOK/MY5VSk4KnJ2jJtXX+HR67bdEfQSwcop80tbLv5nVzWctprNxNp/iK7lt49SsTbCXXjIptvk+1blaT5hjecNkj+ECs7w2v/CPT6JItrcXRsLi8E4/ti3mEiyFvLeIS3HyjBGR8pJ5IJ5qPVYdA0630+X/hHbe5e9lEMMUNpDvLFGcZ3FQBhT1NY0SWusX8MWhaTodvE9m9wRe6cHbespjKHY4C8qRkbvbNb08NKVNqT917trycdbS9fndhLAcrspamvc+G11KbS2a90vTdrajdxeRexEaZNI8DwBcEZO6NmO0EZLDoRmnp2ganrXhvStN1jVNE0lrSK8nZpJo7gG6nuJWBQJMNpRSGDcgb+hIOOeuNdsIbm2ll8OaMmmmxWW4f7MpaGV5JEBzgAx74wM4B+bOcVJJrmjQy+HUn0nw8gu7WC5vQ0KBlM2FURKeuCSxznC/nXYsJiFFRi9ndOybT96/V/wA1tb9Ourw+q093P8/L+vvPcfCWpvrfivwoX8l9RtbOebUYoJUlW3ZkVfmZCQNzk7eckAnHBx6/Xg3gG3h0P4iaOukxR2cGpCaC7hhUIkoSJnRmUcblK4B64Yivea+lyCnTpYKMaW13+b9dPmefjqUqNZwl5HLa1/yE5vw/9BFUqu61/wAhOb8P/QRVKu+W7IjsjtI/uL9BXnPxOvodA8QaF4h1RjFo8Ftd2Vxc4JELzPbtGWAHCnyWXPQErnrXo0f3F+gryH4vot1418PwXIEsEVlc3CRPygk3xKHx/eALAHsCcdTWObQpzwVSNW/K103FhKbq1owi7XZwmr+OdC1PxVpt3J4j0BLOxuxNHMLucuYtpBQ25Ty/MyxHm7sgdAKj8da/4F8U6obifX9Cnhj0m7tIVuSzGO4kMflyD5TgAK3I5BxgUjeanjiGzcWrafLYSzLCtuAwdZIlyzck/fbgYHrnrWN4Vvbi7vdGe7kjuE1SznuZIDBGBasjoAAQoOPnKndk5HXrXwtPA0octWm5Lljp7y63v9nfR+XY9t4F35XLd9vTz80RXk3ggJItpq3haWDdp0wtJywillgMvns/7tsF1cDdgk45FX4/FGiPYajo7a/4YtNIvr/7VJLDdSvJFGSjeUkflKoPyYDbuOuO1S3WuCDW7i1OjWptIb2CyafzQH3yojKQmzoN4B+Yeo9Ky9JubpLfQbye+S6bUbloHs5LeEfLlhujKqrDbtBOc8eldH1VTipTv0avJPpdbRteyvr8yHgYqVlL8PO3cjvJ/DD6tY6laeMNEiuotfe/uU8yQJPaG689VJ2f6xSOOMfMwzjrq+Hde8N6Pq+m62/jmxudQaSdtStycxMs3zOIisQkYh1jwHJ4BA21ynhjxNfG48O22tmAi7WS8e4+zIomg8h2wcLwUde2Mjb71v8AgbVH1a7vLXWbUE3Mf2u3jmsvKCxFiDENyjeFBT5hnO/rWmIwTjCUajbSXdbNtae56+mnYilhY1GuWWr8vR9/M+ifhhbXMHhczXlvJayXl5c3iwyja6JJM7oGHZtpUkds47Vt+Iv+PGP/AK6D+Rrmvgw7t8O7GN3Z1guby1j3HJWOK6ljjX6BEUfQV0viL/jxj/66D+Rr7elGMaEYw2SVvSx4zTU2n3OerrdO/wCPC3/3B/KuSrrdO/48Lf8A3B/KnS3KqbHnPxK1O38K+J9N8Qau/laRNatp0k4BYxS7w8eVHzEMN4yAcEDPBrzm08baBF4tm1m68Y2F3EzMsUUuj3Ikt4Sf9XG4faD0JbYS3fgADr/idif4k2iTfMlrpSyQBuQjPK4dgPUhEGfSvOv7VEXjzULSPUmvJfsAaLTzcRjEoLHYo4wxABy2Tg8nGK+MzjCUa2NquzUuVXs1ZrTvF283dHrYTCOdGM3K132/4KNLxd4k8D+IZdXkbxPHA1/pR0wE2EzmL5y+/OBnkjjjp1qLU/EXg+fV5dT0/wAWW1rdG+gvoRJpk0kamO3aDYwG0sCHJ4Ixx1rJ8DXusz+KNch1tLtJTBby+U7oYrcnzPlQK7cHjnqdpJwdoqaTxDqi6myt9i+wnU200IsbCUDyi4ffux1GMbfxFeesvhSl7KMpNJfzRtZpO3wa7L7jdYOMoqbla77dn6lyz8Q+F0UWV54zt5tFGoyakLWLSpo5Xc3BnVXkJYFVcjgKCcdazjN4GS50C8tfF6w3+kzTymb+zpis6vJJIisv+w0hwcn+LpnjE0LU9+kaPJpOr3l5fy2LNqUZvHuBGPJc723M3lt5m0DGM5IxVTSPEOp6NcaQmrXF1cW6aXLqCStISbgPGhEbc/MyvvA74Za61ltnJQnK+unuq+kk9OTr+TT6K2P1eNlzS/D08zt/D+ueAfDN1pd9p3ii7ea1t3trkSx3U32zfg/KrZWImTDfKMZJHfI93+G1hd6f4Qt01CHyLq4nub14SQTH59xJMEJHGQJAD7ivnnwNNqCS3mj+I0umuJYlulF4ySFwwCyqu1mGwP0BxgMBivevg47P8N9IDsWEfmwIWOSESZ0QfgqqK9fIsPTp4io7uUrLVtO6u30S6vz7dDlx2HdKnGSejvpa36s6nWv+QbN+H/oQrN8N/wCum/3f61pa1/yDZvw/9CFZvhv/AF03+7/WvopfGjgXws6CiiitjMKKKKACiiigAooooAKKKKAOMn/18n+8f50ynz/6+T/eP86ZXGdR1unf8eFv/uD+VeT+JPhpq8t/qo0ifTLjStSllne3vWkieJpSWkUMgbcpZnboCM45rqwzDgMfzpd7f3j+dKtCnXioVY3QUpToy5qbszzi3+EviK3huI4V0hDcbfNlGq3nmtt+6PM27wB6A46+tWbf4Y+JLfSTpkFt4cSxMbRGJbufBVs558vOTk89c81329v7x/Oje394/nXM8DhZbx/F/wCZ0LF4hbS/Bf5Hm918I9eusma30HOyJAyahdIwERJjwVQEEEk560sHwk16FUCW3h/K3Au97X9yztKAQGZihLHBxyTXo+9v7x/Oje394/nR9Rw1rcr/APAn/mL61Xvfm/Bf5Hm9n8I9cstQa9tbPw7HctK9wWF7cY8xwFdtvl4yR7evqa09H+Fmr/bIo9Sl0u10w3YvLmOzeWZ52DhyuXChFYjkjPGQAM5rtd7f3j+dG9v7x/OqWDwykp8uq829tt2J4mu4uPNo/JHa1R1r/kGzfh/6EK5je394/nSFmIwWJH1rtdW6scqp2e4V0Hh3/j1l/wB/+grn6AxHQkfSog+V3LkuZWNXxr4bi8U6I1hLcSWsqSLPb3EYDNDKvIbaeGHUEHqCRx1rg/8AhXPigcf27orY4z/Z8oz+HnHFdRvb+8fzo3t/eP51jXoUMQ06sE7GlGrWoJqnO1zjrH4W+ILFZlttX0WNZpXncfYpjl3OWPM3H0HFZs3wU1GW0jtn1DRjBHA9sq/ZbgYjcgsv+vzyVU57V6Hvb+8fzo3t/eP51msHhk+ZQ19WW8TXas5fgjzwfBTUvKuY31PSZftOwSvNBcyyOFIKje05bAI6ZxT5PgxqcmqSai2oaH9skeOV5BZzjc0YOwlfOxxn+XoK9A3t/eP50b2/vH86r6rh/wCX8X/XRfcL6xW/m/BHHW/wt8QW93dXMOr6Ik1yVMpFlNhyowDjzsDjA6V3PgLwkPC9teNcXpv9RvZBJc3Ij8pTtG1FRMnaoHYkkkkk81X3t/eP50b2/vH86qjQoUJc9OFntcmrWq1Y8s5XR2tcVJ99vqaN7f3j+dJW858xlGPKaXh//j/P+4f5it2+tYb6zntLpA9vOjRSIejKwII/I1yAJHIOPpS72/vH86canKrClDmdziNV+DuqXWnvpY161uNKHyotzbypKY8EBZHilXfx3wAe4qre/BbVL1IVu9V0uXy4/Ky0NzmRM52ufPy657OSK9B3t/eP50b2/vH865FhcOndRt13a3Oj6xXejl+CONu/hd4gu5LV59X0V2tpfOiP2KYbX2lc8Tc8Mwx0rKf4I6hIqD+1NMjCo8eIo7uPcrOXZW23A3AsxODmvR97f3j+dG9v7x/OiOEw0Phhb5v/ADHLE15fFK/yRwMvwZ1OVJke+0ERy2osmQWMwXyQSQgAmwMbjyOfekt/gxqdvp1zYRahogtbmJYZUNpO25FjCBcmbIAUAdffrzXf72/vH86N7f3j+dH1XD2ty/ixfWK2/N+CM/wV8PrjR9ai1bWdTivbi2iaK0ht4Giji3ABmYs7M7EDGSQACeCTmvRa4re394/nRvb+8fzrppclGPJTjZGFTmqy5pu7Lmtf8hOb8P8A0EVSpCSTknJpalu7uUlZWO0j+4v0Fcr428G2/ik2c4u7iw1Gz3CG5gCsdrY3I6sCGU7VOOCCAQRUP2if/ntJ/wB9H/Gj7TP/AM9pP++j/jWkpxmnGSumZxjKLUouzORf4MJJqC6hJrcTX46XLaXCZBgYHzdelOtPg6bS4muLTXlhnnOZZYtMhVn5z8xHWus+0z/89pP++j/jR9pn/wCe0n/fR/xrn+rYa1vZo39vXvfnZyzfCKR5Hd/EAZ3kWVmOmwks64Csf9oYGD1GBUFj8FYrG4e4sdZhtp3yGkh0qBGbJyckV2H2mf8A57Sf99H/ABo+0z/89pP++j/jR9Ww1rezVg9vXevOzkH+C8bwwRSazC0UCtHEjaXCRGrDDKo7AjggdRVlvhNPJNFJJ4ll3xgqkiWEIeNTjcEYg7c4Ht7Gum+0z/8APaT/AL6P+NH2mf8A57Sf99H/ABpPDYZ7019we3r/AM7N3w3o1n4e0W10rTVZba3Uhd7bmYkkszE9WLEkn1NHiL/jxj/66D+RrC+0z/8APaT/AL6P+NNeaSQYeR3HXDEkZrqdRNWSMFTd73G11unf8eFv/uD+VclQGYcBj+dRCXKypR5i14y8FWXieS2uXuruw1C1DLFdWpXfsbGUZWVlZSQDgjII4Irnf+FVy/8AQ2at/wCA9t/8brZ3t/eP50b2/vH86zq0qFV81Smm/NF06lWmuWE2l5GN/wAKrl/6GzVv/Ae2/wDjdH/Cq5f+hs1b/wAB7b/43Wzvb+8fzo3t/eP51n9Uwn/PqP3I0+sYj/n4/vMb/hVcv/Q2at/4D23/AMbo/wCFVy/9DZq3/gPbf/G62d7f3j+dG9v7x/Oj6phP+fUfuQfWMR/z8f3mK3wqaQbJ/FetGM8MI47dGI9A3l8fUc16Do+mWmj6XbadpsIhs7aMRRRgk7VHA5JyfrXMb2/vH86N7f3j+dbUo0qN/ZwSv20MqjqVf4km/U6fWv8AkGzfh/6EKzfDf+um/wB3+tZJZiMFiR9a1vDf+um/3f61pzc0kzNx5YnQUUUV0GIUUUUAFFFFABRRRQAUUUUAcbOrefJ8p+8e3vTNjf3T+VdrRWPsvM19p5HFbG/un8qNjf3T+VdrRR7HzD2vkcVsb+6fyo2N/dP5V2tFHsfMPa+RxWxv7p/KjY390/lXa0Uex8w9r5HFbG/un8qNjf3T+VdrRR7HzD2vkcQQQcHg0tdtRR7HzD2vkcTRXbUUex8w9r5HE0V21FHsfMPa+RxNFdtRR7HzD2vkcTRXbUUex8w9r5HE0V21FHsfMPa+RxNFdtRR7HzD2vkcTRXbUUex8w9r5HE0V2u1f7o/Kk2L/dH5UvY+Ye18ji6K7TYv90flRsX+6Pyo9j5h7XyOLortNi/3R+VGxf7o/Kj2PmHtfI4uiu02L/dH5UbF/uj8qPY+Ye18ji6K7TYv90flRsX+6Pyo9j5h7XyOLortNi/3R+VGxf7o/Kj2PmHtfI4uiu02L/dH5UbF/uj8qPY+Ye18ji6K7TYv90flSFFIwVGPpT9j5h7XyOMorsvJj/55p+Qo8mP/AJ5p+Qpey8w9r5HG0V2Xkx/880/IUeTH/wA80/IUey8w9r5HG0V2Xkx/880/IUeTH/zzT8hR7LzD2vkcbRXZeTH/AM80/IUeTH/zzT8hR7LzD2vkcbRXZeTH/wA80/IUeTH/AM80/IUey8w9r5HG0V2Xkx/880/IUeTH/wA80/IUey8w9r5HG0V2Xkx/880/IUeTH/zzT8hR7LzD2vkcbWt4b/103+7/AFrc8mP/AJ5p+QpRGi/dVR+FONOzuJzurD6KKK2MwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the subunits of the respiratory chain encoded by nuclear DNA (nDNA) in orange and the subunits encoded by mitochondrial DNA&nbsp;(mtDNA) in yellow. As electrons (e-) flow along the electron-transport chain, protons (H+) are pumped from the matrix to the intermembrane space through complexes I, III, and IV and then back into the matrix through complex V, to produce ATP. Coenzyme Q (CoQ) and cytochrome c (Cyt c) are electron-transfer carriers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_48_9990=[""].join("\n");
var outline_f9_48_9990=null;
var title_f9_48_9991="Prevention of Candida infection in neonates";
var content_f9_48_9991=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of Candida infection in neonates",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/48/9991/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/48/9991/contributors\">",
"     Mohan Pammi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/48/9991/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/48/9991/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/48/9991/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/48/9991/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/48/9991/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida is a major cause of neonatal infection in premature infants, especially for extremely low and very low birth weight infants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Successful management of neonatal candidiasis requires effective treatment of Candida infection with appropriate antifungal therapy and supportive care, and preventive measures to reduce the risk of systemic Candida infections.",
"   </p>",
"   <p>",
"    The prevention of Candida infections in neonates will be reviewed here. The clinical manifestations, diagnosis, etiology, risk factors and treatment of neonatal candidal infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24039?source=see_link\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=see_link\">",
"     \"Treatment of Candida infection in neonates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the poor clinical outcome of neonates with candidemia, there have been significant efforts to develop preventive measures to reduce the risk of systemic candidal infections. These efforts have focused on the very low and extremely low birth weight infants (birth weight less than 1500 and 1000 g, respectively) who are at the highest risk for invasive candidal infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24039?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24039?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\", section on 'Risk factors for invasive candidiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preventive management includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      General measures to reduce Candida infection",
"     </li>",
"     <li>",
"      Administration of prophylactic antifungal agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;General measures are focused upon reducing cross-infection of Candida in the NICU and risk factors that increase the likelihood of candidemia. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Handwashing, the use of gloves, and avoidance of artificial fingernails to reduce the rate of horizontal transmission from health care worker to infant. However, these measures alone may not be sufficient to prevent horizontal transmission because of the difficulty in eradicating Candida from the hands of health care workers. In one study, commonly used antiseptics or disinfectants for handwashing demonstrated varying degrees of in vitro inhibition of growth of Candida species recovered from hospitalized patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Single room isolation or cohorting infants who are colonized or infected with Candida. With this intervention, health care workers can be segregated to only caring for infants with candidal colonization or infection and caring for noninfected and noncolonized infants. Although patient isolation or cohorting is often a recommended routine infection control measure, there are no clinical trials demonstrating that this practice prevents Candida cross-infection in the NICU [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduction of risk factors associated with candidal overgrowth (ie, high density of candidal colonization), which increases the likelihood of disseminated systemic infection. Interventions that promote candidal overgrowth include H2 receptor antagonists, proton pump inhibitors, broad-spectrum antibiotics (eg, third generation cephalosporins and imipenems), and glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/7-9\">",
"       7-9",
"      </a>",
"      ]. In addition, the use of topical petrolatum is associated with an increase in invasive fungal infection [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/10\">",
"       10",
"      </a>",
"      ]. Minimizing or avoiding these risk factors, if clinically appropriate, may decrease the density of candidal colonization and the likelihood of candidemia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24039?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology and risk factors for Candida infection in neonates\", section on 'Risk factors for invasive candidiasis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medical hardware, such as central venous catheters, that provides a site for blood-stream invasion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      colonization. Measures to reduce reliance on catheters should be actively considered, such as initiation of early feeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANTIFUNGAL PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antifungal therapy including",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/23/34160?source=see_link\">",
"     nystatin",
"    </a>",
"    , miconazole, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    , appears to reduce the risk of invasive candidal infections in neonates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nystatin and micnoazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/23/34160?source=see_link\">",
"     Nystatin",
"    </a>",
"    and miconazole are local antifungal agents without systemic distribution because they are not well absorbed from the gastrointestinal tract.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/23/34160?source=see_link\">",
"     nystatin",
"    </a>",
"    reduces the risk of invasive candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort of 3991 very low birth weight (VLBW) infants (birth weight &lt;1500 g) and extremely low birth weight (ELBW) infants (birth weight &lt;1000 g), infants who received routine oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/23/34160?source=see_link\">",
"       nystatin",
"      </a>",
"      prophylaxis had significantly lower incidence of invasive Candidiasis than infants who did not [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial of VLBW preterm infants, prophylactic administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/23/34160?source=see_link\">",
"       nystatin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      was equally effective in reducing the incidence of invasive fungal infection compared with placebo (4.3 and 3.2 versus 16.5 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/15\">",
"       15",
"      </a>",
"      ]. The rate of candidal colonization was also reduced in the nystatin and fluconazole groups compared with the control group (11.7, 10.8, and 42.9 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, a study of 600 newborn infants admitted to NICU found oral miconazole prophylaxis reduced rectal fungal colonization but did not influence systemic fungal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/16\">",
"     16",
"    </a>",
"    ]. The baseline fungal infection rate in this study was less than 3 percent. An oral liquid preparation of miconazole is not currently available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since 2001, clinical trials in neonates have primarily focused on the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    antifungal prophylaxis, a systemic antifungal agent. These studies have demonstrated that prophylactic fluconazole reduced candidal colonization and invasive infection in preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/17-22\">",
"     17-22",
"    </a>",
"    ]. However, it remains uncertain whether or not fluconazole affects mortality.",
"   </p>",
"   <p>",
"    This was best illustrated in a meta-analysis of four trials of 536 very low birth weight infants that compared prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/17\">",
"     17",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonates who received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      compared to those treated with placebo had a lower incidence of invasive fungal infection (RR 0.23, 95% CI 0.11-0.46). In the largest included trial of 322 very low birth weight infants, patients were randomized to receive either fluconazole at a dose of 6 mg or 3 mg per kg, or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/19\">",
"       19",
"      </a>",
"      ]. The incidences of invasive fungal infection for patients were 2.7, 3.8, and 13.2 percent in the groups that received 6 mg and 3 mg dose of fluconazole, and placebo, respectively.",
"     </li>",
"     <li>",
"      In three of the trials that included data on mortality, there were no differences in mortality prior to hospital discharge, although there appeared to be a trend towards lower mortality with the administration of prophylactic",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      (RR 0.61, 95% CI 0.37-1.03). In the previously mentioned trial of 322 very low birth weight infants, the incidences of death were 8, 8.7, and 9.4 percent in the groups that received 6 mg and 3 mg dose of fluconazole, and placebo, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an analysis of three trials in preterm infants, [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/18-20\">",
"       18-20",
"      </a>",
"      ],",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      prophylaxis reduced the combined outcome of invasive candida infection or mortality compared to placebo (OR 0.36 [95% CI 0.23-0.58]) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There appeared to be no increase in candidal resistance to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      after fluconazole prophylaxis. However, the follow-up periods of the trials are probably insufficient to detect clinically significant changes in the resistance profile of fungal isolates.",
"     </li>",
"     <li>",
"      There was no difference between the two groups in the incidence of adverse events.",
"     </li>",
"     <li>",
"      The number of patients who were ELBW was insufficient to perform a subgroup analysis. ELBW infants had the highest rate of candidemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In subsequent studies, ELBW infants treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    prophylaxis were less likely to develop invasive candidal infection compared to historical controls.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first study,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      prophylaxis therapy between 2002 and 2006 reduced invasive Candidiasis by 3.6-fold compared to historical controls from 2000 to 2001. Deaths attributable to Candida decreased from four to zero during the two time periods. Fluconazole candidal resistance in Candida species was not observed [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The second study also demonstrated a decrease in the rate of invasive fungal infections from 7.1 percent in historical controls to 1.8 percent in infants treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      prophylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third study, targeted",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      prophylactic therapy was associated with lower rates of candidiasis compared with historical controls (15.5 versus 6.2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/26\">",
"       26",
"      </a>",
"      ]. The targeted recipients were preterm infants with birth weights less than 1500 g and who received broad spectrum antibiotics &gt;2 days, and had at least one additional risk factor for candidiasis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A major issue with routine neonatal antifungal prophylaxis is the possibility of emergence of resistant candida after antifungal prophylaxis. In these meta-analyses mentioned above, there appeared to be no increased risk for the emergence of resistant Candida species with prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    , however, the follow-up periods were probably not sufficient to detect changes in the resistance pattern.",
"   </p>",
"   <p>",
"    There are retrospective studies that have reported conflicting results regarding the emergence of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    resistant Candida species.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study reported that",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      resistant C. parapsilosis emerged in a NICU after a 10-year duration of using prophylactic fluconazole [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In other retrospective studies, prophylactic",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      decreased the incidence of candidemia in selected very low birth weight (VLBW) infants (birth weight below 1500 g) and in ELBW infants without evidence of increasing fluconazole resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/24,28,29\">",
"       24,28,29",
"      </a>",
"      ]. Of note, in one study, approximately 30 percent of the infants who received fluconazole developed cholestasis, two-thirds of whom had other predisposing conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/24\">",
"       24",
"      </a>",
"      ]. There was not an increase in length of parenteral nutrition or risk for necrotizing enterocolitis associated with prophylactic fluconazole.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One also must interpret retrospective data that use historical controls with caution, as a systematic analysis reported a publication bias with an overestimation of the benefit of prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    in these retrospective studies compared to clinical trials [24].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112287551\">",
"    <span class=\"h3\">",
"     Long-term outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be no long-term adverse effects of prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    therapy in ELBW survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/30\">",
"     30",
"    </a>",
"    ]. This was illustrated in a follow-up study of one of the trials included in the above meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/20,30\">",
"     20,30",
"    </a>",
"    ]. Of the original 100 patients enrolled in the initial study, 38 of the 86 survivors who were still alive at the time of the follow-up study were evaluated regarding their neurodevelopmental status and quality of life. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were no differences in communication, social, motor, and daily living skills, and the rate of behavioral and emotional problems between children who had received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      prophylaxis (n=21) and those (n=17) assigned placebo.",
"     </li>",
"     <li>",
"      The quality of life including satisfaction with school and self-esteem was also similar between the two groups.",
"     </li>",
"     <li>",
"      In a larger cohort of survivors (n=59), there was no difference in regards to growth (ie, head circumference, height, and weight) between the two groups.",
"     </li>",
"     <li>",
"      Additional information regarding liver function studies showed at discharge there were three cases of cholestasis in the",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      group, and one case in the placebo group. However, there were no reported cases of hepatitis in either group. Cholestasis resolved in all four patients by one year of age and did not recur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the currently available literature, our approach is not to start antifungal prophylaxis for all premature infants because of the concern of promoting resistant Candida species within the NICU. In addition, universal prophylaxis in a NICU with a low incidence of candidiasis would expose large number of infants to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    , the preferred agent, to prevent a single case of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This approach is in agreement with the 2009 Infectious Diseases Society of America guidelines that state prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    be considered only for extremely low birth (ELBW) infants (birth weight below 1,000 g) who are cared for in a NICU where the baseline rate of systemic fungal infection is high [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Others have suggested that prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    be used in ELBW infants in NICUs with a baseline rate of invasive candidiasis of 5 to 10 percent and which have excellent adherence to infection control measures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In this setting, fluconazole dosing of 3 or 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 2nd or 3rd day appears to be equally effective [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/35\">",
"     35",
"    </a>",
"    ]. Prophylactic fluconazole may also be considered in infants with birthweights between 1000 and 1500 who are at risk for disseminated candidal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24039?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\", section on 'Risk factors for invasive candidiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although data are limited demonstrating equally effectiveness, an alternative prophylactic agent is oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/23/34160?source=see_link\">",
"     nystatin",
"    </a>",
"    . We currently prefer",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    based on the currently available evidence. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Nystatin and micnoazole'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Surveillance cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic screening for Candida colonization has been suggested as a possible tool in preventing fungal infections in high-risk patients by initiating antifungal therapy when colonization is detected.",
"   </p>",
"   <p>",
"    In one retrospective study that obtained candidal surveillance cultures in 51 preterm infants born at &le;28 weeks gestation, 16 infants developed candidal colonization (ie, stool or bronchoalveolar lavage",
"    <span class=\"nowrap\">",
"     fluid/nasopharyngeal",
"    </span>",
"    secretions) and were treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/3/31799?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/46/27365?source=see_link\">",
"     flucytosine",
"    </a>",
"    . All colonized infants developed Candida infection within 24 to 72 hours after colonization was detected &mdash; 12 with candidemia, 2 with mucocutaneous candidiasis, and 2 with Candida pneumonia. Although six infants with Candida infections died, only one death was attributed to Candida infection. Thirty-five non-colonized infants did not develop Candida infection and did not receive antifungal therapy.",
"   </p>",
"   <p>",
"    However, further studies are needed to determine if the benefits outweigh the risks and costs of screening for fungal colonization in high-risk neonates and if antifungal therapy should be initiated when colonization is detected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207853895\">",
"    <span class=\"h1\">",
"     EMPIRIC ANTIFUNGAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no guidelines for initiating empiric therapy for invasive candidiasis like those that exist for group B Streptococcus infections. An observational study of 136 ELBW infants with invasive candidiasis who were cared for at National Institute Child Health and Human Development Neonatal Research Network sites in the United States suggested that empiric antifungal therapy for invasive candidiasis (ie, prior to receiving culture results) increased survival without neurological impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/37\">",
"     37",
"    </a>",
"    ]. However, there was no difference in mortality between treated and untreated. The authors suggest that a large multicenter trial is warranted to see if there is a benefit of empirical antifungal therapy in ELBW infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H454916249\">",
"    <span class=\"h1\">",
"     OTHER POTENTIAL INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of probiotics to reduce gastrointestinal Candida colonization has been suggested. In one prospective study of preterm infants, gastrointestinal Candida colonization rates were lower in patients who received either",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/5/1108?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    reuteri or rhamnosus compared with patients who received no probiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondary analyses of data from a large multicenter randomized controlled study showed the use of bovine lactoferrin (with or without",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/5/1108?source=see_link\">",
"     lactobacillus",
"    </a>",
"    rhamnosus) was not associated with a decrease in fungal colonization rate compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9991/abstract/39\">",
"     39",
"    </a>",
"    ]. However, the risk of invasive fungal infections was lower in preterm VLBW infants, who received prophylactic bovine lactoferrin (both with and without lactobacillus rhamnosus) compared with controls.",
"   </p>",
"   <p>",
"    The current use of probiotics needs to be limited to clinical trials until it has been shown that this intervention is beneficial, safe, and an effective standardized regimen has been developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the poor clinical outcome of neonates with candidemia, there have been significant efforts to prevent systemic candidal infections. These efforts have focused on the very low and extremely low birth weight infants (birth weight less than 1500 and 1000 g, respectively) who are at the highest risk for invasive candidal infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24039?source=see_link\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preventive general measures to reduce neonatal candidal infection include reducing candidal cross-infection (eg, handwashing and use of gloves) and risk factors that increase the likelihood of candidemia (eg, broad-spectrum antibiotics). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not suggest the routine use of prophylactic",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      in all premature infants (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Prophylactic fluconazole may be considered in infants with a high-risk of invasive fungal infections such as extremely low birth weight infants (birth weight below 1000 g) with additional risk factors, such as treatment with systemic broad-spectrum antibiotics or the placement of a central venous catheter. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Antifungal prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/1\">",
"      Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 1998; 17:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/2\">",
"      Beck-Sague CM, Azimi P, Fonseca SN, et al. Bloodstream infections in neonatal intensive care unit patients: results of a multicenter study. Pediatr Infect Dis J 1994; 13:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/3\">",
"      Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/4\">",
"      Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006; 117:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/5\">",
"      Silverman J, Vazquez JA, Sobel JD, Zervos MJ. Comparative in vitro activity of antiseptics and disinfectants versus clinical isolates of Candida species. Infect Control Hosp Epidemiol 1999; 20:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/6\">",
"      Mohan P, Eddama O, Weisman LE. Patient isolation measures for infants with candida colonization or infection for preventing or reducing transmission of candida in neonatal units. Cochrane Database Syst Rev 2007; :CD006068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/7\">",
"      Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/8\">",
"      Saiman L, Ludington E, Dawson JD, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001; 20:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/9\">",
"      Kaufman DA. Challenging issues in neonatal candidiasis. Curr Med Res Opin 2010; 26:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/10\">",
"      Campbell JR, Zaccaria E, Baker CJ. Systemic candidiasis in extremely low birth weight infants receiving topical petrolatum ointment for skin care: a case-control study. Pediatrics 2000; 105:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/11\">",
"      Kaufman D. Strategies for prevention of neonatal invasive candidiasis. Semin Perinatol 2003; 27:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/12\">",
"      Sims ME, Yoo Y, You H, et al. Prophylactic oral nystatin and fungal infections in very-low-birthweight infants. Am J Perinatol 1988; 5:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/13\">",
"      Ozturk MA, Gunes T, Koklu E, et al. Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit. Mycoses 2006; 49:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/14\">",
"      Ganesan K, Harigopal S, Neal T, Yoxall CW. Prophylactic oral nystatin for preterm babies under 33 weeks' gestation decreases fungal colonisation and invasive fungaemia. Arch Dis Child Fetal Neonatal Ed 2009; 94:F275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/15\">",
"      Aydemir C, Oguz SS, Dizdar EA, et al. Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed 2011; 96:F164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/16\">",
"      Wainer S, Cooper PA, Funk E, et al. Prophylactic miconazole oral gel for the prevention of neonatal fungal rectal colonization and systemic infection. Pediatr Infect Dis J 1992; 11:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/17\">",
"      Clerihew L, Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2007; :CD003850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/18\">",
"      Kicklighter SD, Springer SC, Cox T, et al. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001; 107:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/19\">",
"      Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007; 356:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/20\">",
"      Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/21\">",
"      Kaufman D, Boyle R, Hazen KC, et al. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of &lt;1000 grams birth weight. J Pediatr 2005; 147:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/22\">",
"      Cabrera C, Frank M, Carter D, et al. Fluconazole prophylaxis against systemic candidiasis after colonization: a randomized double-blinded study. J Perinatol 2002; 22:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/23\">",
"      Kaufman D. Fluconazole prophylaxis decreases the combined outcome of invasive Candida infections or mortality in preterm infants. Pediatrics 2008; 122:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/24\">",
"      Healy CM, Campbell JR, Zaccaria E, Baker CJ. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics 2008; 121:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/25\">",
"      Aziz M, Patel AL, Losavio J, et al. Efficacy of fluconazole prophylaxis for prevention of invasive fungal infection in extremely low birth weight infants. Pediatr Infect Dis J 2010; 29:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/26\">",
"      Martin A, Pappas A, Lulic-Botica M, Natarajan G. Impact of 'targeted' fluconazole prophylaxis for preterm neonates: efficacy of a highly selective approach? J Perinatol 2012; 32:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/27\">",
"      Sarvikivi E, Lyytik&auml;inen O, Soll DR, et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 2005; 43:2729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/28\">",
"      McCrossan BA, McHenry E, O'Neill F, et al. Selective fluconazole prophylaxis in high-risk babies to reduce invasive fungal infection. Arch Dis Child Fetal Neonatal Ed 2007; 92:F454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/29\">",
"      Manzoni P, Leonessa M, Galletto P, et al. Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr Infect Dis J 2008; 27:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/30\">",
"      Kaufman DA, Cuff AL, Wamstad JB, et al. Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10 years of age. J Pediatr 2011; 158:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/31\">",
"      Benjamin DK Jr. First, do no harm. Pediatrics 2008; 121:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/32\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/33\">",
"      Kaufman DA. Why prevent invasive Candida infections? J Perinatol 2008; 28:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/34\">",
"      Healy CM, Baker CJ. Fluconazole prophylaxis in the neonatal intensive care unit. Pediatr Infect Dis J 2009; 28:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/35\">",
"      Manzoni P, Mostert M, Jacqz-Aigrain E, Farina D. The use of fluconazole in neonatal intensive care units. Arch Dis Child 2009; 94:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/36\">",
"      Rolnitsky A, Levy I, Sirota L, et al. Targeted fluconazole prophylaxis for high-risk very low birth weight infants. Eur J Pediatr 2012; 171:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/37\">",
"      Greenberg RG, Benjamin DK Jr, Gantz MG, et al. Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis. J Pediatr 2012; 161:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/38\">",
"      Romeo MG, Romeo DM, Trovato L, et al. Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcome. J Perinatol 2011; 31:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9991/abstract/39\">",
"      Manzoni P, Stolfi I, Messner H, et al. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics 2012; 129:116.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5042 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_48_9991=[""].join("\n");
var outline_f9_48_9991=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL MEASURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANTIFUNGAL PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nystatin and micnoazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112287551\">",
"      - Long-term outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Surveillance cultures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H207853895\">",
"      EMPIRIC ANTIFUNGAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454916249\">",
"      OTHER POTENTIAL INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=related_link\">",
"      Clinical manifestations and diagnosis of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24039?source=related_link\">",
"      Epidemiology and risk factors for Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=related_link\">",
"      Treatment of Candida infection in neonates",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_48_9992="Prevention of fire and burn injuries";
var content_f9_48_9992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of fire and burn injuries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/48/9992/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/48/9992/contributors\">",
"     Michael D Peck, MD, ScD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/48/9992/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/48/9992/contributors\">",
"     Marc G Jeschke, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/48/9992/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/48/9992/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/48/9992/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burn injuries are one of the most devastating of all injuries and a major global public health concern [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Approximately 90 percent of burns occur in low to middle income countries, regions that generally lack the necessary infrastructure to reduce the incidence and severity of burns [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/4\">",
"     4",
"    </a>",
"    ]. Burn injury prevention includes four stages: surveillance, analysis, intervention and evaluation and involves the three E's: education, engineering, and enforcement.",
"   </p>",
"   <p>",
"    This topic reviews the interventions that are effective and necessary to reduce the risk of burns. The epidemiology and costs of burn injuries are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23865?source=see_link\">",
"     \"Epidemiology of burn injuries globally\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17716?source=see_link\">",
"     \"Global costs of fires and burns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to burn injury prevention includes: surveillance, analysis, intervention and evaluation. A precise description of the magnitude of the risks for burn injuries is the basis for planning effective interventions. Accurate data on the incidence of burns and the causes are scarce for many low to low middle income countries. A lack of reliable data on risk factors further hampers the development and enactment of effective burn prevention strategies. Incomplete reporting of burn incidents leads to an underestimate of the magnitude of the public health problem.",
"   </p>",
"   <p>",
"    The Childhood Burn Foundation in Taiwan is an excellent example of a model surveillance system [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/5\">",
"     5",
"    </a>",
"    ]. The foundation provided resources to 43 hospitals to collect data on hospitalized burn patients. This comprehensive database, which utilizes the Internet for data entry, captured information on over 12,000 patients from 1997 to 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/5\">",
"     5",
"    </a>",
"    ]. The leading causes of all burn injuries include: scald (43.2 percent), flame (32.5 percent), contact (11.2 percent), chemical (6.6 percent), and electrical (5.6 percent). The most common locations for incurring a burn injury include: occupational setting (32.1 percent) and domestic setting (31.8 percent). The ultimate goal of a surveillance program is to convert the results into an action plan to prevent burn injuries.",
"   </p>",
"   <p>",
"    Overall, the positive factors associated with burn prevention include: improvement in socioeconomic status, improved housing, provision of basic amenities (eg, water), proper regulation and design of industrial products (eg, kerosene stove), proper storage of flammable substances, and supervision of children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional approach to burn injury prevention involves the three E's: education, engineering, and enforcement. Education is an active process that requires behavior modification. There are very little data on the effectiveness of fire prevention educational programs. Passive measures, such as engineering or product design and legislation, have been more effective [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of 30 pediatric burn prevention strategies from 16",
"    <span class=\"nowrap\">",
"     developing/developed",
"    </span>",
"    countries found only two papers that evaluated the effectiveness of the intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. It appears, based on limited data, that multipronged community-based interventions were most effective to reduce the risk of burn injuries.",
"   </p>",
"   <p>",
"    Injury prevention programs conducted in Israel between 1998 and 2000 were effective in reducing pediatric burn-related hospitalizations from 1.39 to 1.05 per 1000 infants, in contrast to areas where the program did not exist [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/8\">",
"     8",
"    </a>",
"    ]. The effect was greatest among infants and toddlers from affluent areas; there was no significant change in burn-related hospitalizations among school-aged children.",
"   </p>",
"   <p>",
"    A comprehensive community-based injury prevention program in Harstad, Norway, resulted in a 52.9 percent reduction in burn injuries in children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/9\">",
"     9",
"    </a>",
"    ]. This educational program strengthened public participation and enhanced community empowerment by recording and using the local burn injury data.",
"   </p>",
"   <p>",
"    Although many resources are expended on community education, the beneficial effects are not clear. Two previous publications reviewing the literature to 1999 did not identify evidence of beneficial effects from community, school, or clinic-based fire safety education on fire injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Counseling and educational interventions had only a modest effect on the likelihood of owning a smoke alarm, or having a functional alarm, but these effects were enhanced in the setting of primary child health care surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Engineering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Engineering (modification of agents or environment) and enforcement (creation and implementation of guidelines, codes and laws) require more resources than education programs, but also are more effective. The following are examples of successful approaches to reducing the incidence and severity of burns:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Smoke detectors and alarms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoke detectors serve as an early warning of fire, and hence, reduce the risk of burns by allowing occupants to escape the burning building. Sprinklers are a passive protection of burns, important for children, the handicapped and the elderly, who may not be sufficiently mobile to escape a fire.",
"   </p>",
"   <p>",
"    Early smoke detection systems include different types of fire warning equipment that detect heat or smoke. The rapid rate of installation in US homes (less than 5 percent in 1970 compared to 67 percent in 1982) was attributed to market price reduction, intensive marketing, programs led by local fire departments and building code modification and legislation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/14\">",
"     14",
"    </a>",
"    ]. Ninety-six percent of occupants of homes surveyed have at least one working smoke alarm [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The death rate per 100 reported home structure fires from 2003 to 2006 in the US was twice as high when no working smoke alarm was present (eg, either no smoke alarm was present or an alarm was present but did not operate) compared with the rate with working smoke alarms (1.16 versus 0.59). Having a working smoke alarm decreases the chances of dying in a residential fire by 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inversely correlating with the rise in usage of smoke detectors has been the decline in residential fire and flame deaths. The age-adjusted death rate in 1981 from residential fires was 2.28 per 100,000; by 1997 that rate was reduced by almost 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/18\">",
"     18",
"    </a>",
"    ]. Although smoke alarms have contributed significantly to this reduction in mortality, other factors have been beneficial as well, including safer heating and cooking appliances, child-resistant lighters, flame resistant mattresses, furniture, and clothing, and improvement in acute care of burn victims.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Water temperature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although scald burns are nearly as common as flame burns, a WHO report found that only 5.4 percent of all burn deaths were attributed to scalds compared with 93 percent of fire-related deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/19\">",
"     19",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23865?source=see_link\">",
"     \"Epidemiology of burn injuries globally\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17716?source=see_link\">",
"     \"Global costs of fires and burns\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hot tap water causes nearly one-quarter of all pediatric scald burns, and most of these occur in the bathroom. The damage caused by hot tap water burns tends to be more severe than that by other types of scald burns [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/20\">",
"     20",
"    </a>",
"    ]. In an animal study, partial or full-thickness burns occurred after six hours of exposure to water at 111&ordm;F (44&ordm;C) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/21\">",
"     21",
"    </a>",
"    ]. Yet if the temperature of the water was increased to 140&ordm;F (60&ordm;C), burns occurred within three seconds of exposure. Water at 120&ordm;F (49&ordm;C) took 10 minutes to cause significant thermal injury to the skin and this temperature is considered to be the ideal setting to reduce the risk of a serious burn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Lamps and stoves",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is anticipated that the global use of kerosene in lamps and stoves will continue for years to come. In low income communities in particular, kerosene is used for cooking, light, and heat [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/22\">",
"     22",
"    </a>",
"    ]. Although there is slow progress in providing electricity to residences in low income countries, less than one-quarter of the homes in Sub-Saharan Africa had access to electricity in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/23\">",
"     23",
"    </a>",
"    ]. A retrospective review of 11,196 burn admissions found that 82 percent of burns were due to flames and 35 percent of flame burns were due to malfunctioning kerosene stoves [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/24\">",
"     24",
"    </a>",
"    ]. A prospective study of 345 burn patients found that 41 percent of accidental burns were the result of",
"    <span class=\"nowrap\">",
"     fire/flame",
"    </span>",
"    from a kerosene bottle lamp [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/25\">",
"     25",
"    </a>",
"    ]. Wicks placed in discarded beverage or medicine bottles, and even from burned-out light bulbs serve as makeshift lamps [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of kerosene stoves is even more widespread than homemade kerosene lamps, and the magnitude of injury, death, and destruction that accompanies them places a tremendous burden on low income communities. The National Fire Protection Association states that space heating poses a much higher risk of fire, death, injury, and loss per million users than central heating [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention of lamp burns in low and middle income countries (LMIC) includes three approaches:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first approach is to use an educational campaign that teaches safe handling and use of kerosene lamps, including avoiding replenishment of the fuel reservoir while the wick is lit and placing the lamps on stable surfaces. A prospective quasiexperimental design study in low income South African communities found that there was a significant increase in self-reported knowledge, safety practices, and recognition of injury risk associated with kerosene in the intervention community [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The second approach is to use safer oil, such as vegetable oils (eg, coconut and sesame oils). Unfortunately, these oils are too heavy to rise to the top of the wick, and do not perform well.",
"     </li>",
"     <li>",
"      The third approach is to provide impoverished families with an inexpensive and safe lamp. Such a lamp was designed by a surgeon in 1992 in Sri Lanka [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/27\">",
"       27",
"      </a>",
"      ]. The lamp is compact and heavy, so that it does not easily tip over, and has two flat sides that prevent it from rolling if it does tip over. The screw-top lid averts fuel spillage, and the thick slow-cooled glass used for construction is essentially unbreakable. Over 775,000 safe bottle lamps have been distributed in Sri Lanka as of December 2009 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/28\">",
"       28",
"      </a>",
"      ]. It is produced from recycled glass for approximately US$ 0.25 each, and its production also provides a boost to the local economy. The safe lamp has been credited in the lay press with a significant reduction in burn injuries and fires in Sri Lanka [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Fireworks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fireworks are associated with national and cultural celebrations throughout the world [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/30\">",
"     30",
"    </a>",
"    ]. On Independence Day in the US each year, more fires are reported than on any other day of the year [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/26\">",
"     26",
"    </a>",
"    ]. As a prelude to the arrival of spring since at least 1700 BCE, Persians have celebrated Chaharshanbe-Suri on the last Wednesday night of the year. The festivities include participants jumping over bonfires in the streets and setting off fireworks, both hazardous activities. Despite the ubiquity of these practices in Persia and their persistence since ancient times, only 1 percent of surveyed families acknowledged having any education on the safe use of fireworks in 2007 in Tehran, Iran; over 98 percent of families were ignorant of fireworks safety standards [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Flame retardant materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the development of flame retardant clothes, the burn mortality rate of girls exceeded that of boys [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/32\">",
"     32",
"    </a>",
"    ]. This excess mortality was attributed to loosely fitting, easily flammable nightgowns and dresses. When children's sleepwear was made of a flame retardant material 2,3-dibromopropyl (referred to as \"tris\"), burn admissions were reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/33\">",
"     33",
"    </a>",
"    ]. However, tris was found to be highly mutagenic and was banned as a clothing additive [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/34\">",
"     34",
"    </a>",
"    ]. Most synthetic fabrics are fire resistant, but melt when exposed to high heat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Low ignition propensity cigarettes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarettes are responsible for approximately 10 to 20 percent of fire-related burns in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/35,36\">",
"     35,36",
"    </a>",
"    ] and one-third of fire-related deaths and most nonfatal fire injuries in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/37\">",
"     37",
"    </a>",
"    ]. Most fire deaths are associated with ignition of upholstered furniture, mattresses, and bedding by dropped cigarettes. One-quarter of fatalities from tobacco-related fires were victims, not smokers.",
"   </p>",
"   <p>",
"    The wrapping paper for a cigarette varies in degree of porosity. The porosity allows ventilation of the burning ember. Burning agents in the cigarette paper are responsible for fires. The application of microcrystalline cellulose to the paper controls the burning rate and stability of the ash, and reducing the burning agents in the paper reduces the ignition propensity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paper wrapping with thin bands of paper of different porosity lowers ignition propensity. These bands are inserted at intervals down the length of the cigarette, causing the cigarette to extinguish if not repeatedly smoked [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/36,41\">",
"     36,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Enforcement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Passage and enforcement of legislation in any country is often challenging, and education programs may be the best option for injury prevention in some cases. Only with an accurate appreciation of the burden of burn injuries within a region can effective lobbying efforts move forward in funding agencies and government health departments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Smoke detector legislation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoke detector installation is an effective and inexpensive strategy to reduce the risk of burns in residential settings [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/42\">",
"     42",
"    </a>",
"    ]. In 1975, the US Building Officials and Code Administrators (BOCA) building code was amended to require a smoke detector protecting the bedroom area in each dwelling unit of new construction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/43\">",
"     43",
"    </a>",
"    ]. Inversely correlating with the rise in usage of smoke detectors has been the decline in residential fire and flame deaths. The age-adjusted death rate in 1981 from residential fires was 2.28; by 1997 that rate was reduced by almost 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Water temperature regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1977, 80 percent of homes in Washington state had tap water temperatures greater than 129&ordm;F (54&ordm;C). In 1983 a Washington state law was passed, requiring new water heaters to be preset at 120&ordm;F (49&ordm;C). Five years later, 77 percent of homes (84 percent of homes with postlaw and 70 percent of homes with prelaw water heaters) had tap water temperatures of less than 129&ordm;F (54&ordm;C). Mean temperature in 1988 was 122&ordm;F (50&ordm;C) compared with 142&ordm;F (61&ordm;C) in 1977.",
"   </p>",
"   <p>",
"    Few people increase their heater temperature after installation. The impact of this measure was substantial in reducing the number of patients treated for scald burns. Eighteen burn victims were identified from July 1979 through May 1988, for an average admission rate of 2.4 per 100,000 per year, compared with 5.5 per year prior to enacting this legislation. Thus, the combination of education and legislation appeared to have resulted in a reduction in frequency, morbidity, and mortality of tap water burn injuries in children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Stove design and fuel regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Verification of fuel quality, safety of fuel storage and usage, and dispersion of appropriately designed appliances should reduce burn hazards. Compulsory standards covering the performance, safety, and requirements for nonpressure paraffin fueled cooking stoves and heaters intended primarily for domestic use were enacted by the South African government in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/45\">",
"     45",
"    </a>",
"    ]. The standard for nonpressure stoves and heaters is the only compulsory standard in place. The standard for pressurized kerosene-fueled appliances is voluntary and none of the pressure appliances on the market have applied for approval from South Africa Bureau of Standards Commercial against this standard [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inevitable transition from open fires and unregulated kerosene appliances toward more sophisticated devices for cooking, heating, and lighting to reduce burn injuries in low middle income countries (LMIC) is not without hazard. In Delhi, for example, liquefied petroleum gas (LPG) related burns accounted for less than 1 percent of admissions to a single burn center from 1993 to 2000, but from 2001 to 2007 were responsible for over 10 percent of admissions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electrification reduces the risk of disasters caused by malfunctioning kerosene stoves, but increases the risk of fires and burns from electrical injury because of substandard wiring techniques, unsafe practices, illegal poaching of power and scavenging copper from overhead lines, and inadequate barriers around high-voltage poles and towers. Thus, as developing communities convert to more common use of LPG and electricity, steps must be taken to ensure safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Fireworks legislation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduction in fireworks-related injuries has been observed as a result of focused campaigns. The US government prohibits the sale of the most dangerous types of fireworks to consumers, including reloadable shells, cherry bombs, aerial bombs, M-80 salutes, firecrackers containing more than two grains of powder, and mail-order kits for building fireworks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of legislation on the incidence of fireworks-related injuries suggests a reduction in the number of related burns. Presumably because of proliferation of fireworks legislation, the number of fireworks injuries in the UK decreased from 707 in 2001 to 494 in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/48\">",
"     48",
"    </a>",
"    ]. Conversely, after repeal of a law banning private fireworks in Minnesota, there was an increase in the number of children suffering fireworks-related burns [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Denmark, where fireworks are commonly used at New Years' celebrations, prohibition of the sale of firecrackers coupled with school education programs led to a reduction in the number of children treated for fireworks injuries at two Danish burn centers from 17 in 1991 to 1992 to only three children in 1993 to 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In India, fireworks injuries commonly occur during Diwali (Festival of Lights). The experience at one hospital in Mumbai from 1997 through 2006 was that the prevalence of fireworks injuries was decreasing, due to aggressive education campaigns by government and nongovernment organizations. Forty-one injuries were treated at the beginning of the study period; only three injuries were treated in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Flammable Fabrics Act",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Flammable Fabric Act was passed in the US in 1953 to regulate the manufacture of highly flammable clothing, and amended in 1967 to expand coverage to internal furnishings. This legislation regulates the material construction of a broad range of consumer products (eg, carpets, night clothes, mattresses, upholstered furniture, tents, curtains, sleeping bags and children's clothing) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/14,42\">",
"     14,42",
"    </a>",
"    ]. A retrospective study of children admitted to the Shriners Burns Institute of Boston from 1969 through 1976 showed that the promulgation of flammability standards reduced the incidence of flame burns from the ignition of sleepwear in children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/33\">",
"     33",
"    </a>",
"    ]. The National Fire Protection Association (NFPA) estimated that the enactment of the flammability standards for sleepwear in 1971 resulted in a ten-fold decrease in childhood deaths caused by ignition of sleepwear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Fire-safe cigarette legislation",
"    </span>",
"    &nbsp;&mdash;&nbsp;US consumer safety movements since the 1970s have focused on legislating mandatory production of fire-safe cigarettes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/52\">",
"     52",
"    </a>",
"    ]. Under the \"fire-safe\" cigarette laws, a cigarette must burn out 75 percent of the time when not in active use [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2003, the first state law requiring all cigarettes to be low-ignition was passed in the state of New York [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/54\">",
"     54",
"    </a>",
"    ]. By the end of 2009, all states except Wyoming had either passed or enacted fire-safe cigarette legislation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/53\">",
"     53",
"    </a>",
"    ]. There has been a reduction in smoking material fires of 57 percent from 1980 to 2006. Both the decline in cigarette consumption as well as standards and regulations that have made mattresses and upholstered furniture more resistant to ignition have contributed to this trend [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Canada has passed a similar nation-wide legislation based on the same standards as the US [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/55\">",
"     55",
"    </a>",
"    ]. The European Union expects to ban cigarettes that are not fire-safe by 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Nonaccidental burn legislation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elimination of acts of violence (eg, acid throwing or bride burning) requires a multitude of coordinated actions involving passage and enforcement of protective legislation, education of men and boys about appropriate behavior toward women, and resources for women in need of shelter or care [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23865?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology of burn injuries globally\", section on 'Intentional versus accidental'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Acid Survivors Foundation (ASF) of Bangladesh is an effective program designed to reduce acid attacks on children and women. ASF has been raising public awareness, building institutional capacity and lobbying, working with other nongovernmental organizations, the media, celebrities, and student groups to elevate community consciousness. It has also fostered advocacy and lobbying efforts with the government to ensure the passage and enforcement of laws and to create systems to provide service to acid survivors. As a result, the number of victims has dropped from 490 in 2002 to 171 in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/59\">",
"     59",
"    </a>",
"    ]. Based on the success of ASF, similar organizations have been formed in Cambodia, India, Pakistan and Uganda.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ROLE OF THE WORLD HEALTH ORGANIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of the World Health Organization (WHO) are to promote the development of burn control measures, to include improvements in burn prevention and strengthened burn care, to improve information and surveillance systems, and to encourage investment in research and training in burn prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The WHO Burn Plan is organized into seven main components that correspond to the challenges in burn prevention and care [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/61\">",
"     61",
"    </a>",
"    ]. For each component, there are full descriptions of areas of work needing to be done, expected products and output, and timeline. The components are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advocacy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Raising awareness",
"     </li>",
"     <li>",
"      Promoting and supporting action",
"     </li>",
"     <li>",
"      International, multisectoral cooperation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Policy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Effective and sustainable burn prevention and care policies",
"     </li>",
"     <li>",
"      Action plans, legislation, regulations, enforcement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data and measurement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Magnitude and burden",
"     </li>",
"     <li>",
"      Risk factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Research",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Set agenda of priorities",
"     </li>",
"     <li>",
"      Promote and foster trials of promising interventions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stronger, more effective burn prevention programs",
"     </li>",
"     <li>",
"      More countries with national burn strategies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Services",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Strengthen treatment services available",
"     </li>",
"     <li>",
"      Acute care",
"     </li>",
"     <li>",
"      Rehabilitation",
"     </li>",
"     <li>",
"      Recovery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Capacity building",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sufficient knowledge and skill to effectively carry out all of the above components of the Burn Plan",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PRACTICAL APPROACHES TO REDUCE THE RISK OF BURN INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are practical suggestions to reduce the risk of fires, scalds, and burns resulting from accidents in the home [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9992/abstract/62\">",
"     62",
"    </a>",
"    ]. Most burn injuries in adults and children occur in the kitchen or bathroom (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23865?source=see_link\">",
"     \"Epidemiology of burn injuries globally\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Home safety",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Keep a working fire extinguisher in the home. Learn how to use it properly.",
"     </li>",
"     <li>",
"      Install and maintain smoke alarms. Change batteries twice a year.",
"     </li>",
"     <li>",
"      Install and maintain sprinkler systems.",
"     </li>",
"     <li>",
"      Have an emergency exit plan for the household. Practice fire drills.",
"     </li>",
"     <li>",
"      Set water heater to low or medium (90 to 120&ordm;F).",
"     </li>",
"     <li>",
"      Use antiscald devises to test water temperature from the faucets.",
"     </li>",
"     <li>",
"      Secure flammable liquids in the original containers in a location away from the home.",
"     </li>",
"     <li>",
"      Store household cleaners out of the reach of children. Keep in original containers with labels.",
"     </li>",
"     <li>",
"      Read and follow instructions for storage of flammable liquids, household products and solvent-soaked rags.",
"     </li>",
"     <li>",
"      Keep sparks, lit cigarettes, and open flames away from combustible and flammable materials.",
"     </li>",
"     <li>",
"      Cover electrical outlets with child-proof covers.",
"     </li>",
"     <li>",
"      Discard damaged electrical cords.",
"     </li>",
"     <li>",
"      Maintain electrical sockets and replace bare wires with appropriate devices.",
"     </li>",
"     <li>",
"      Use protective screens and safety guards around fireplaces, ovens, space heaters, and radiators.",
"     </li>",
"     <li>",
"      Do not leave cooking pots unattended.",
"     </li>",
"     <li>",
"      Remove combustible debris from around the home.",
"     </li>",
"     <li>",
"      Never place torch lamps, (eg, candles or hurricane lamps), near curtains, bedding, or flammable materials.",
"     </li>",
"     <li>",
"      Never pour flammable liquids over hot coals.",
"     </li>",
"     <li>",
"      Never place bed, crib, or flammable furniture near radiators.",
"     </li>",
"     <li>",
"      Do not place electrical appliances near water (eg, baths).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Personal safety",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provide supervision of small children at all times, especially in the bathroom and kitchen.",
"     </li>",
"     <li>",
"      Keep small children out of the kitchen while cooking.",
"     </li>",
"     <li>",
"      Provide supervision for elderly adults with comorbid conditions, especially in the bathroom and kitchen.",
"     </li>",
"     <li>",
"      Wear pajamas and Halloween costumes made of flame resistant fabrics that fit snugly against the skin.",
"     </li>",
"     <li>",
"      Always check water temperature in a bath before placing child in water.",
"     </li>",
"     <li>",
"      Do not place pots, cups, or bowls with hot liquids near the edge of a table, counter or stove. Turn handles away from the edge. Use insulated mitts and pot holders.",
"     </li>",
"     <li>",
"      Do not leave heated oven door open or unattended.",
"     </li>",
"     <li>",
"      Do not heat the baby's bottle in the microwave and always test the temperature of food or liquid before feeding a baby or child.",
"     </li>",
"     <li>",
"      Do not pass hot liquids directly over children.",
"     </li>",
"     <li>",
"      Keep curling irons, irons, and other hot devices stored in a location out of the reach of children.",
"     </li>",
"     <li>",
"      Keep cigarette lighters, matches, gasoline, and flammable materials out of the reach of children.",
"     </li>",
"     <li>",
"      Keep lit cigarettes and cigars out of the reach of children.",
"     </li>",
"     <li>",
"      Do not allow children to play with firecrackers or sparklers.",
"     </li>",
"     <li>",
"      Keep small children away from electrical cords and outlets.",
"     </li>",
"     <li>",
"      Never smoke in bed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Education is an active process that requires behavior modification. Although many resources are expended on community education, the beneficial effects are not clear. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Engineering (modification of agents or environment) and enforcement (creation and implementation of guidelines, codes and laws) require more resources than education programs, but also are more effective. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Passage of legislation in any country is often challenging, and enforcement is particularly difficult, particularly in low and middle income countries (LMIC). Education programs and especially design changes and modification of the environment may be the best option for injury prevention in LMIC. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The reduction in number of burn injuries in high-income countries is attributed to legislation regulating installation of smoke detectors, hot water temperature, fireworks, and flammable sleepwear, and to engineering safer products for heating and cooking. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/1\">",
"      Forjuoh SN. Burns in low- and middle-income countries: a review of available literature on descriptive epidemiology, risk factors, treatment, and prevention. Burns 2006; 32:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/2\">",
"      Peck MD, Kruger GE, van der Merwe AE, et al. Burns and fires from non-electric domestic appliances in low and middle income countries Part I. The scope of the problem. Burns 2008; 34:303.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. The Global Burden of Disease: 2004 Update. World Health Organization, Geneva 2008 www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf (Accessed on April 02, 2010).",
"    </li>",
"    <li>",
"     Murray CJL, Lopez, AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020, World Health Organization, Swizerland 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/5\">",
"      Tung KY, Chen ML, Wang HJ, et al. A seven-year epidemiology study of 12,381 admitted burn patients in Taiwan--using the Internet registration system of the Childhood Burn Foundation. Burns 2005; 31 Suppl 1:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/6\">",
"      Daisy S, Mostaque AK, Bari TS, et al. Socioeconomic and cultural influence in the causation of burns in the urban children of Bangladesh. J Burn Care Rehabil 2001; 22:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/7\">",
"      Linares AZ, Linares HA. Burn prevention: the need for a comprehensive approach. Burns 1990; 16:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/8\">",
"      Peleg K, Goldman S, Sikron F. Burn prevention programs for children: do they reduce burn-related hospitalizations? Burns 2005; 31:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/9\">",
"      Ytterstad B, S&oslash;gaard AJ. The Harstad Injury Prevention Study: prevention of burns in small children by a community-based intervention. Burns 1995; 21:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/10\">",
"      Parbhoo A, Louw QA, Grimmer-Somers K. Burn prevention programs for children in developing countries require urgent attention: a targeted literature review. Burns 2010; 36:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/11\">",
"      Warda L, Tenenbein M, Moffatt ME. House fire injury prevention update. Part II. A review of the effectiveness of preventive interventions. Inj Prev 1999; 5:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/12\">",
"      DiGuiseppi C, Higgins JP. Systematic review of controlled trials of interventions to promote smoke alarms. Arch Dis Child 2000; 82:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/13\">",
"      DiGuiseppi C, Higgins JP. Interventions for promoting smoke alarm ownership and function. Cochrane Database Syst Rev 2001; :CD002246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/14\">",
"      Atiyeh BS, Costagliola M, Hayek SN. Burn prevention mechanisms and outcomes: pitfalls, failures and successes. Burns 2009; 35:181.",
"     </a>",
"    </li>",
"    <li>",
"     US Fire Administration. Residential Smoke and Fire Detector Coverage in the United States: Findings from a 1982 Survey. Federal Emergency Management Agency, Washington, DC 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/16\">",
"      Ahrens, M. Home smoke alarms: the data as context for decision. Fire Technol 2008; 44:313.",
"     </a>",
"    </li>",
"    <li>",
"     Ahrens, M. Smoke alarms in US home fires. National Fire Protection Association, Fire Analysis and Research Division, September 2009. Available online at: www.nfpa.org (Accessed on April 2, 2010).",
"    </li>",
"    <li>",
"     Centers for Disease Control. Web-based injury and statistics query and reporting system (WISQARS&trade;) 2009. webappa.cdc.gov/sasweb/ncipc/mortrate9.html (Accessed on April 02, 2010).",
"    </li>",
"    <li>",
"     Peden, M, Oyegbite, K, Ozanne-Smith, J, et al. World Report on Child Injury Prevention. World Health Organization, Geneva 2008. p.78. whqlibdoc.who.int/publications/2008/9789241563574_eng.pdf (Accessed on April 02, 2010).",
"    </li>",
"    <li>",
"     NSKC (National SAFE KIDS Campaign). Burn Injury Fact Sheet. NSKC, Washington, DC 2004. Available online at: www.preventinjury.org/PDFs/BURN_INJURY.pdf (Accessed on April 2, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/21\">",
"      Moritz AR, Henriques FC. Studies of Thermal Injury: II. The Relative Importance of Time and Surface Temperature in the Causation of Cutaneous Burns. Am J Pathol 1947; 23:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/22\">",
"      Schwebel DC, Swart D, Simpson J, et al. An intervention to reduce kerosene-related burns and poisonings in low-income South African communities. Health Psychol 2009; 28:493.",
"     </a>",
"    </li>",
"    <li>",
"     World Bank. Africa results and monitoring system: Improve access to and the reliability of clean energy. Available online at: web.worldbank.org/WBSITE/EXTERNAL/COUNTRIES/AFRICAEXT/EXTAFRRES/0,,menuPK:3506948~pagePK:64168427~piPK:64168435~theSitePK:3506896,00.html (Accessed on April 2, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/24\">",
"      Ahuja RB, Bhattacharya S. An analysis of 11,196 burn admissions and evaluation of conservative management techniques. Burns 2002; 28:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/25\">",
"      Lalo&euml; V. Epidemiology and mortality of burns in a general hospital of Eastern Sri Lanka. Burns 2002; 28:778.",
"     </a>",
"    </li>",
"    <li>",
"     Hall, JR. Fireworks. National Fire Protection Association Fire Analysis and Research Division. National Fire Protection Association, Quincy, MA 2009. Available online at: www.nfpa.org/assets/files/pdf/os.fireworks.pdf (Accessed on April 2, 2010).",
"    </li>",
"    <li>",
"     Safe Bottle Lamp Foundation: www.safebottlelamp.org (Accessed on April 2, 2010).",
"    </li>",
"    <li>",
"     Sri Lanka project wins BBC World Challenge '09. Now Public crowd powered media. nowpublic.com/world/sri-lanka-project-wins-bbc-world-challenge-09. Accessed May 5, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/29\">",
"      Lau YS. An insight into burns in a developing country: a Sri Lankan experience. Public Health 2006; 120:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/30\">",
"      Al-Qattan MM, Al-Zahrani K. A review of burns related to traditions, social habits, religious activities, festivals and traditional medical practices. Burns 2009; 35:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/31\">",
"      Saadat S, Naseripour M, Rahimi B. Safety preparedness of urban community for New Year fireworks in Tehran. Burns 2009; 35:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/32\">",
"      McLoughlin E, Crawford JD. Burns. Pediatr Clin North Am 1985; 32:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/33\">",
"      McLoughlin E, Clarke N, Stahl K, Crawford JD. One pediatric burn unit's experience with sleepwear-related injuries. Pediatrics 1977; 60:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/34\">",
"      McLoughlin E, Langley JD, Laing RM. Prevention of children's burns: legislation and fabric flammability. N Z Med J 1986; 99:804.",
"     </a>",
"    </li>",
"    <li>",
"     Hall, JR. The Smoking-Material Fire Problem. National Fire Protection Association Fire Analysis and Research Division. National Fire Protection Association, Quincy, MA 2008. Available online at: www.nfpa.org/assets/files//PDF/OS.Smoking.pdf (Accessed on April 2, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/36\">",
"      Brunnemann KD, Hoffmann D, Gairola CG, Lee BC. Low ignition propensity cigarettes: smoke analysis for carcinogens and testing for mutagenic activity of the smoke particulate matter. Food Chem Toxicol 1994; 32:917.",
"     </a>",
"    </li>",
"    <li>",
"     Fire statistics, United Kingdom 2007. Available online at: www.communities.gov.uk (Accessed May 6, 2010).",
"    </li>",
"    <li>",
"     JTI, Composite List of Ingredients in Non-Tobacco Materials. Available online at: www.jti.com (Accessed on June 9, 2010).",
"    </li>",
"    <li>",
"     Smoking article wrapper for controlling burn rate and method for making same. Available online at: www.freepatentsonline.com (Accessed on June 8, 2010).",
"    </li>",
"    <li>",
"     Method and apparatus for making banded smoking article wrappers. Available online at: www.patentstorm.us (Accessed on June 9, 2010).",
"    </li>",
"    <li>",
"     What is a fire-safe cigarette? Available online at: firesafecigarettes.org (Accessed on June 9, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/42\">",
"      Liao CC, Rossignol AM. Landmarks in burn prevention. Burns 2000; 26:422.",
"     </a>",
"    </li>",
"    <li>",
"     National Fire Prevention, Control Administration. Smoke detectors and legislation. Washington, DC: US Department of Commerce, 1977.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/44\">",
"      Erdmann TC, Feldman KW, Rivara FP, et al. Tap water burn prevention: the effect of legislation. Pediatrics 1991; 88:572.",
"     </a>",
"    </li>",
"    <li>",
"     Government Gazette. Compulsory specification for non-pressurized paraffin stoves and heaters. Government Notice No. R 1091, 2006. Available online at: https://www.sabs.co.za/content/uploads/files/VC9089.pdf (Accessed on April 2, 2010).",
"    </li>",
"    <li>",
"     Paraffin Safety Association of Southern Africa. The status of paraffin appliances in South Africa-October, 2008. Paraffin Safety Association of Southern Africa, Cape Town, SA 2008. Available online at: www.pasasa.org. (Accessed on April 2, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/47\">",
"      Ahuja RB, Bhattacharya S, Rai A. Changing trends of an endemic trauma. Burns 2009; 35:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/48\">",
"      Edwin AF, Cubison TC, Pape SA. The impact of recent legislation on paediatric fireworks injuries in the Newcastle upon Tyne region. Burns 2008; 34:953.",
"     </a>",
"    </li>",
"    <li>",
"     Roesler, JS, Day, H. Sparklers, Smoke Bombs, and Snakes, Oh My! Effect of Legislation on Fireworks-Related Injuries in Minnesota, 1999-2005. Clinical and Health Affairs Minnesota Medicine July 2007. Available online at: www.minnesotamedicine.com/PastIssues/PastIssues2007/July2007/ClinicalFireworksJuly2007/tabid/1959/Default.aspx (Accessed on June 8, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/50\">",
"      Sheller JP, Muchardt O, J&oslash;nsson B, Mikkelsen MB. Burn injuries caused by fireworks: effect of prophylaxis. Burns 1995; 21:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/51\">",
"      Puri V, Mahendru S, Rana R, Deshpande M. Firework injuries: a ten-year study. J Plast Reconstr Aesthet Surg 2009; 62:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/52\">",
"      Barillo DJ, Brigham PA, Kayden DA, et al. The fire-safe cigarette: a burn prevention tool. J Burn Care Rehabil 2000; 21:162.",
"     </a>",
"    </li>",
"    <li>",
"     Coalition for Fire-Safe Cigarettes. State-by-state efforts. National Fire Protection Association 2009. Available online at: www.firesafecigarettes.org (Accessed on April 2, 2010).",
"    </li>",
"    <li>",
"     Gann, RG. Measuring the ignition properties of cigarettes. National Institute of Standards and Technology. 2007; www.fire.nist.gov/bfrlpubs/fire07/PDF/f07068.pdf (Accessed on May 6, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/55\">",
"      C&ocirc;t&eacute; F, L&eacute;tourneau C, Mullard G, Voisine R. Estimation of nicotine and tar yields from human-smoked cigarettes before and after the implementation of the cigarette ignition propensity regulations in Canada. Regul Toxicol Pharmacol 2011; 61:S51.",
"     </a>",
"    </li>",
"    <li>",
"     AFP news. \"Les cigarettes anti-incendie seront obligatoires en 2011\" (in French). www.lexpansion.com (Accessed on May 6, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/57\">",
"      Greenbaum AR, Donne J, Wilson D, Dunn KW. Intentional burn injury: an evidence-based, clinical and forensic review. Burns 2004; 30:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9992/abstract/58\">",
"      Jutla RK, Heimbach D. Love burns: An essay about bride burning in India. J Burn Care Rehabil 2004; 25:165.",
"     </a>",
"    </li>",
"    <li>",
"     Acid Survivors Foundation. www.acidsurvivors.org.",
"    </li>",
"    <li>",
"     Mock, C, et al. A WHO plan for burn prevention and care. World Health Organization, Geneva 2008. Available online at: www.who.int (Accessed on April 2, 2010).",
"    </li>",
"    <li>",
"     World Health Organization. A WHO plan for burn prevention and care. Geneva, Switzerland. 2008. whqlibdoc.who.int/publications/2008/9789241596299_eng.pdf (Accessed on June 8, 2010).",
"    </li>",
"    <li>",
"     About Burns. How to prevent burn injuries. UC San Diego Health System Specialties &amp; Programs. Available online at: health.ucsd.edu/specialties/burn/about.htm (Accessed on June 9, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 824 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_48_9992=[""].join("\n");
var outline_f9_48_9992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Engineering",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Smoke detectors and alarms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Water temperature",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Lamps and stoves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Fireworks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Flame retardant materials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Low ignition propensity cigarettes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Enforcement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Smoke detector legislation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Water temperature regulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Stove design and fuel regulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Fireworks legislation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Flammable Fabrics Act",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Fire-safe cigarette legislation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Nonaccidental burn legislation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ROLE OF THE WORLD HEALTH ORGANIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PRACTICAL APPROACHES TO REDUCE THE RISK OF BURN INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Home safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Personal safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23865?source=related_link\">",
"      Epidemiology of burn injuries globally",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17716?source=related_link\">",
"      Global costs of fires and burns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_48_9993="Epidemiology and pathogenesis of Listeria monocytogenes infection";
var content_f9_48_9993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of Listeria monocytogenes infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/48/9993/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/48/9993/contributors\">",
"     Michael S Gelfand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/48/9993/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/48/9993/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/48/9993/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/48/9993/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/48/9993/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/48/9993/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Listeria monocytogenes is an important bacterial pathogen in immunosuppressed patients, individuals at the extremes of age including neonates and elderly adults, pregnant women, and occasionally, previously healthy individuals. Invasion of the central nervous system (meningitis or meningoencephalitis) and bacteremia are the principal clinical manifestations of listerial infection in these hosts. In contrast, normal hosts who ingest high numbers of Listeria may develop self-limited febrile gastroenteritis.",
"   </p>",
"   <p>",
"    The microbiology, epidemiology, and pathogenesis of listerial infection will be reviewed here. The clinical manifestations, diagnosis, treatment, prognosis, and prevention of listerial infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Listeria monocytogenes infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=see_link\">",
"     \"Treatment, prognosis, and prevention of Listeria monocytogenes infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;L. monocytogenes is the only Listeria species that regularly infects humans, although rare cases of human infections with Listeria ivanovii (a pathogen of ruminants) and Listeria grayi have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Listeria is an aerobic and facultatively anaerobic, motile, beta-hemolytic, non-spore-forming, short, gram-positive rod that exhibits characteristic tumbling motility by light microscopy (",
"    <a class=\"graphic graphic_movie graphicRef61238 \" href=\"UTD.htm?35/2/35887\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef55443 \" href=\"UTD.htm?4/26/4526\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Listeria occurs singly or in short chains. On Gram stain, Listeria may resemble pneumococci (diplococci), enterococci or diphtheroids (Corynebacteria), or be gram-variable and be confused with Haemophilus species (",
"    <a class=\"graphic graphic_picture graphicRef79633 \" href=\"UTD.htm?12/47/13040\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In particular, when a positive blood or cerebrospinal fluid culture is preliminarily identified as diphtheroids, the clinician should consider the possibility that the isolate represents Listeria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Listeria produces a characteristic appearance on blood agar with small zones of clear beta-hemolysis around each colony (",
"    <a class=\"graphic graphic_picture graphicRef57140 \" href=\"UTD.htm?9/7/9343\">",
"     picture 3",
"    </a>",
"    ). Listeria grows well at refrigeration temperatures (4&deg; to 10&deg;C). Rarely, the \"cold enrichment\" technique and selective media are used when attempting to isolate Listeria from mixed cultures, such as stool [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Listeria is a facultative intracellular parasite. The primary habitat of Listeria is the soil and decaying vegetable matter. Most Listeria infections in adults are thought to result from oral ingestion and subsequent intestinal mucosal penetration and systemic infection.",
"   </p>",
"   <p>",
"    Immunity to Listeria relies mainly on T-cell lymphokine activation of macrophages, which clear Listeria from the blood [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Interleukin (IL)-18 appears to play a role in protection against Listeria by enhancing bacterial clearance, even in the absence of interferon (IFN)-gamma, and by stimulating macrophages to secrete tumor necrosis factor (TNF) and nitric oxide [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/7\">",
"     7",
"    </a>",
"    ]. On the other hand, factors that impair macrophage survival or function are associated with increased susceptibility to listerial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is increasing evidence that IFN signaling enhances susceptibility to L. monocytogenes infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Mice deficient in either IFN regulatory factor or the IFN receptor are profoundly resistant to infection caused by L. monocytogenes compared with wild-type mice [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Listeria can initially enter cells by a mechanism that may involve binding of a bacterial protein (internalin) to E-cadherin (CDH1) on the host cell [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Another possible mechanism is via LapB, a sortase A-anchored surface protein that may be necessary for adhesion to and entry into mammalian cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/15\">",
"     15",
"    </a>",
"    ]. The organism then uses a unique mechanism of spreading from cell-to-cell, without exposing itself to an extracellular environment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/14\">",
"     14",
"    </a>",
"    ]. It accomplishes this by subverting the actin-based cellular contractile mechanism; propulsion within the cytoplasm of infected host cells and cell-to-cell spread are thought to be driven by actin polymerization at the bacterial cell surface and the formation of a comet tail [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/6\">",
"     6",
"    </a>",
"    ]. Both protein components in the host cell cytoplasm (particularly profilin, a host actin monomer-binding protein) and a bacterial surface protein (called ActA) are required for actin assembly by Listeria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Listeria has a predilection for the placenta and central nervous system. How this occurs is not well understood. Listeria crosses the placenta during maternal bacteremia and infects the fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of Listeria monocytogenes infection\", section on 'Infection in pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Listeriolysin O, a pore-forming toxin, is a cholesterol-dependent cytolysin and is the main virulence factor of L. monocytogenes. It induces T cell receptor (TCR) unresponsiveness by driving the expression of negative regulators of TCR signaling and suppresses antigen-induced T cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, listeriolysin O impairs post-translational modification of host cell proteins and interferes with the host immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary habitat of Listeria is the soil and decaying vegetable matter. It has been isolated from dust, numerous human food products, animal feed, water, sewage, numerous species of animals, and asymptomatic humans [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Approximately 0.8 to 3.4 percent of healthy individuals are fecal excretors of Listeria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/21\">",
"     21",
"    </a>",
"    ]. Dietary preferences and food processing techniques may contribute to the differences in rates of asymptomatic excretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Incidence of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the incidence of laboratory-confirmed cases of listeriosis between 2004 and 2009 was 0.25 to 0.32 cases per 100,000 persons [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/22\">",
"     22",
"    </a>",
"    ]. A study of foodborne illness in the United States between 2000 and 2008 estimated that 1600 cases of listeriosis occur annually, with a 16 percent reported mortality rate (approximately 255 deaths) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/23\">",
"     23",
"    </a>",
"    ]. Among foodborne infections in the United States, Listeria has the third highest mortality rate (approximately 16 percent compared with 35 percent with Vibrio vulnificus and 17 percent with botulism), and accounts for approximately 19 percent of all deaths from foodborne infection. However, it should be noted that mortality rates are often subject to reporting bias. Since it is more likely that severe or fatal cases are reported and that mild cases are unreported, the actual case-fatality rate is probably lower than 16 percent. Nonperinatal listeriosis-associated deaths in the United States have decreased from 1990 to 2005, paralleling the decreasing trend in incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increasing rate of listeriosis has been reported in several European countries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/25\">",
"     25",
"    </a>",
"    ]. Decreased concentration of salt in prepared foods has been proposed as a possible cause of this trend. In a study from England, an association between living in a socioeconomically depressed neighborhood and becoming ill with listeriosis was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/26\">",
"     26",
"    </a>",
"    ]. Individuals who purchased food from small local food stores and convenience stores were more likely to develop listeriosis than the general population.",
"   </p>",
"   <p>",
"    The types of illness that can occur are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Listeria monocytogenes infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sporadic illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Listeriosis is more often a sporadic illness than an illness that occurs in outbreaks. This was illustrated in a report from the Foodborne Diseases Active Surveillance Network (FoodNet) in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/27\">",
"     27",
"    </a>",
"    ]. Among 249 cases of culture-confirmed cases of listeriosis in nine states between 2000 and 2003, 95 percent were sporadic. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Food epidemiology and outbreaks'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Sporadic gastroenteritis due to L. monocytogenes appears to be an uncommon illness as illustrated in a two year population-based survey of stool specimens submitted for evaluation of diarrheal illness [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/21\">",
"     21",
"    </a>",
"    ]. Listeria spp were recovered in only 39 of 7775 (0.5 percent) stool specimens. Thus, routine screening of stool samples for Listeria is unwarranted.",
"   </p>",
"   <p>",
"    The source of infection in sporadic cases is usually not known but most cases are thought to be secondary to ingestion of contaminated food [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/3,4,27-29\">",
"     3,4,27-29",
"    </a>",
"    ]. Clinical infection is more likely after ingestion of foods with higher levels of contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/30\">",
"     30",
"    </a>",
"    ]. Infections from animal contact are uncommon, primarily occurring in veterinarians, abattoir workers, and farmers.",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings: two were from the Listeria Study Group involving patients seen between 1988 and 1990 and one was from the Foodborne Diseases Active Surveillance Network:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case-control study of 165 patients with culture-confirmed sporadic listeriosis from the Listeria Study Group, 32 percent of cases could be attributed to eating soft cheeses or foods purchased from delicatessen counters [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/28\">",
"       28",
"      </a>",
"      ]. Almost 70 percent of patients were immunosuppressed (cancer, HIV infection, organ transplant recipient, or glucocorticoid therapy); among these patients undercooked chicken also increased the risk of listeriosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Predisposing conditions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      An accompanying report from the Listeria Study Group involved 123 patients with sporadic listeriosis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/29\">",
"       29",
"      </a>",
"      ]. L. monocytogenes grew from at least one food specimen (mostly ready-to-eat foods) in the refrigerators of 79 of these patients (64 percent); in 26 (33 percent of patients), at least one food isolate was the same strain as that detected in the corresponding patient. Foods containing higher concentrations of L. monocytogenes were associated with an increased risk of infection.",
"     </li>",
"     <li>",
"      A later case-control study from the Foodborne Diseases Active Surveillance Network (FoodNet) in the United States was performed between 2000 and 2003, after the implementation of large-scale pathogen-reduction measures and dissemination of dietary guidelines to the public [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/27\">",
"       27",
"      </a>",
"      ]. In this study, 169 patients with sporadic listeriosis were matched to 376 controls. In multivariable analysis, L. monocytogenes infection was linked to two previously unrecognized foods: eating melons at a commercial establishment; or hummus prepared in a commercial establishment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are, however, limitations to such case-control studies: only foods associated with a marked elevation in relative risk can be identified; multiple testing may lead to false-positive results; and contaminated foods to which exposure is either rare or common may be missed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methods used to prevent foodborne infection are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment, prognosis, and prevention of Listeria monocytogenes infection\", section on 'Prevention of foodborne infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Predisposing conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most systemic, invasive listerial infections occur in individuals with one or more predisposing conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/28,31-33\">",
"     28,31-33",
"    </a>",
"    ]. These include pregnancy, glucocorticoid therapy, other immunocompromising conditions, and age. In an epidemic of 57 cases, for example, 42 percent had an underlying disease and more than one-half were at least 65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/32\">",
"     32",
"    </a>",
"    ]. Of 760 cases of listeriosis identified in the United States between 2004 and 2009 in the Foodborne Diseases Active Surveillance Network (FoodNet), 53 percent occurred in patients &ge;65 years of age, 31 percent in non-pregnant patients &lt;65 years of age, and 17 percent in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of age was better illustrated in a four-state, multicenter survey of bacterial meningitis in the United States in 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/34\">",
"     34",
"    </a>",
"    ]. Listeria accounted for 22 percent of cases in elderly adults, 23 percent in neonates, and only 4 percent between the ages of 2 and 60. In a FoodNet surveillance study, among non-pregnancy-associated cases in the United States from 2004 to 2009, the incidence of listeriosis increased with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/35\">",
"     35",
"    </a>",
"    ]. In persons aged 45 to 59 years, the relative risk of infection was 4.7 (95% CI 3.3-6.8) compared with individuals aged 15 to 44 years. Among individuals &ge;85 years of age, the relative risk was 53.8 (95% CI 37.3-78.9). Among children with listeriosis who are outside the neonatal age range, approximately one-half do not have an identifiable underlying condition [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Listeria is the most common cause of bacterial meningitis in patients with underlying neoplastic disease, especially lymphoma, in organ transplant recipients, and in those receiving glucocorticoids for any reason [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/3,37\">",
"     3,37",
"    </a>",
"    ]. In a retrospective review of 820 cases of central nervous system listeriosis not associated with pregnancy or the neonatal period, hematologic malignancies and renal transplantation were the two most common predisposing conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/37\">",
"     37",
"    </a>",
"    ]. However, 36 percent of patients had no recognizable underlying diseases.",
"   </p>",
"   <p>",
"    In the FoodNet study from the United States described above, Hispanics were at increased risk of listeriosis compared with non-Hispanics (RR 1.8, 95% CI 1.3-2.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women, especially those in the third trimester, are particularly susceptible to Listeria infection and account for up to one-third of reported cases. In the FoodNet study, among women of reproductive age (15 to 44 years), pregnant women were at much greater risk of listeriosis than non-pregnant women (RR 114.6, 95% CI 68.9-205.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/35\">",
"     35",
"    </a>",
"    ]. For unknown reasons, women with twin or triplet pregnancies are at increased risk (risk ratio 3.8 compared with single pregnancies) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Listeria infection in pregnant women can lead to fetal death, premature birth, or infected newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of Listeria monocytogenes infection\", section on 'Infection in pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid therapy is the most important predisposing factor in nonpregnant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In one report of patients with chronic lymphocytic leukemia, for example, Listeria infection occurred in 7 of 248 patients (2.8 percent) treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/43\">",
"     43",
"    </a>",
"    ]. In comparison, no listerial infections occurred in 160 patients treated with fludarabine alone or in 387 patients treated with conventional chemotherapeutic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other immunosuppressive treatments or conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to glucocorticoid therapy, a number of diseases and medications are risk factors for Listeria infection, most of which are associated with at least some degree of immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/3,28,31,33,45,46\">",
"     3,28,31,33,45,46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematologic malignancies",
"     </li>",
"     <li>",
"      Solid tumors",
"     </li>",
"     <li>",
"      Organ transplantation (especially renal) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/28,33,47,48\">",
"       28,33,47,48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      AIDS [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Treatment with tumor necrosis factor-alpha antagonists (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link&amp;anchor=H7#H7\">",
"       \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\", section on 'Listeriosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      End-stage renal disease (including hemodialysis and peritoneal dialysis) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Iron overload [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Collagen-vascular diseases",
"     </li>",
"     <li>",
"      Other serious chronic nonmalignant diseases",
"     </li>",
"     <li>",
"      Colonoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Liver disease and alcoholism [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/53\">",
"       53",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of underlying diseases was illustrated in a series of 165 adults with culture-proven, invasive Listeria infection: 69 percent of cases in nonpregnant adults occurred in patients with cancer, AIDS, organ transplant recipients, or glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/28\">",
"     28",
"    </a>",
"    ]. Similar results were noted in a report from Finland: 66 percent had an underlying disease and 43 percent had been treated with immunosuppressive drugs within one week of the onset of listeriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemochromatosis with cirrhosis and transfusional iron overload in dialysis patients are additional risk factors for listerial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Several factors may contribute in these settings. Iron overload of macrophages can diminish phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/50\">",
"     50",
"    </a>",
"    ], while high serum iron levels may increase bacterial virulence.",
"   </p>",
"   <p>",
"    Prior to the use of highly active antiretroviral therapy, the frequency of listerial infection in a prospective population-based surveillance study was increased 65 to 145 fold in patients with AIDS, although still relatively uncommon (115 per 100,000 patients per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/54\">",
"     54",
"    </a>",
"    ]. A low CD4 cell count was presumed to be a predisposing factor, however, the widespread use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    prophylaxis for Pneumocystis jirovecii (formerly P. carinii) infection has made the occurrence of Listeria infection in this population less common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Nosocomial acquisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospital-acquired listeriosis in adults has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/55-60\">",
"     55-60",
"    </a>",
"    ]. The mode of acquisition is from ingestion of contaminated foods. In a review of 369 adults with listeriosis worldwide, 16 percent of cases were thought to be nosocomially acquired [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/55\">",
"     55",
"    </a>",
"    ]. In a study from Spain of 102 non-pregnant adults with listeriosis, 30 percent had hospital-acquired infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/56\">",
"     56",
"    </a>",
"    ]. While a potentially lengthy incubation period and gastrointestinal carriage make it possible that the microorganism may not have been acquired in the hospital in all patients, two cases of listeriosis in an oncology unit associated with sandwiches consumed in the hospital have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/57\">",
"     57",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=see_link&amp;anchor=H418301#H418301\">",
"     \"Clinical manifestations and diagnosis of Listeria monocytogenes infection\", section on 'Incubation period'",
"    </a>",
"    ). Increased immunosuppression associated with hospitalization may be an important factor in the development of listeriosis in patients who were colonized prior to admission [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A nosocomial outbreak of listeriosis involving 17 patients in a hospital in Norway was linked to Camembert cheese [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/58\">",
"     58",
"    </a>",
"    ]. A nosocomial outbreak of listeriosis affected 10 patients at five hospitals in Texas in the United States over a seven-month period and was linked to diced celery prepared at a produce processing facility [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/59\">",
"     59",
"    </a>",
"    ]. All of the patients had at least one immunocompromising condition or were receiving a glucocorticoid or an acid-reducing medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FOOD EPIDEMIOLOGY AND OUTBREAKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Listeria species account for less than 1 percent of reported cases of microbial foodborne disease (",
"    <a class=\"graphic graphic_table graphicRef75429 \" href=\"UTD.htm?33/24/34190\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/23\">",
"     23",
"    </a>",
"    ]. As noted above, most cases (95 percent in a report from FoodNet) are sporadic [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=see_link&amp;anchor=H33#H33\">",
"     \"Differential diagnosis of microbial foodborne disease\", section on 'Listeria monocytogenes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Listeria is a common low-level contaminant of both processed and unprocessed foods of plant and animal origin. On the other hand, hot cooked foods are not a vehicle of Listeria transmission. The organism can survive and multiply at refrigerator temperatures and over a wide range of pH; as a result, even a small amount of contamination may be significant [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/4\">",
"     4",
"    </a>",
"    ]. Although usually a low-level contaminant, many outbreaks have had high numbers of organisms in the food. It is typically these outbreaks in which febrile gastroenteritis in immunocompetent hosts is observed.",
"   </p>",
"   <p>",
"    In a multistate population-based study, Listeria grew from at least one food specimen in the refrigerators of 64 percent of 123 patients with Listeria infection; one-third of refrigerators had at least one food isolate that grew the same strain of Listeria as that infecting the corresponding patient [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Foodborne outbreaks, many of which are manifested by febrile gastroenteritis, have been described with a variety of foods [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/32,39-42,61-74\">",
"     32,39-42,61-74",
"    </a>",
"    ]. The most common are",
"    <span class=\"nowrap\">",
"     processed/delicatessen",
"    </span>",
"    meats, hot dogs, soft cheeses, smoked seafood, meat spreads, and p&acirc;t&eacute;s [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/61\">",
"     61",
"    </a>",
"    ]. The attack rate in various outbreaks of gastroenteritis varied from 50 to 100 percent, and the mean incubation period was about 24 hours (range 6 hours to 10 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=see_link&amp;anchor=H418301#H418301\">",
"     \"Clinical manifestations and diagnosis of Listeria monocytogenes infection\", section on 'Incubation period'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Outbreaks have occurred in various settings, as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large outbreak of febrile gastroenteritis due to L. monocytogenes in Italy was traced to the consumption of a cold corn salad in two primary school cafeterias in Italy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/62\">",
"       62",
"      </a>",
"      ]. Among the 2189 people interviewed, 1566 (72 percent) had symptoms of gastroenteritis. Hospitalization was required in 292 patients (19 percent). L. monocytogenes was isolated from 123 of 141 stool samples and from the blood in one patient. DNA from all of the isolates was identical.",
"     </li>",
"     <li>",
"      In the United States, a multistate outbreak of L. monocytogenes occurred between May and December 2000 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/39\">",
"       39",
"      </a>",
"      ]. Thirty patients infected with L. monocytogenes with identical pulsed-field gel electrophoresis patterns were identified in 11 states. A case-control study implicated delicatessen turkey meat from a single processing plant as the likely source of the outbreak. Infection was associated with four deaths and three miscarriages.",
"     </li>",
"     <li>",
"      A subsequent multistate outbreak from delicatessen turkey meat occurred between July and October 2002 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/40\">",
"       40",
"      </a>",
"      ]. Fifty-four patients were identified; eight died, and three pregnant women had fetal deaths. Two meat-processing plants were implicated, leading to a recall of more than 30 million pounds of products. Investigation of this outbreak led to policy changes designed to prevent future L. monocytogenes contamination of ready-to-eat meat and poultry products.",
"     </li>",
"     <li>",
"      A small outbreak of listeriosis associated with pasteurized milk from a local dairy occurred in Massachusetts in 2007 and involved five individuals, three of whom died [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/71\">",
"       71",
"      </a>",
"      ]. Contamination likely occurred after pasteurization.",
"     </li>",
"     <li>",
"      A large outbreak of L. monocytogenes occurred in seven provinces in Canada in 2008 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/75\">",
"       75",
"      </a>",
"      ]. This outbreak included 57 confirmed cases and 23 deaths and was linked to ready-to-eat meat products from a single manufacturer [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/75,76\">",
"       75,76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An outbreak of L. monocytogenes occurred in the United States between July and October 2011; infections by four outbreak-related strains of L. monocytogenes were detected in 146 people in 28 states and were linked to 30 deaths [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9993/abstract/77\">",
"       77",
"      </a>",
"      ]. The source was cantaloupes from a farm in Colorado. Most patients were &ge;60 years of age (median age 77 years, range &lt;1 to 96 years), and seven cases were related to a pregnancy. Three cases occurred in newborns and four were diagnosed in pregnant women, one of whom had a miscarriage. Among the patients who died, the median age was 82.5 years (range 48 to 96 years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Methods used to prevent foodborne infection are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment, prognosis, and prevention of Listeria monocytogenes infection\", section on 'Prevention of foodborne infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/29/28114?source=see_link\">",
"       \"Patient information: Listeria (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Listeria is an aerobic and facultatively anaerobic gram-positive rod that exhibits characteristic tumbling motility by light microscopy (",
"      <a class=\"graphic graphic_movie graphicRef61238 \" href=\"UTD.htm?35/2/35887\">",
"       movie 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef55443 \" href=\"UTD.htm?4/26/4526\">",
"       picture 1",
"      </a>",
"      ). On Gram stain, Listeria may resemble pneumococci (diplococci) or diphtheroids (Corynebacteria), or may be gram-variable and be confused with Haemophilus species. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary habitat of Listeria is the soil and decaying vegetable matter. Most Listeria infections in adults are thought to result from oral ingestion and subsequent intestinal mucosal penetration and systemic infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most systemic, invasive listerial infections occur in individuals with one or more predisposing conditions. These include pregnancy, glucocorticoid therapy, and other immunosuppressive treatments or conditions. Pregnant women, especially in the third trimester, are particularly susceptible and account for up to one-third of reported cases. Glucocorticoid therapy is the most important predisposing factor in nonpregnant patients. Sporadic gastroenteritis is an uncommon illness. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Listeria is a common low-level contaminant of both processed and unprocessed foods of plant and animal origin. On the other hand, hot cooked foods are not a vehicle of Listeria transmission. The organism can survive and multiply at refrigerator temperatures and over a wide range of pH; as a result, even a small amount of contamination may be significant. Most cases (95 percent in a report from FoodNet) are sporadic. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Sporadic illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Foodborne outbreaks, many of which are manifested by febrile gastroenteritis, have been described with a variety of foods. The most common are",
"      <span class=\"nowrap\">",
"       processed/delicatessen",
"      </span>",
"      meats, hot dogs, soft cheeses, smoked seafood, meat spreads, and pates. The attack rate in various outbreaks of gastroenteritis varied from 50 to 100 percent and the mean incubation period was about 24 hours (range 6 hours to 10 days). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Food epidemiology and outbreaks'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=see_link&amp;anchor=H418301#H418301\">",
"       \"Clinical manifestations and diagnosis of Listeria monocytogenes infection\", section on 'Incubation period'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/1\">",
"      Guillet C, Join-Lambert O, Le Monnier A, et al. Human listeriosis caused by Listeria ivanovii. Emerg Infect Dis 2010; 16:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/2\">",
"      Salimnia H, Patel D, Lephart PR, et al. Listeria grayi: vancomycin-resistant, gram-positive rod causing bacteremia in a stem cell transplant recipient. Transpl Infect Dis 2010; 12:526.",
"     </a>",
"    </li>",
"    <li>",
"     Lorber B. Listeria monocytogenes. In: Principles and Practice of Infectious Diseases, 7th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2010. p.2707.",
"    </li>",
"    <li>",
"     Bille J. Listeria and Erysipelothrix. In: Manual of Clinical Microbiology, 9th ed, ASM Press, Washington, DC 2007. p.474.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/5\">",
"      Lavetter A, Leedom JM, Mathies AW Jr, et al. Meningitis due to Listeria monocytogenes. A review of 25 cases. N Engl J Med 1971; 285:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/6\">",
"      Southwick FS, Purich DL. Intracellular pathogenesis of listeriosis. N Engl J Med 1996; 334:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/7\">",
"      Neighbors M, Xu X, Barrat FJ, et al. A critical role for interleukin 18 in primary and memory effector responses to Listeria monocytogenes that extends beyond its effects on Interferon gamma production. J Exp Med 2001; 194:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/8\">",
"      Helmy KY, Katschke KJ Jr, Gorgani NN, et al. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 2006; 124:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/9\">",
"      Joseph SB, Bradley MN, Castrillo A, et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 2004; 119:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/10\">",
"      Carrero JA, Calderon B, Unanue ER. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J Exp Med 2004; 200:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/11\">",
"      Auerbuch V, Brockstedt DG, Meyer-Morse N, et al. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J Exp Med 2004; 200:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/12\">",
"      O'Connell RM, Saha SK, Vaidya SA, et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J Exp Med 2004; 200:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/13\">",
"      Mengaud J, Ohayon H, Gounon P, et al. E-cadherin is the receptor for internalin, a surface protein required for entry of L. monocytogenes into epithelial cells. Cell 1996; 84:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/14\">",
"      Drevets DA, Sawyer RT, Potter TA, Campbell PA. Listeria monocytogenes infects human endothelial cells by two distinct mechanisms. Infect Immun 1995; 63:4268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/15\">",
"      Reis O, Sousa S, Camejo A, et al. LapB, a novel Listeria monocytogenes LPXTG surface adhesin, required for entry into eukaryotic cells and virulence. J Infect Dis 2010; 202:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/16\">",
"      Theriot JA, Rosenblatt J, Portnoy DA, et al. Involvement of profilin in the actin-based motility of L. monocytogenes in cells and in cell-free extracts. Cell 1994; 76:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/17\">",
"      Kocks C, Gouin E, Tabouret M, et al. L. monocytogenes-induced actin assembly requires the actA gene product, a surface protein. Cell 1992; 68:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/18\">",
"      Welch MD, Iwamatsu A, Mitchison TJ. Actin polymerization is induced by Arp2/3 protein complex at the surface of Listeria monocytogenes. Nature 1997; 385:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/19\">",
"      Gekara NO, Zietara N, Geffers R, Weiss S. Listeria monocytogenes induces T cell receptor unresponsiveness through pore-forming toxin listeriolysin O. J Infect Dis 2010; 202:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/20\">",
"      Ribet D, Hamon M, Gouin E, et al. Listeria monocytogenes impairs SUMOylation for efficient infection. Nature 2010; 464:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/21\">",
"      Schlech WF 3rd, Schlech WF 4th, Haldane H, et al. Does sporadic Listeria gastroenteritis exist? A 2-year population-based survey in Nova Scotia, Canada. Clin Infect Dis 2005; 41:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/22\">",
"      Silk BJ, Date KA, Jackson KA, et al. Invasive listeriosis in the Foodborne Diseases Active Surveillance Network (FoodNet), 2004-2009: further targeted prevention needed for higher-risk groups. Clin Infect Dis 2012; 54 Suppl 5:S396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/23\">",
"      Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States--major pathogens. Emerg Infect Dis 2011; 17:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/24\">",
"      Bennion JR, Sorvillo F, Wise ME, et al. Decreasing listeriosis mortality in the United States, 1990-2005. Clin Infect Dis 2008; 47:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/25\">",
"      Allerberger F, Wagner M. Listeriosis: a resurgent foodborne infection. Clin Microbiol Infect 2010; 16:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/26\">",
"      Gillespie IA, Mook P, Little CL, et al. Human listeriosis in England, 2001-2007: association with neighbourhood deprivation. Euro Surveill 2010; 15:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/27\">",
"      Varma JK, Samuel MC, Marcus R, et al. Listeria monocytogenes infection from foods prepared in a commercial establishment: a case-control study of potential sources of sporadic illness in the United States. Clin Infect Dis 2007; 44:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/28\">",
"      Schuchat A, Deaver KA, Wenger JD, et al. Role of foods in sporadic listeriosis. I. Case-control study of dietary risk factors. The Listeria Study Group. JAMA 1992; 267:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/29\">",
"      Pinner RW, Schuchat A, Swaminathan B, et al. Role of foods in sporadic listeriosis. II. Microbiologic and epidemiologic investigation. The Listeria Study Group. JAMA 1992; 267:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/30\">",
"      Goulet V. What can we do to prevent listeriosis in 2006? Clin Infect Dis 2007; 44:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/31\">",
"      Goulet V, Hebert M, Hedberg C, et al. Incidence of listeriosis and related mortality among groups at risk of acquiring listeriosis. Clin Infect Dis 2012; 54:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/32\">",
"      B&uuml;la CJ, Bille J, Glauser MP. An epidemic of food-borne listeriosis in western Switzerland: description of 57 cases involving adults. Clin Infect Dis 1995; 20:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/33\">",
"      Skogberg K, Syrj&auml;nen J, Jahkola M, et al. Clinical presentation and outcome of listeriosis in patients with and without immunosuppressive therapy. Clin Infect Dis 1992; 14:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/34\">",
"      Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997; 337:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/35\">",
"      Pouillot R, Hoelzer K, Jackson KA, et al. Relative risk of listeriosis in Foodborne Diseases Active Surveillance Network (FoodNet) sites according to age, pregnancy, and ethnicity. Clin Infect Dis 2012; 54 Suppl 5:S405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/36\">",
"      Tim MW, Jackson MA, Shannon K, et al. Non-neonatal infection due to Listeria monocytogenes. Pediatr Infect Dis 1984; 3:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/37\">",
"      Mylonakis E, Hohmann EL, Calderwood SB. Central nervous system infection with Listeria monocytogenes. 33 years' experience at a general hospital and review of 776 episodes from the literature. Medicine (Baltimore) 1998; 77:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/38\">",
"      Mascola L, Ewert DP, Eller A. Listeriosis: a previously unreported medical complication in women with multiple gestations. Am J Obstet Gynecol 1994; 170:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/39\">",
"      Olsen SJ, Patrick M, Hunter SB, et al. Multistate outbreak of Listeria monocytogenes infection linked to delicatessen turkey meat. Clin Infect Dis 2005; 40:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/40\">",
"      Gottlieb SL, Newbern EC, Griffin PM, et al. Multistate outbreak of Listeriosis linked to turkey deli meat and subsequent changes in US regulatory policy. Clin Infect Dis 2006; 42:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/41\">",
"      Linnan MJ, Mascola L, Lou XD, et al. Epidemic listeriosis associated with Mexican-style cheese. N Engl J Med 1988; 319:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/42\">",
"      MacDonald PD, Whitwam RE, Boggs JD, et al. Outbreak of listeriosis among Mexican immigrants as a result of consumption of illicitly produced Mexican-style cheese. Clin Infect Dis 2005; 40:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/43\">",
"      Anaissie E, Kontoyiannis DP, Kantarjian H, et al. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 1992; 117:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/44\">",
"      Chang J, Powles R, Mehta J, et al. Listeriosis in bone marrow transplant recipients: incidence, clinical features, and treatment. Clin Infect Dis 1995; 21:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/45\">",
"      Lorber B. Listeriosis. Clin Infect Dis 1997; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/46\">",
"      Gantz NM, Myerowitz RL, Medeiros AA, et al. Listeroisis in immunosuppressed patients. A cluster of eight cases. Am J Med 1975; 58:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/47\">",
"      Stamm AM, Dismukes WE, Simmons BP, et al. Listeriosis in renal transplant recipients: report of an outbreak and review of 102 cases. Rev Infect Dis 1982; 4:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/48\">",
"      Fern&agrave;ndez-Sab&eacute; N, Cervera C, L&oacute;pez-Medrano F, et al. Risk factors, clinical features, and outcomes of listeriosis in solid-organ transplant recipients: a matched case-control study. Clin Infect Dis 2009; 49:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/49\">",
"      Myers JP, Peterson G, Rashid A. Peritonitis due to Listeria monocytogenes complicating continuous ambulatory peritoneal dialysis. J Infect Dis 1983; 148:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/50\">",
"      van Asbeck BS, Verbrugh HA, van Oost BA, et al. Listeria monocytogenes meningitis and decreased phagocytosis associated with iron overload. Br Med J (Clin Res Ed) 1982; 284:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/51\">",
"      Mossey RT, Sondheimer J. Listeriosis in patients with long-term hemodialysis and transfusional iron overload. Am J Med 1985; 79:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/52\">",
"      Witlox MA, Klinkenberg-Knol EC, Meuwissen SG. Listeria sepsis as a complication of endoscopy. Gastrointest Endosc 2000; 51:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/53\">",
"      Mook P, O'Brien SJ, Gillespie IA. Concurrent conditions and human listeriosis, England, 1999-2009. Emerg Infect Dis 2011; 17:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/54\">",
"      Jurado RL, Farley MM, Pereira E, et al. Increased risk of meningitis and bacteremia due to Listeria monocytogenes in patients with human immunodeficiency virus infection. Clin Infect Dis 1993; 17:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/55\">",
"      Siegman-Igra Y, Levin R, Weinberger M, et al. Listeria monocytogenes infection in Israel and review of cases worldwide. Emerg Infect Dis 2002; 8:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/56\">",
"      Mitj&agrave; O, Pigrau C, Ruiz I, et al. Predictors of mortality and impact of aminoglycosides on outcome in listeriosis in a retrospective cohort study. J Antimicrob Chemother 2009; 64:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/57\">",
"      Shetty A, McLauchlin J, Grant K, et al. Outbreak of Listeria monocytogenes in an oncology unit associated with sandwiches consumed in hospital. J Hosp Infect 2009; 72:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/58\">",
"      Johnsen BO, Lingaas E, Torfoss D, et al. A large outbreak of Listeria monocytogenes infection with short incubation period in a tertiary care hospital. J Infect 2010; 61:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/59\">",
"      Gaul LK, Farag NH, Shim T, et al. Hospital-acquired listeriosis outbreak caused by contaminated diced celery--Texas, 2010. Clin Infect Dis 2013; 56:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/60\">",
"      Wang HL, Ghanem KG, Wang P, et al. Listeriosis at a tertiary care hospital in beijing, china: high prevalence of nonclustered healthcare-associated cases among adult patients. Clin Infect Dis 2013; 56:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/61\">",
"      Ooi ST, Lorber B. Gastroenteritis due to Listeria monocytogenes. Clin Infect Dis 2005; 40:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/62\">",
"      Aureli P, Fiorucci GC, Caroli D, et al. An outbreak of febrile gastroenteritis associated with corn contaminated by Listeria monocytogenes. N Engl J Med 2000; 342:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/63\">",
"      Dalton CB, Austin CC, Sobel J, et al. An outbreak of gastroenteritis and fever due to Listeria monocytogenes in milk. N Engl J Med 1997; 336:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/64\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of listeriosis associated with homemade Mexican-style cheese--North Carolina, October 2000-January 2001. MMWR Morb Mortal Wkly Rep 2001; 50:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/65\">",
"      Heir E, Lindstedt BA, R&oslash;tterud OJ, et al. Molecular epidemiology and disinfectant susceptibility of Listeria monocytogenes from meat processing plants and human infections. Int J Food Microbiol 2004; 96:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/66\">",
"      Salamina G, Dalle Donne E, Niccolini A, et al. A foodborne outbreak of gastroenteritis involving Listeria monocytogenes. Epidemiol Infect 1996; 117:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/67\">",
"      Sim J, Hood D, Finnie L, et al. Series of incidents of Listeria monocytogenes non-invasive febrile gastroenteritis involving ready-to-eat meats. Lett Appl Microbiol 2002; 35:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/68\">",
"      Frye DM, Zweig R, Sturgeon J, et al. An outbreak of febrile gastroenteritis associated with delicatessen meat contaminated with Listeria monocytogenes. Clin Infect Dis 2002; 35:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/69\">",
"      Miettinen MK, Siitonen A, Heiskanen P, et al. Molecular epidemiology of an outbreak of febrile gastroenteritis caused by Listeria monocytogenes in cold-smoked rainbow trout. J Clin Microbiol 1999; 37:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/70\">",
"      Carrique-Mas JJ, H&ouml;keberg I, Andersson Y, et al. Febrile gastroenteritis after eating on-farm manufactured fresh cheese--an outbreak of listeriosis? Epidemiol Infect 2003; 130:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/71\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of Listeria monocytogenes infections associated with pasteurized milk from a local dairy--Massachusetts, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:1097.",
"     </a>",
"    </li>",
"    <li>",
"     Listeria monocytogenes outbreak file://www.phac-aspc.gc.ca/alert-alerte/listeria/listeria_2008-eng.php (Accessed on October 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/73\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of invasive listeriosis associated with the consumption of hog head cheese--Louisiana, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/74\">",
"      Cartwright EJ, Jackson KA, Johnson SD, et al. Listeriosis outbreaks and associated food vehicles, United States, 1998-2008. Emerg Infect Dis 2013; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     Public Health Agency of Canada. Update to 2008 Listeria mnocytogenes case numbers file://www.phac-aspc.gc.ca/alert-alerte/listeria/listeria_20100413-eng.php (Accessed on October 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9993/abstract/76\">",
"      Taillefer C, Boucher M, Laferri&egrave;re C, Morin L. Perinatal listeriosis: Canada's 2008 outbreaks. J Obstet Gynaecol Can 2010; 32:45.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Multistate outbreak of listeriosis linked to whole cantaloupes from Jensen Farms, Colorado. December 8, 2011 (final update). file://www.cdc.gov/listeria/outbreaks/cantaloupes-jensen-farms/120811/index.html (Accessed on January 06, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1280 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-218.189.88.190-9543B823DE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_48_9993=[""].join("\n");
var outline_f9_48_9993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Incidence of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sporadic illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Predisposing conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other immunosuppressive treatments or conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Nosocomial acquisition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FOOD EPIDEMIOLOGY AND OUTBREAKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1280\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1280|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/26/4526\" title=\"picture 1\">",
"      L monocytogenes motility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/47/13040\" title=\"picture 2\">",
"      Listeria monocytogenes in CSF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/7/9343\" title=\"picture 3\">",
"      Beta hemolysis 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1280|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?35/2/35887\" title=\"movie 1\">",
"      L monocytogenes tumbling motility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1280|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/24/34190\" title=\"table 1\">",
"      Foodborne illnesses in the United States",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=related_link\">",
"      Clinical manifestations and diagnosis of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=related_link\">",
"      Differential diagnosis of microbial foodborne disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/29/28114?source=related_link\">",
"      Patient information: Listeria (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=related_link\">",
"      Treatment, prognosis, and prevention of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_48_9994="Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction";
var content_f9_48_9994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/48/9994/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/48/9994/contributors\">",
"     C Michael Gibson, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/48/9994/contributors\">",
"     Joseph P Carrozza, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/48/9994/contributors\">",
"     Roger J Laham, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/48/9994/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/48/9994/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/48/9994/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/48/9994/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/48/9994/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary reperfusion after acute ST elevation (STEMI) improves patient outcomes. This can be achieved by primary percutaneous coronary intervention (PCI), usually with stenting, or fibrinolytic therapy. Primary PCI is preferred if it can be performed (door-to-balloon time) within 90 to 120 minutes of presentation to the hospital because of greater efficacy in achieving coronary perfusion and better clinical outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link&amp;anchor=H3#H3\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\", section on 'Primary PCI versus fibrinolytic trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of revascularization with primary PCI can be assessed using the TIMI flow grading system (originally developed to assess reperfusion after fibrinolysis) (",
"    <a class=\"graphic graphic_table graphicRef51941 \" href=\"UTD.htm?1/49/1819\">",
"     table 1",
"    </a>",
"    ). Trials of fibrinolytic therapy have shown that the clinical benefits of reperfusion correlate with the restoration of TIMI grade 3 (normal) epicardial coronary flow (",
"    <a class=\"graphic graphic_figure graphicRef75629 \" href=\"UTD.htm?15/40/16013\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70952 \" href=\"UTD.htm?9/52/10061\">",
"     figure 2",
"    </a>",
"    ), which is only attained in 50 to 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H3#H3\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'TIMI flow grade'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Attainment of TIMI 3 flow is much more common with primary PCI, being achieved in 93 to 96 percent in the PAMI and CADILLAC trials of more than 5400 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, some patients do not recover normal epicardial flow despite the absence of vessel obstruction. This phenomenon is called no-reflow and is a predictor of worse outcome. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'No-reflow phenomenon'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Issues related to suboptimal reperfusion after primary PCI will be reviewed here. Other issues related to primary PCI and the clinical use of fibrinolytic therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suboptimal reperfusion after primary PCI may be caused by one or more of several factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent stenosis or thrombosis",
"     </li>",
"     <li>",
"      Coronary dissection",
"     </li>",
"     <li>",
"      Intramural hematoma",
"     </li>",
"     <li>",
"      Side branch occlusion",
"     </li>",
"     <li>",
"      Coronary spasm",
"     </li>",
"     <li>",
"      Distal macroembolism",
"     </li>",
"     <li>",
"      Acute stent thrombosis",
"     </li>",
"     <li>",
"      No-reflow phenomenon",
"     </li>",
"     <li>",
"      Reperfusion injury",
"     </li>",
"     <li>",
"      Capillary blistering and edema of endothelial cells",
"     </li>",
"     <li>",
"      Edema and swelling of myocytes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the 232 patients (7 percent) with a final TIMI flow grade &le;2 in the PAMI trials, persistent stenosis &gt;50 percent, thrombus, and dissection were present in 28, 26, and 40 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/6\">",
"     6",
"    </a>",
"    ]. These complications of PCI are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link&amp;anchor=H8#H8\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Coronary artery complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An analysis of data from the PAMI trial revealed the following risk factors for a final TIMI flow grade &le;2 after primary PCI (",
"    <a class=\"graphic graphic_table graphicRef51941 \" href=\"UTD.htm?1/49/1819\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &ge;70 years",
"     </li>",
"     <li>",
"      Diabetes",
"     </li>",
"     <li>",
"      Longer time to reperfusion",
"     </li>",
"     <li>",
"      Initial TIMI flow grade &le;1",
"     </li>",
"     <li>",
"      Left ventricular ejection fraction &lt;50 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who present with heart failure also appear to be more likely to have suboptimal reperfusion after primary PCI. In a report of 1548 patients, there was a significant correlation between Killip class (",
"    <a class=\"graphic graphic_table graphicRef65592 \" href=\"UTD.htm?3/59/4027\">",
"     table 2",
"    </a>",
"    ) and postprocedural TIMI flow grade &le;2 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A correlate of suboptimal reperfusion is incomplete ST segment elevation resolution. In a series of 1005 consecutive patients with an STEMI who were treated with primary PCI, 42 percent had incomplete ST segment elevation resolution (defined as &ge;1 mm ST segment elevation after PCI) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/9\">",
"     9",
"    </a>",
"    ]. Independent predictors of incomplete resolution were anterior MI, Killip class 3 to 4 (",
"    <a class=\"graphic graphic_table graphicRef65592 \" href=\"UTD.htm?3/59/4027\">",
"     table 2",
"    </a>",
"    ), and TIMI flow grade &lt;2 before PCI and &lt;3 (3 represents normal flow) after PCI. Incomplete ST segment elevation resolution was an independent predictor of mortality and also predicts adverse outcomes in patients treated with fibrinolytic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H7#H7\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'ST segment elevation resolution'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NO-REFLOW PHENOMENON",
"    </span>",
"    &nbsp;&mdash;&nbsp;The no-reflow phenomenon is defined as a profound reduction in antegrade coronary blood flow (TIMI flow grade &le;2 ) despite vessel patency and the absence of dissection, spasm, or distal macroembolus, which is defined as a distal filling defect with an abrupt \"cutoff\" in one of the peripheral coronary artery branches of the infarct-related vessel, distal to the site of PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. It is presumed to reflect microvascular dysfunction and appears to be more common in diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Direct angiographic visualization of distal embolization is limited to macrovascular events and is characterized as a distal filling defect with an abrupt 'cutoff' in one of the peripheral coronary artery branches of the infarct-related vessel, distal to the site of PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The published incidence of no-reflow has varied widely and depends in part upon the method used for detection. Using the criterion of TIMI flow grade &le;2 without macrovascular obstruction, the incidence of no-reflow during PCI has ranged 12 to 25 percent in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In contrast, the rate was much lower in the PAMI and CADILLAC trials in which only 4 to 7 percent had a TIMI flow grade &le;2; the subset of these patients considered to have no-reflow was not specified [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Higher rates have been noted with other modalities that can assess microvascular flow: 29 percent using the TIMI myocardial perfusion grade [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/17\">",
"     17",
"    </a>",
"    ] and 34 to 39 percent using myocardial contrast echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Detection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The likelihood that no-reflow will occur correlates with the severity of myocardial damage during the infarct and TIMI flow. Reported predictors of no-reflow are Killip class, the number of Q waves, the wall motion score on echocardiogram, and the presence of TIMI flow grade 0 on the initial coronary angiogram [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/8,20\">",
"     8,20",
"    </a>",
"    ]. In addition, the likelihood of severe microvascular dysfunction is increased with a longer time from symptom onset to reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link&amp;anchor=H3#H3\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Time from symptom onset on outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, preinfarction angina appears to attenuate the no-reflow phenomenon, suggesting a protective effect from ischemic preconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9673?source=see_link\">",
"     \"Definition and pathogenesis of ischemic preconditioning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=see_link\">",
"     \"Clinical implications of ischemic preconditioning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors probably contribute to no-reflow. These include distal embolization of plaque",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombus, microvascular damage, myocardial necrosis and stunning, reperfusion injury resulting from oxygen free radical production, release of active tissue factor from the dissected plaque, and vasoconstriction secondary to alpha adrenergic tone, thromboxane A2, or serotonin released from platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/10,18,22-25\">",
"     10,18,22-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of distal embolization was suggested in an intravascular ultrasound study that evaluated total plaque volume before and after primary PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/26\">",
"     26",
"    </a>",
"    ]. Plaque volume decreased after the procedure in all patients, but a significantly greater decrease in plaque volume was seen in patients with inadequate reflow. Plaque volume after PCI also correlated with the corrected TIMI frame count.",
"   </p>",
"   <p>",
"    A relationship between plaque volume and distal coronary perfusion after PCI was also observed in a study of 71 patients with STEMI who underwent Virtual Histology intravascular ultrasound (Volcano Therapeutics, Inc) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/27\">",
"     27",
"    </a>",
"    ]. Although total plaque volume was similar, the necrotic core volume was significantly higher in the 11 patients with recurrent ST segment elevation than in those without recurrent ST segment elevation. This suggests that the release of material from the necrotic core of plaques is related to, if not causal, in distal microvascular obstruction.",
"   </p>",
"   <p>",
"    Similar findings have been noted in patients with stable angina undergoing PCI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical studies, no-reflow has often been defined as a TIMI flow grade &le;2 in the absence of macrovascular obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, microvascular perfusion may also be reduced in patients with TIMI flow grade 3.",
"   </p>",
"   <p>",
"    Other angiographic measures that have been developed to assess microvascular perfusion include the TIMI frame count and the TIMI myocardial perfusion (TMP) grade (or myocardial blush grade) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/17,28,29\">",
"     17,28,29",
"    </a>",
"    ]. The definition of these variables and their predictive value after fibrinolysis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H4#H4\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'Myocardial tissue perfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to angiographic methods, a coronary Doppler flow wire can be used to assess no-reflow. Doppler flow measurements reveal a characteristic pattern of both systolic retrograde flow and rapid deceleration of diastolic flow in vessels with no-reflow [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In comparison, a residual stenosis is characterized by slow diastolic flow velocity, prolonged diastolic deceleration time, and a smaller",
"    <span class=\"nowrap\">",
"     diastolic/systolic",
"    </span>",
"    flow velocity ratio. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13672?source=see_link\">",
"     \"Clinical use of coronary artery pressure and Doppler flow measurements\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Myocardial contrast echocardiography (MCE) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/18,33\">",
"     18,33",
"    </a>",
"    ] and contrast-enhanced cardiovascular magnetic resonance (CEMR) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/19,34,35\">",
"     19,34,35",
"    </a>",
"    ] are other methods that have been used to detect no-reflow. Both have the advantage that they can also define the extent of myocardium affected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=see_link&amp;anchor=H13#H13\">",
"     \"Contrast echocardiography: Clinical applications\", section on 'Myocardial perfusion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H36992805#H36992805\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Infarct detection and sizing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible approaches to preventing the no-reflow phenomenon include the use of thrombectomy, distal embolic protection, direct stenting, systemic infusion of glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    (GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa)",
"    </span>",
"    inhibitors, and intracoronary infusion of vasodilating or",
"    <span class=\"nowrap\">",
"     antithrombotic/thrombolytic",
"    </span>",
"    agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Thrombectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One potential approach to improving reperfusion in patients with STEMI is by performing thrombectomy prior to PCI, using either a manual thrombus aspiration device (Pronto, Export, Diver) or a mechanical thrombectomy device (X-sizer, AngioJet, Rescue). Some but not all small randomized trials suggest benefit from manual thrombectomy, while the value of mechanical thrombectomy is less clear.",
"   </p>",
"   <p>",
"    With regard to manual (aspiration) thrombectomy, improvements in both nonclinical endpoints, such as markers of reperfusion, and survival have been demonstrated in some [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/36-41\">",
"     36-41",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TAPAS is the largest (and first) trial to demonstrate both angiographic and clinical benefit from thrombus aspiration. In TAPAS, 1071 patients were randomly assigned to treatment with either manual thrombus aspiration with direct stenting or conventional PCI with balloon pretreatment. The primary endpoint of a myocardial blush grade of 0 or 1 (no or minimal reperfusion) occurred significantly less often in the thrombus aspiration group (17.1 versus 26.3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/39\">",
"       39",
"      </a>",
"      ], as did the secondary endpoint of cardiac death or nonfatal myocardial infarction at one year (5.6 versus 9.9 percent; hazard ratio 0.6, 95% CI 0.4-0.8) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/41\">",
"       41",
"      </a>",
"      ]. Most of the benefit of thrombus aspiration was attributable to a significantly lower rate of cardiac death (3.6 versus 6.7).",
"     </li>",
"     <li>",
"      The benefits of manual aspiration have been confirmed in meta-analyses, in which TAPAS provided a substantial proportion of the patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No reduction in infarct size was seen in the INFUSE-AMI trial, which randomly assigned 452 patients with acute occlusion of the left anterior descending coronary artery to either manual aspiration or no manual aspiration thrombectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/42\">",
"     42",
"    </a>",
"    ]. Likewise, there was no improvement in the secondary endpoints of myocardial blush score or ST segment resolution for patients assigned to manual aspiration. &nbsp;",
"   </p>",
"   <p>",
"    With regard to mechanical thrombectomy, the results of trials do not show benefit for the most part.",
"    <br/>",
"    <br/>",
"    No benefit was seen in the AIMI trial, which randomly assigned 480 patients to either the AngioJet catheter or primary PCI without thrombectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/45\">",
"     45",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    The JETSTENT trial randomly assigned 501 patients to either mechanical thrombectomy with Angiojet or before direct stenting or direct stenting. There was no difference was found in the co-primary outcomes of early ST-segment elevation resolution at 30 minutes and scintigraphic infarct size the secondary endpoint of the rate of one year event free survival (death, myocardial infarction, target vessel revascularization [TVR], or stroke) was significantly better with thrombectomy (85 versus 75 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/46\">",
"     46",
"    </a>",
"    ]. As only bare-metal stents were used, the use of drug-eluting stents might have led less of a difference in the rate of TVR, and thus potentially nullified the significant difference between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/47\">",
"     47",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    A meta-analysis of mechanical thrombectomy published prior to JETSTENT did not find a significant benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term prognosis may vary with the age of the aspirated thrombus. The importance of thrombus age was evaluated in a retrospective study of 989 patients with successful aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/48\">",
"     48",
"    </a>",
"    ]. Cumulative all-cause mortality at four years was significantly higher in patients with thrombus age of more than one day (16.0 versus 7.4 percent with thrombus age of more than one day). While this study suggests a cause and effect relationship between thrombus age and outcome, it does not alter patient care.",
"   </p>",
"   <p>",
"    We believe that most patients with STEMI undergoing primary PCI with stenting of the native circulation should undergo manual (aspiration) thrombectomy, as long as it does not cause a significant delay in the time to balloon inflation. Thrombectomy is not appropriate for all patients, such as those with who have patent arteries with culprit lesions not associated with significant thrombus. Also, in patients with severe coronary tortuosity or calcification, the delivery of these large caliber devices may not be possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Distal embolic protection devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal embolic protection devices are increasingly used with PCI in saphenous vein grafts due to the substantial potential for embolization of both thrombus and atheromatous material. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=see_link&amp;anchor=H24#H24\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\", section on 'Embolic protection devices'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of a distal embolic protective device in acute STEMI was addressed in the multicenter EMERALD trial of 501 patients who presented within six hours of symptom onset and underwent primary PCI or rescue intervention after failed fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/49\">",
"     49",
"    </a>",
"    ]. The patients were randomly assigned to primary PCI alone or with a distal occlusion balloon and aspiration distal microcirculation system (GuardWire,",
"    <span class=\"nowrap\">",
"     PercuSurge/Medtronic).",
"    </span>",
"    Among the patients assigned to distal protection, aspiration was performed in 97 percent and visible debris was retrieved from 73 percent.",
"   </p>",
"   <p>",
"    Despite the removal of debris, there was",
"    <strong>",
"     no difference",
"    </strong>",
"    between the two groups in terms of the coprimary end points of ST segment resolution at 30 minutes (63 versus 62 percent) and left ventricular infarct size (12.0 versus 9.5 percent). In addition, the secondary end point of major adverse cardiac events at six months was equivalent in the two groups (10 versus 11 percent). The lack of benefit persisted when only the 83 percent of patients undergoing primary PCI (not rescue) were evaluated and was seen in all subsets.",
"   </p>",
"   <p>",
"    A lack of benefit was also noted in two later randomized trials, PROMISE and DEDICATION, which were of similar design but used a different distal embolic protection device (FilterWire) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. There were no differences between the two groups in maximal adenosine-induced flow velocity, infarct size, or 30-day mortality in the PROMISE trial or complete (&ge;70 percent) ST segment resolution detected by continuous ST-segment monitoring in the DEDICATION trial.",
"   </p>",
"   <p>",
"    Potential mechanisms for the lack of benefit in these trials include smaller embolic burden than seen in saphenous vein grafts, embolization caused by crossing the lesion with the embolic protection device, delayed reperfusion due to the occlusive nature of the device, other nonembolic causes of microcirculatory dysfunction, difficulty protecting side branches, difficulty in detecting benefit against the background of established myocardial infarction, and embolization of vasoconstrictor materials not captured by the device [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, although distal embolization was presumably reduced with the device, aspiration of debris with embolization into proximal branches may have minimized efficacy. It is notable in this regard that the device is effective in saphenous vein grafts where there are no branches. It is possible that distal protection using filter devices may overcome some of these limitations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=see_link&amp;anchor=H24#H24\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\", section on 'Embolic protection devices'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The type of lesion also may be a determinant of efficacy. This was suggested in a report that retrospectively evaluated 110 consecutive patients with an acute MI who underwent primary PCI without distal protection and 81 consecutive subsequent patients who were treated with distal protection; all patients also underwent angioscopy and ruptured plaque was seen in 106 of the 191 patients (55 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/55\">",
"     55",
"    </a>",
"    ]. No-reflow was most common in patients with a ruptured plaque treated without distal protection and clinical benefit from distal protection (as estimated from ST segment resolution, myocardial blush grade, and left ventricular ejection fraction) was only seen in patients with ruptured plaque (incidence of no-reflow 4.5 versus 19.4 without distal protection). These findings have limited clinical significant, since angioscopy is not routinely performed during primary PCI.",
"   </p>",
"   <p>",
"    Based upon the results of the randomized trials, we do not recommend a distal embolic protection device as routine adjunctive therapy to primary PCI with stenting in patients with acute STEMI in the native circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Direct stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct stenting, without predilation, may lower the incidence of no-reflow. The role of direct stenting in STEMI patients with suboptimal reperfusion after primary PCI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=see_link&amp;anchor=H24756041#H24756041\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management\", section on 'Direct stenting'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5881390\">",
"    <span class=\"h3\">",
"     Systemic GP IIb/IIIa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients undergoing primary PCI for acute STEMI, glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors given peripherally improve outcomes in patients who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and in selected patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    . The supportive data are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H25#H25\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Use in primary PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear whether GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors when infused peripherally reduce the incidence of no-reflow, since data addressing this issue is limited and has inconsistent results. In a randomized trial of 200 patients undergoing primary PCI with stenting, those assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    therapy with low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , compared with those assigned to standard-dose heparin alone, had significantly greater improvements in both peak coronary flow velocity by Doppler flow wire measurement and in wall motion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/56\">",
"     56",
"    </a>",
"    ]. In contrast, in a post hoc analysis from the CADILLAC trial of patients undergoing primary PCI with or without stenting and with or without abciximab, patients assigned and not assigned to abciximab therapy had a similar incidence of a normal postprocedure myocardial blush grade (17.3 versus 17.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors should be given according to the recommendations for use in primary PCI, not to prevent no-reflow. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=see_link&amp;anchor=H24756069#H24756069\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management\", section on 'Antithrombotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Intracoronary infusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intracoronary infusion of adenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , streptokinase, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    has been evaluated in small studies for its ability to improve myocardial reperfusion, prevent reperfusion injury, and salvage ischemic myocardium at the time of primary PCI. None of these agents is associated with a convincing improvement in outcomes (either myocardial flow or clinical), and",
"    <strong>",
"     we do not recommend their use for this purpose",
"    </strong>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5880821\">",
"    <span class=\"h4\">",
"     Vasodilator therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small randomized trials have evaluated the efficacy of two vasodilators, intracoronary adenosine and intracoronary",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    in patients undergoing PCI. Two trials of patients who were randomly assigned to either intracoronary adenosine or placebo came to differing conclusions but used different methods of revascularization:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of 54 patients who underwent primary percutaneous transluminal coronary (balloon) angioplasty, intracoronary adenosine significantly decreased the rate of no-reflow (1 versus 7 patients) and lowered the proportion of dyssynergic segments (36 versus 64 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a later trial of 112 patients undergoing primary PCI with stenting, which is preferred to balloon angioplasty, adenosine use was not associated with an improvement in the degree of microvascular obstruction or in a decrease in infarct size at four months [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another small trial of 40 patients evaluated the efficacy of intracoronary",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or placebo following balloon angioplasty; verapamil significantly improved the wall motion score as evaluated by myocardial contrast echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=see_link\">",
"     \"Contrast echocardiography: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5880829\">",
"    <span class=\"h4\">",
"     Antithrombotic/thrombolytic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracoronary GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors and streptokinase have been evaluated in randomized trials for their ability to improve microvascular perfusion in patients undergoing primary PCI. (See",
"    <a class=\"local\" href=\"#H5881390\">",
"     'Systemic GP IIb/IIIa inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following are representative trials of intracoronary",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    from the stent era:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of 534 patients randomly assigned to either an intracoronary or an intravenous bolus of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      after primary PCI with thrombus aspiration, there was no significant difference in the incidence of complete ST-segment resolution, which was the primary end point (64 versus 62 percent respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/61\">",
"       61",
"      </a>",
"      ]. The secondary end points of myocardial blush grade and enzymatic infarct size were better in the intracoronary infusion group.",
"     </li>",
"     <li>",
"      In a trial of 154 patients randomly assigned to either an intravenous or an intracoronary bolus of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      , both of which were followed by a 12 hour infusion, the primary end point of median infarct size at two days, as determined by magnetic resonance imaging (MRI), was significantly reduced in the group treated with intracoronary abciximab (15.1 versus 23.4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/62\">",
"       62",
"      </a>",
"      ]. The extent of microvascular obstruction seen on MRI and early ST segment resolution were also significantly improved. There was also a trend toward fewer major adverse cardiovascular events. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H36992805#H36992805\">",
"       \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Infarct detection and sizing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A third trial of 50 patients evaluated the efficacy of intracoronary",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      delivered either through the guiding catheter or a dedicated perfusion catheter at the site of occlusion [",
"      <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/63\">",
"       63",
"      </a>",
"      ]. Local intracoronary delivery significantly reduced the thrombus score after PCI as determined by optical coherence tomography (4 versus 34 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The possible of efficacy of low dose intracoronary streptokinase (250,000 U) was compared with no additional therapy in a trial of 41 patients who had undergone successful PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/64\">",
"     64",
"    </a>",
"    ]. The TIMI frame count and multiple measures of microvascular perfusion (coronary flow reserve, index of microvascular resistance, and collateral flow index) were significantly better in the streptokinase group at 48 hours. However, there was no significant difference between the two groups in left ventricular size or function at six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Chronic statin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible protective effect of chronic statin therapy on no-reflow was suggested in an observational study from Japan of 293 consecutive patients who underwent primary PCI followed by intracoronary myocardial contrast echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/65\">",
"     65",
"    </a>",
"    ]. No-reflow was present in 93 patients. The statin-treated patients had a much lower rate of no-reflow (9 versus 35 percent), better wall motion, and a higher left ventricular ejection fraction.",
"   </p>",
"   <p>",
"    These findings are consistent with other studies suggesting that statin therapy reduces myocardial injury after PCI. Plaque stabilization and other pleiotropic effects of statin therapy could contribute to such an effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=see_link&amp;anchor=H22#H22\">",
"     \"General principles of the use of intracoronary stents\", section on 'Statin therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management strategy for no-reflow after the establishment of proximal coronary artery patency with PCI is unknown. For those patients with hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoperfusion, intravenous vasopressors and inotropic agents and intraaortic balloon pump support may be of benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link&amp;anchor=H42#H42\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Summary and Recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intracoronary therapy has also been evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/16,66-69\">",
"     16,66-69",
"    </a>",
"    ]. In small series, intracoronary",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    was used with apparent success in treating no reflow [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/16,70\">",
"     16,70",
"    </a>",
"    ]. Intracoronary",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    at doses of 50 to 200 &micro;g has also shown promising results when given alone or with intracoronary adenosine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/58,67-69\">",
"     58,67-69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with fibrinolysis, the 4 to 7 percent of patients who do not achieve TIMI 3 (normal) flow after primary PCI have worse outcomes (",
"    <a class=\"graphic graphic_table graphicRef51941 \" href=\"UTD.htm?1/49/1819\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/6,71\">",
"     6,71",
"    </a>",
"    ]. The magnitude of this effect was illustrated in a report from the PAMI trials [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/6\">",
"     6",
"    </a>",
"    ]. The 232 patients who had a final TIMI flow grade &le;2 after PCI (7 percent of all patients) had significantly higher rates of in-hospital mortality (15 versus 2 percent) and in-hospital major adverse cardiac events (20 versus 6 percent) than those with TIMI 3 flow [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/6\">",
"     6",
"    </a>",
"    ]. At one year, significant differences persisted for mortality (23 versus 5 percent), major adverse cardiac events (37 versus 20 percent), and reinfarction (9 versus 4 percent). A similar significant increase in early (30-day) mortality with TIMI flow &le;2 was noted in the GUSTO-IIb trial (11.7 versus 1.5 percent with TIMI 3 flow) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A higher rate of adverse outcomes has been noted in other studies in patients with no-reflow, regardless of the method of detection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/6,8,15,17,18,29,30,34,35,72,73\">",
"     6,8,15,17,18,29,30,34,35,72,73",
"    </a>",
"    ]. These include increases in in-hospital heart failure and mortality (18 versus 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/72\">",
"     72",
"    </a>",
"    ], left ventricular remodeling at six months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/34,35,73\">",
"     34,35,73",
"    </a>",
"    ], and mortality at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/8\">",
"     8",
"    </a>",
"    ]. In a study of 120 patients, the frequency of cardiac mortality (37 versus 10 percent) and the combined cardiac end point of recurrent MI, heart failure, malignant arrhythmia, or cardiac mortality continued to increase over a mean follow-up of almost six years&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both the TMP grade and the presence of persistent ST segment elevation are powerful predictors of prognosis. This was illustrated in a review of 253 consecutive high-risk patients who underwent PCI on a native vessel [",
"    <a class=\"abstract\" href=\"UTD.htm?9/48/9994/abstract/29\">",
"     29",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A TMP grade on the last angiogram after revascularization of",
"      <span class=\"nowrap\">",
"       0/1,",
"      </span>",
"      indicating little or no tissue perfusion, was associated with a marked increase in mortality compared to TMP grades 2 and 3 at both 30 days (26 versus 10 and 4 percent) and one year (35 versus 13 and 9 percent).",
"     </li>",
"     <li>",
"      The adjusted odds ratio for cumulative mortality was 2.17 for a TMP grade of",
"      <span class=\"nowrap\">",
"       0/1",
"      </span>",
"      and 3.61 for persistent ST elevation in more than two leads one hour after PCI.",
"     </li>",
"     <li>",
"      Among patients with a TMP grade of",
"      <span class=\"nowrap\">",
"       0/1",
"      </span>",
"      or 2, cumulative mortality was much higher in patients who also had persistent ST elevation in more than two leads (47 versus 13 percent). The added value of persistent ST elevation is that it, but not the TMP grade, reflects the size of the area with endangered perfusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the TIMI frame count, another measure of myocardial tissue perfusion, was not an independent predictor of outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary percutaneous coronary intervention establishes normal or near normal antegrade blood flow, as assessed by the TIMI flow grade 3, in over 90 percent of cases. The 4 to 7 percent of patients who do not achieve TIMI 3 flow have worse outcomes. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The most common causes of TIMI flow grade &le;2 are persistent stenosis, thrombus, dissection, spasm or distal macroembolism. Age &ge;70 years, diabetes, longer time to reperfusion, initial TIMI flow grade &le;1, left ventricular ejection fraction &lt;50 percent, heart failure on presentation, and incomplete ST segment elevation resolution are predictors of suboptimal reperfusion. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    No-reflow, often defined as a TIMI flow grade &le;2 in the absence of macrovascular obstruction, is a less common cause of suboptimal reperfusion. Possible mechanisms include distal embolization of plaque",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombus, microvascular damage, myocardial necrosis and stunning, reperfusion injury resulting from oxygen free radical production, release of active tissue factor from the dissected plaque, and alpha-adrenergic-mediated vasoconstriction. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Mechanisms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Direct stenting lessens the likelihood of the development of no-reflow, while the benefit of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors or the intracoronary infusion of adenosine remains speculative. Thrombus aspiration has led to improved clinical outcomes at one year in one large trial and should be considered for use in many patients with STEMI. Distal embolic protection does not appear to protect against no-reflow in the native coronary circulation but is effective in saphenous vein grafts. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Prevention'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with TIMI flow grade &le;2 due to persistent stenosis, thrombus, dissection, spasm or distal macroembolism, treatment is directed at correcting the underlying problem. The optimal management strategy for no-reflow after the establishment of proximal coronary artery patency with PCI is unknown. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoperfusion should be treated with the same approach used in other patients with cardiogenic shock following acute myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link&amp;anchor=H42#H42\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Summary and Recommendations'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/1\">",
"      An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/2\">",
"      Simes RJ, Topol EJ, Holmes DR Jr, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995; 91:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/3\">",
"      Ross AM, Coyne KS, Moreyra E, et al. Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 1998; 97:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/4\">",
"      Vogt A, von Essen R, Tebbe U, et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993; 21:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/5\">",
"      Karagounis L, Sorensen SG, Menlove RL, et al. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. J Am Coll Cardiol 1992; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/6\">",
"      Mehta RH, Harjai KJ, Cox D, et al. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003; 42:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/7\">",
"      Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/8\">",
"      De Luca G, van 't Hof AW, de Boer MJ, et al. Impaired myocardial perfusion is a major explanation of the poor outcome observed in patients undergoing primary angioplasty for ST-segment-elevation myocardial infarction and signs of heart failure. Circulation 2004; 109:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/9\">",
"      Brodie BR, Stuckey TD, Hansen C, et al. Relation between electrocardiographic ST-segment resolution and early and late outcomes after primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005; 95:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/10\">",
"      Rezkalla SH, Kloner RA. Coronary No-reflow Phenomenon. Curr Treat Options Cardiovasc Med 2005; 7:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/11\">",
"      Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 2001; 22:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/12\">",
"      Henriques JP, Zijlstra F, Ottervanger JP, et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 2002; 23:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/13\">",
"      Prasad A, Stone GW, Stuckey TD, et al. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol 2005; 45:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/14\">",
"      Timmer JR, van der Horst IC, de Luca G, et al. Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. Am J Cardiol 2005; 95:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/15\">",
"      Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/16\">",
"      Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/17\">",
"      Dibra A, Mehilli J, Dirschinger J, et al. Thrombolysis in myocardial infarction myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis. J Am Coll Cardiol 2003; 41:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/18\">",
"      Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996; 93:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/19\">",
"      Tarantini G, Cacciavillani L, Corbetti F, et al. Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. J Am Coll Cardiol 2005; 46:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/20\">",
"      Iwakura K, Ito H, Kawano S, et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol 2001; 38:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/21\">",
"      Kondo M, Nakano A, Saito D, Shimono Y. Assessment of \"microvascular no-reflow phenomenon\" using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction. J Am Coll Cardiol 1998; 32:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/22\">",
"      Hearse DJ, Bolli R. Reperfusion induced injury: manifestations, mechanisms, and clinical relevance. Cardiovasc Res 1992; 26:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/23\">",
"      Kloner RA, Rude RE, Carlson N, et al. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation 1980; 62:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/24\">",
"      Bonderman D, Teml A, Jakowitsch J, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002; 99:2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/25\">",
"      Gregorini L, Marco J, Koz&agrave;kov&agrave; M, et al. Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation 1999; 99:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/26\">",
"      Yu Y, Ohmori K, Chen Y, et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 2004; 44:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/27\">",
"      Kawaguchi R, Oshima S, Jingu M, et al. Usefulness of virtual histology intravascular ultrasound to predict distal embolization for ST-segment elevation myocardial infarction. J Am Coll Cardiol 2007; 50:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/28\">",
"      Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002; 105:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/29\">",
"      Haager PK, Christott P, Heussen N, et al. Prediction of clinical outcome after mechanical revascularization in acute myocardial infarction by markers of myocardial reperfusion. J Am Coll Cardiol 2003; 41:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/30\">",
"      Kawamoto T, Yoshida K, Akasaka T, et al. Can coronary blood flow velocity pattern after primary percutaneous transluminal coronary angioplasty [correction of angiography] predict recovery of regional left ventricular function in patients with acute myocardial infarction? Circulation 1999; 100:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/31\">",
"      Iwakura K, Ito H, Takiuchi S, et al. Alternation in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction. Circulation 1996; 94:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/32\">",
"      Furber AP, Prunier F, Nguyen HC, et al. Coronary blood flow assessment after successful angioplasty for acute myocardial infarction predicts the risk of long-term cardiac events. Circulation 2004; 110:3527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/33\">",
"      Lepper W, Hoffmann R, Kamp O, et al. Assessment of myocardial reperfusion by intravenous myocardial contrast echocardiography and coronary flow reserve after primary percutaneous transluminal coronary angioplasty [correction of angiography] in patients with acute myocardial infarction. Circulation 2000; 101:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/34\">",
"      Taylor AJ, Al-Saadi N, Abdel-Aty H, et al. Detection of acutely impaired microvascular reperfusion after infarct angioplasty with magnetic resonance imaging. Circulation 2004; 109:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/35\">",
"      Baks T, van Geuns RJ, Biagini E, et al. Effects of primary angioplasty for acute myocardial infarction on early and late infarct size and left ventricular wall characteristics. J Am Coll Cardiol 2006; 47:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/36\">",
"      Lef&egrave;vre T, Garcia E, Reimers B, et al. X-sizer for thrombectomy in acute myocardial infarction improves ST-segment resolution: results of the X-sizer in AMI for negligible embolization and optimal ST resolution (X AMINE ST) trial. J Am Coll Cardiol 2005; 46:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/37\">",
"      Kaltoft A, B&oslash;ttcher M, Nielsen SS, et al. Routine thrombectomy in percutaneous coronary intervention for acute ST-segment-elevation myocardial infarction: a randomized, controlled trial. Circulation 2006; 114:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/38\">",
"      Silva-Orrego P, Colombo P, Bigi R, et al. Thrombus aspiration before primary angioplasty improves myocardial reperfusion in acute myocardial infarction: the DEAR-MI (Dethrombosis to Enhance Acute Reperfusion in Myocardial Infarction) study. J Am Coll Cardiol 2006; 48:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/39\">",
"      Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008; 358:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/40\">",
"      Sardella G, Mancone M, Bucciarelli-Ducci C, et al. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. J Am Coll Cardiol 2009; 53:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/41\">",
"      Vlaar PJ, Svilaas T, van der Horst IC, et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet 2008; 371:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/42\">",
"      Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 2012; 307:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/43\">",
"      De Luca G, Dudek D, Sardella G, et al. Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. Eur Heart J 2008; 29:3002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/44\">",
"      Burzotta F, De Vita M, Gu YL, et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. Eur Heart J 2009; 30:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/45\">",
"      Ali A, Cox D, Dib N, et al. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. J Am Coll Cardiol 2006; 48:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/46\">",
"      Migliorini A, Stabile A, Rodriguez AE, et al. Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction. The JETSTENT trial. J Am Coll Cardiol 2010; 56:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/47\">",
"      Kastrati A, Byrne RA, Sch&ouml;mig A. Is it time to jettison complex mechanical thrombectomy in favor of simple manual aspiration devices? J Am Coll Cardiol 2010; 56:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/48\">",
"      Kramer MC, van der Wal AC, Koch KT, et al. Presence of older thrombus is an independent predictor of long-term mortality in patients with ST-elevation myocardial infarction treated with thrombus aspiration during primary percutaneous coronary intervention. Circulation 2008; 118:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/49\">",
"      Stone GW, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA 2005; 293:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/50\">",
"      Gick M, Jander N, Bestehorn HP, et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation 2005; 112:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/51\">",
"      Kelbaek H, Terkelsen CJ, Helqvist S, et al. Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trial. J Am Coll Cardiol 2008; 51:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/52\">",
"      Sch&ouml;mig A, Kastrati A. Distal embolic protection in patients with acute myocardial infarction: attractive concept but no evidence of benefit. JAMA 2005; 293:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/53\">",
"      Gorog DA, Foale RA, Malik I. Distal myocardial protection during percutaneous coronary intervention: when and where? J Am Coll Cardiol 2005; 46:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/54\">",
"      Limbruno U, De Caterina R. EMERALD, AIMI, and PROMISE: is there still a potential for embolic protection in primary PCI? Eur Heart J 2006; 27:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/55\">",
"      Mizote I, Ueda Y, Ohtani T, et al. Distal protection improved reperfusion and reduced left ventricular dysfunction in patients with acute myocardial infarction who had angioscopically defined ruptured plaque. Circulation 2005; 112:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/56\">",
"      Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98:2695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/57\">",
"      Costantini CO, Stone GW, Mehran R, et al. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. J Am Coll Cardiol 2004; 44:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/58\">",
"      Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000; 101:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/59\">",
"      Desmet W, Bogaert J, Dubois C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J 2011; 32:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/60\">",
"      Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/61\">",
"      Gu YL, Kampinga MA, Wieringa WG, et al. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial. Circulation 2010; 122:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/62\">",
"      Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008; 118:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/63\">",
"      Prati F, Capodanno D, Pawlowski T, et al. Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes. JACC Cardiovasc Interv 2010; 3:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/64\">",
"      Sezer M, Oflaz H, G&ouml;ren T, et al. Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J Med 2007; 356:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/65\">",
"      Iwakura K, Ito H, Kawano S, et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 2006; 27:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/66\">",
"      Lee CH, Wong HB, Tan HC, et al. Impact of reversibility of no reflow phenomenon on 30-day mortality following percutaneous revascularization for acute myocardial infarction-insights from a 1,328 patient registry. J Interv Cardiol 2005; 18:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/67\">",
"      Hillegass WB, Dean NA, Liao L, et al. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 2001; 37:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/68\">",
"      Wang HJ, Lo PH, Lin JJ, et al. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv 2004; 63:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/69\">",
"      Barcin C, Denktas AE, Lennon RJ, et al. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv 2004; 61:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/70\">",
"      Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002; 57:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/71\">",
"      Berger PB, Ellis SG, Holmes DR Jr, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation 1999; 100:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/72\">",
"      Yamamuro A, Akasaka T, Tamita K, et al. Coronary flow velocity pattern immediately after percutaneous coronary intervention as a predictor of complications and in-hospital survival after acute myocardial infarction. Circulation 2002; 106:3051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/48/9994/abstract/73\">",
"      Bolognese L, Carrabba N, Parodi G, et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 2004; 109:1121.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 81 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_48_9994=[""].join("\n");
var outline_f9_48_9994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NO-REFLOW PHENOMENON",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Thrombectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Distal embolic protection devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Direct stenting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5881390\">",
"      - Systemic GP IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Intracoronary infusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5880821\">",
"      Vasodilator therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5880829\">",
"      Antithrombotic/thrombolytic therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Chronic statin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/81\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/81|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/40/16013\" title=\"figure 1\">",
"      Mortality after thrombolysis based on TIMI flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/52/10061\" title=\"figure 2\">",
"      TIMI flow and survival after thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/81|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/49/1819\" title=\"table 1\">",
"      TIMI flow grades",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/59/4027\" title=\"table 2\">",
"      Killip classification of acute MI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=related_link\">",
"      Clinical implications of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13672?source=related_link\">",
"      Clinical use of coronary artery pressure and Doppler flow measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=related_link\">",
"      Contrast echocardiography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9673?source=related_link\">",
"      Definition and pathogenesis of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=related_link\">",
"      General principles of the use of intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=related_link\">",
"      Prevention, presentation, and management of saphenous vein graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=related_link\">",
"      Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_48_9995="Benefits strength training";
var content_f9_48_9995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential benefits of strength training for children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Adds variety to an overall exercise and conditioning program.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May increase the likelihood that a child will participate in other activities, thereby developing positive physical activity behaviors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased strength of muscles, tendons, and ligaments.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased stability of a joint.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased bone density and bone mass.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Improved muscle balance between agonist and antagonist muscle groups.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Improved body composition.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased motor unit recruitment and synchronization.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Improved motor coordination and performance.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_48_9995=[""].join("\n");
var outline_f9_48_9995=null;
var title_f9_48_9996="MDS classification WHO";
var content_f9_48_9996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    World Health Organization (WHO) classification system for myelodysplastic syndrome (MDS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Disease",
"      </td>",
"      <td class=\"subtitle1\">",
"       Marrow blasts",
"      </td>",
"      <td class=\"subtitle1\">",
"       Clinical presentation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cytogenetic abnormalities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Refractory anemia (RA)",
"      </td>",
"      <td>",
"       &lt;5 percent",
"      </td>",
"      <td>",
"       Anemia",
"      </td>",
"      <td>",
"       25 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       RA with ring sideroblasts (RARS)",
"      </td>",
"      <td>",
"       &lt;5 percent",
"      </td>",
"      <td>",
"       Anemia, &ge;15 percent ringed sideroblasts in erythroid precursors",
"      </td>",
"      <td>",
"       5 to 20 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       MDS with isolated del(5q) (5q- syndrome)",
"      </td>",
"      <td>",
"       &lt;5 percent",
"      </td>",
"      <td>",
"       Anemia, normal platelets",
"      </td>",
"      <td>",
"       100 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Refractory cytopenia with multilineage dysplasia (RCMD)",
"      </td>",
"      <td>",
"       &lt;5 percent",
"      </td>",
"      <td>",
"       <p>",
"        Bicytopenia or pancytopenia",
"       </p>",
"       <p>",
"        &plusmn;15 ring sideroblasts",
"       </p>",
"      </td>",
"      <td>",
"       50 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Refractory anemia with excess blasts-1",
"      </td>",
"      <td>",
"       5 to 9 percent",
"      </td>",
"      <td>",
"       Cytopenias +/- peripheral blood blasts (&lt;5 percent)",
"      </td>",
"      <td>",
"       30 to 50 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Refractory anemia with excess blasts-2",
"      </td>",
"      <td>",
"       10 to 19 percent",
"      </td>",
"      <td>",
"       Cytopenias, peripheral blood blasts present",
"      </td>",
"      <td>",
"       50 to 70 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Myelodysplastic syndrome, unclassified",
"      </td>",
"      <td>",
"       &lt;5 percent",
"      </td>",
"      <td>",
"       Neutropenia or thrombocytopenia",
"      </td>",
"      <td>",
"       50 percent",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MDS: myelodysplastic syndrome.",
"    </div>",
"    <div class=\"reference\">",
"     Source: Vardiman, JW, Brunning, RD, Arber, DA, et al. Introduction and overview of the classification of myeloid neoplasms. In: WHO classification of tumors of hematopoietic and lymphoid tissues, Swerdlow, SH, Campo, E, Harris, NL, et al. (Eds), WHO Press, 2008. p.18.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_48_9996=[""].join("\n");
var outline_f9_48_9996=null;
var title_f9_48_9997="Survival chronic AR LV size";
var content_f9_48_9997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival in severe chronic aortic regurgitation varies with left ventricular volume",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 246px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 246 patients with severe aortic regurgitation managed conservatively, the 10-year survival of those with a baseline left ventricular end systolic dimension (LVESD) &ge;25 mm/m",
"    <sup>",
"     2",
"    </sup>",
"    was significantly lower than that of patients with an LVESD &lt;25 mm/m",
"    <sup>",
"     2",
"    </sup>",
"    (34 versus 81 percent). Survival in the patients without left ventricular dilatation was not different from expected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Dujardin KS, Enriquez-Sarano M, Schaff HV, et al. Circulation 1999; 99:1851.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_48_9997=[""].join("\n");
var outline_f9_48_9997=null;
var title_f9_48_9998="Heteroduplex analysis";
var content_f9_48_9998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heteroduplex analysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 545px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This representation of heteroduplex analysis shows how this technique can be used to distinguish between an individual with normal DNA and heterozygous for a gene mutation. An individual's DNA is amplified by polymerase chain reaction&nbsp;(PCR), and the PCR products from both alleles are mixed and denatured (top section). The PCR products are then reannealed, allowing all combinations of DNA pairing. Homoduplexes are generated by the pairing of normal with normal and mutant with mutant DNA; heteroduplexes are generated from the pairing of of normal with mutant DNA. (middle section). The mutation is denoted by an \"X\".",
"    <br>",
"     Lane 2: DNA from an individual homozygous for the normal gene forms only homoduplexes, which run faster through the gel.",
"     <br>",
"      Lane 3: DNA from an individual heterozygous for the gene mutation forms heteroduplexes, which contain bubbles. This makes the DNA run more slowly through the gel.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_48_9998=[""].join("\n");
var outline_f9_48_9998=null;
var title_f9_48_9999="Meningococcal vaccination indications in the US";
var content_f9_48_9999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Meningococcal vaccination indications in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"35%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"15%\">",
"     </colgroup>",
"     <colgroup width=\"35%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Groups for which vaccination is recommended",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended formulation*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Primary series",
"       </td>",
"       <td class=\"subtitle1\">",
"        Revaccination",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Ages 2 months to 18 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infants with anatomic or functional asplenia (including sickle cell disease)",
"       </td>",
"       <td>",
"        HibMenCY (MenHibrix)",
"       </td>",
"       <td>",
"        Four doses, given at ages 2, 4, 6, and 12 to 15 months",
"       </td>",
"       <td>",
"        The United States Advisory Committee on Immunization Practices has not made recommendations about the revaccination schedule for individuals who received HibMenCY, although immunity wanes over time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Infants and toddlers with persistent complement component deficiency (eg, C5-C9, properdin, factor D, factor H)",
"       </td>",
"       <td>",
"        HibMenCY (MenHibrix)",
"       </td>",
"       <td>",
"        Four doses, given at ages 2, 4, 6, and 12 to 15 months",
"       </td>",
"       <td rowspan=\"3\">",
"        The United States Advisory Committee on Immunization Practices has not made recommendations about the revaccination schedule for individuals who received HibMenCY, although immunity wanes over time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Menactra",
"       </td>",
"       <td>",
"        At 9 and 12 months",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Infants and toddlers who are present during an outbreak caused by a vaccine serogroup",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        HibMenCY (MenHibrix)",
"       </td>",
"       <td>",
"        Administer an age-appropriate series, as recommended by public health authorities",
"       </td>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Menactra",
"       </td>",
"       <td>",
"        For infants &ge;9 months of age: two doses, given at least 8 weeks apart",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Ages 19 to 23 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Children with persistent complement component deficiency (eg, C5-C9, properdin, factor D, factor H) who have not received a complete series of HibMenCY (MenHibrix) or Menactra",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        Menactra",
"       </td>",
"       <td>",
"        Two doses, given at least 8 weeks apart",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Children who remain at increased risk should receive a booster dose three years after the primary series",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Children traveling to an area where meningococcal disease is epidemic or endemic who have not previously received Menactra",
"       </td>",
"       <td>",
"        Menactra",
"       </td>",
"       <td>",
"        Two doses, given at least 8 weeks apart",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Children who remain at increased risk should receive a booster dose three years after the primary series",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Children who are present during an outbreak caused by a vaccine serogroup who have not previously received a vaccine against the serogroup causing the outbreak",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Menactra",
"       </td>",
"       <td>",
"        Two doses, given at least 8 weeks apart",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Ages 2 to 10 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Children with persistent complement component deficiency (eg, C5-C9, properdin, factor D, factor H) or functional or anatomic asplenia who have not previously received a complete series of HibMenCY or Menactra",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        Menactra or Menveo",
"       </td>",
"       <td>",
"        Two doses, given 8 weeks apart",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        Every five years; if a 1-dose primary series was administered, revaccinate at the earliest opportunity, then every five years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Children with prolonged increased risk for exposure who have not previously received a complete series of Menactra",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        Menactra or Menveo",
"       </td>",
"       <td rowspan=\"2\">",
"        One dose",
"       </td>",
"       <td>",
"        Ages two through six years: after three years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age &ge;7 years: after five years",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Ages 11 to 18 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Healthy children and adolescents",
"       </td>",
"       <td rowspan=\"2\">",
"        Menactra or Menveo",
"       </td>",
"       <td rowspan=\"2\">",
"        One dose, preferably at 11 or 12 years",
"       </td>",
"       <td>",
"        At age 16 if primary dose at age 11 or 12 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At age 16 through 18 years if primary dose at age 13 through 15 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Children and adolescents with persistent complement component deficiency (eg, C5-C9, properdin, factor D, factor H) or functional or anatomic asplenia",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        Menactra or Menveo",
"       </td>",
"       <td>",
"        Two doses, given 8 weeks apart",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        Every five years; if a 1-dose primary series was administered, revaccinate at the earliest opportunity, then every five years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        HIV-infected children and adolescents",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        Menactra or Menveo",
"       </td>",
"       <td rowspan=\"3\">",
"        Two doses, given 8 weeks apart, preferably at 11 or 12 years",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        At age 16 if primary series at age 11 or 12 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At age 16 through 18 years if primary dose at age 13 through 15 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No booster needed if the primary was administered at age 16 years or later",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Ages 19 to 55 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adults with persistent complement component deficiency (eg, C5-C9, properdin, factor D, factor H) or functional or anatomic asplenia",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        Menactra or Menveo",
"       </td>",
"       <td>",
"        Two doses, given 8 weeks apart",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        Every five years; if a 1-dose primary series was administered, revaccinate at the earliest opportunity, then every five years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adults with prolonged increased risk for exposure",
"        <sup>",
"         ������,**",
"        </sup>",
"       </td>",
"       <td>",
"        Menactra or Menveo",
"       </td>",
"       <td>",
"        One dose",
"       </td>",
"       <td>",
"        Every five years",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Ages 56 years and older",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adults with persistent complement component deficiency (eg, C5-C9, properdin, factor D, factor H) or functional or anatomic asplenia or with prolonged increased risk for exposure",
"        <sup>",
"         ������,**",
"        </sup>",
"       </td>",
"       <td>",
"        Menomune",
"       </td>",
"       <td>",
"        One dose",
"       </td>",
"       <td>",
"        Every five years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The quadrivalent meningococcal conjugate vaccines are Menactra and Menveo. The quadrivalent meningococcal polysaccharide vaccine is Menomune (MPSV4). MenHibrix (HibMenCY) is a combination conjugate vaccine against meningococcus serogroups C and Y and Haemophilus influenzae type B.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Individuals between ages 2 and 55 who previously received the meningococcal polysaccharide vaccine should be revaccinated with a quadrivalent meningococcal conjugate vaccine according to the revaccination schedule recommended in the table.",
"     <br/>",
"     &Delta; A 2-dose series is required for any child whose first dose was received prior to his or her second birthday. Children requiring protection prior to travel may receive the second dose as early as two months after the first dose.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Specific recommendations for meningococcal vaccination during an outbreak are made by public health authorities.",
"     <br/>",
"     &sect; When administered together, Menactra may interfere with the protection conferred by the 7-valent pneumococcal conjugate vaccine (PCV7), although protective levels of PCV7 antibodies were still achieved. Because of the lack of data on the clinical significance of this finding and because pneumococcal disease is a more significant threat than meningococcal disease to children with sickle cell disease or anatomic asplenia, the ACIP is not recommending Menactra for children between 9 and 23 months of age who have either of these conditions.",
"     <br/>",
"     &yen; Individuals with complement component deficiency, asplenia, or HIV infection who previously received only a single dose of Menactra or Menveo should receive a booster dose at the earliest opportunity.",
"     <br/>",
"     &Dagger; A 2-dose primary vaccine series is recommended for individuals with persistent complement component deficiency or functional or anatomic or functional asplenia, as well as for HIV-infected children, because the vaccine is less immunogenic in these groups.",
"     <br/>",
"     &dagger; Risk factors for exposure include travelers to regions in which meningococcal disease is hyperendemic or epidemic (eg, the meningitis belt of sub-Saharan Africa during the dry season [December through June]), military recruits, college freshmen living in a dormitory, and microbiologists exposed to Neisseria meningitidis.",
"     <br/>",
"     ** Given the current outbreak of meningococcal disease (in the fall of 2012) in men who have sex with men (MSM) in New York City, we recommend meningococcal vaccination for MSM, especially if HIV-infected, if their residence, travel, or social interactions put them in close contact with other MSM from New York City. The appropriate formulation depends upon the age of the patient, as outlined above. HIV-infected individuals should receive two doses, with the second dose administered eight weeks or more after the first dose, plus booster doses every five years.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Akinsanya-Beysolow I, Jenkins R, Meissner HC, Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC. Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Persons Aged 0 Through 18 Years - United States, 2013. MMWR Surveill Summ 2013; 62:2.",
"      </li>",
"      <li>",
"       Bridges CB, Woods L, Coyne-Beasley T, Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC. Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Adults Aged 19 Years and Older - United States, 2013. MMWR Surveill Summ 2013; 62:9.",
"      </li>",
"      <li>",
"       Centers for Disease Control and Prevention (CDC). Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep 2013; 62:52.",
"      </li>",
"      <li>",
"       Notes from the Field: serogroup C invasive meningococcal disease among men who have sex with men &mdash; New York City, 2010&ndash;2012. MMWR Morb Mortal Wkly Rep 2013; 61:1048.",
"      </li>",
"      <li>",
"       New York State Department of Health. New York State Department of Health expands vaccination recommendation in response to meningococcal disease outbreak among high risk HIV positive men in New York City. file://www.health.ny.gov/press/releases/2012/2012-10-05_meningitis.htm (Accessed on October 26, 2012).",
"      </li>",
"      <li>",
"       Commonwealth of Massachusetts Department of Public Health. Health Advisory: Meningococcal vaccine recommendations for men who have sex with men. October 25, 2012.",
"      </li>",
"      <li>",
"       Centers for Disease Control and Prevention (CDC). Recommendation of the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease. MMWR Morb Mortal Wkly Rep 2011; 60:1391.",
"      </li>",
"      <li>",
"       Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease--Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1018.",
"      </li>",
"      <li>",
"       Committee on Infectious Diseases. Meningococcal conjugate vaccines policy update: booster dose recommendations. Pediatrics 2011; 128:1213.",
"      </li>",
"      <li>",
"       Centers for Disease Control and Prevention (CDC). Updated Recommendations for Use of Meningococcal Conjugate Vaccines - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011; 60:72.",
"      </li>",
"      <li>",
"       Centers for Disease Control and Prevention (CDC). Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb Mortal Wkly Rep 2009; 58:1042.",
"      </li>",
"      <li>",
"       Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54:1.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_48_9999=[""].join("\n");
var outline_f9_48_9999=null;
